SEARCH

Search Details

Cho Kyu Yong

Hokkaido University Hospital Institute of Health Science Innovation for Medical CareSpecially Appointed Lecturer

Researcher basic information

■ Degree
  • 博士(医学), 北海道大学, Mar. 2013
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 30801617
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Field
  • Life Science, Metabolism and endocrinology
  • Life Science, Medical management and medical sociology

Career

■ Career
Career
  • Jan. 2025 - Present
    Hokkaido University Hospital, Research Planning Division, Clinical Research and Medical Innovation Center, Institute of Health Science Innovation for Medical Care(HELIOS), Japan
  • Oct. 2022 - Dec. 2024
    Pharmaceuticals and Medical Devices Agency, Office of New Drug 1, 審査専門員
  • Apr. 2017 - Sep. 2022
    Hokkaido University Hospital, Clinical Research and Medical Innovation Center, Assistant Professor, Japan
Educational Background
  • Apr. 2023 - Mar. 2025, The University of Tokyo, Medical Real World Data Utilization Human Resource Development Project, an extended educational program, Japan
  • Apr. 2008 - Mar. 2013, Hokkaido University, Graduate School of Medicine, 医学研究科
  • Apr. 1988 - Mar. 2004, Hokkaido University, School of Medicine, 医学科

Research activity information

■ Awards
  • Sep. 2026, The Japanese Society of Informatics for Diabetes Mellitus, Young Investigator Award
  • Oct. 2019, Japan Association for Diabetes Education and Care, International Exchange Research Encouragement Award
■ Papers
  • Central adiposity is associated with the severity and multiligamentous involvement of ossification of the posterior longitudinal ligament
    Huohuo Xue; Tsutomu Endo; Yoshinao Koike; Ryo Fujita; Akinobu Nakamura; Kyu Yong Cho; Yuki Oe; M Alaa Terkawi; Masahiro Kanayama; Katsuhisa Yamada; Ken Kadoya; Hideki Sudo; Misaki Ishii; Norimasa Iwasaki
    JBMR Plus, 27 Oct. 2026
    Scientific journal
  • What Does the Proinsulin/C-Peptide Ratio Reflect?
    Akinobu Nakamura; Maiko Miyamoto; Hiraku Kameda; Kyu Yong Cho; Kazufumi Okada; Tatsuya Atsumi
    Diabetes, obesity & metabolism, 28, 10, 9704, 9706, Oct. 2026, [International Magazine]
    English
  • Effect of pemafibrate on LDL‐cholesterol properties in type 2 diabetes and hypertriglyceridemia by lipid management status: PARM‐T2Dpost hoc analysis
    Hiroya Kitsunai; Kenichi Kito; Kazuno Omori; Kyu Yong Cho; Akinobu Nakamura; Jun Takeuchi; So Nagai; Ichiro Sakuma; Hiroshi Nomoto
    Journal of Diabetes Investigation, 25 Sep. 2026, [Domestic magazines]
    English, Scientific journal, Although pemafibrate attracts attention for reducing LDL-C in patients with high baseline LDL-C, its comprehensive effects remain unclear in patients with type 2 diabetes. This post hoc analysis of the PARM-T2D study investigated the effects of pemafibrate on LDL-C concentration and particle size in 156 subjects with type 2 diabetes and hypertriglyceridemia, categorized by baseline LDL-C levels. While triglycerides and remnant lipoprotein cholesterol significantly improved across all groups over 52 weeks, the impact on LDL-C was multifaceted and dependent on baseline status. In participants with low baseline LDL-C, concentrations increased without a rise in ApoB, suggesting an improvement in particle size. Conversely, in those with high baseline LDL-C, both LDL-C and ApoB decreased, reflecting favorable modifications according to baseline LDL-C control status. These findings suggest that pemafibrate exerts beneficial, status-dependent effects on LDL-C properties, potentially reducing cardiovascular risk by improving LDL particle quality and quantity in high-risk patients with diabetes.
  • Pemafibrate Improves Lipid and Liver Metabolism in Adult GH Deficiency: A Prospective Observational Study.
    Hiroshi Iesaka; Kyu Yong Cho; So Nagai; Aika Miya; Hiraku Kameda; Hiroshi Nomoto; Akinobu Nakamura; Tatsuya Atsumi
    Journal of the Endocrine Society, 10, 2, bvaf222, Feb. 2026, [International Magazine]
    English, Scientific journal, CONTEXT: The outcomes of pemafibrate administration on hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease associated with adult growth hormone deficiency (AGHD) are unknown. OBJECTIVE: To evaluate the effects of pemafibrate on hypertriglyceridemia and liver parameters in AGHD in a real-world setting. DESIGN: A prospective observational study (December 2019-August 2023). SETTING: Two referral hospitals in Japan. PATIENTS: Thirty-four consecutive Japanese patients with AGHD complicated with hypertriglyceridemia. Hypertriglyceridemia was defined using a fasting serum triglyceride (TG) concentration of ≥1.7 mmol/L or treated with lipid-lowering medication. TREATMENT: Patients were prescribed pemafibrate or continued conventional therapy for 24 weeks. MAIN OUTCOME MEASURE: The percentage reduction in fasting serum TG level between baseline and 24 weeks was evaluated. Hepatic parameters, including hepatic steatosis index (HSI) derived from aspartate aminotransferase, alanine aminotransferase, and body mass index, were also evaluated, along with other metabolic parameters. The Mann-Whitney U-test and Fisher's exact test were used to compare the change between groups. A multiple regression was performed to identify predictors of TG change. RESULTS: The change in serum TG level was significantly larger in the pemafibrate group than that in the conventional group (median: -51.0% [interquartile range (IQR): -69.0% to -21.0%] vs -13.0% [IQR: -34.0% to 9.0%], P = .0138). HSI decreased after 24 weeks of pemafibrate. Relative TG change correlated with baseline body mass index [regression coefficient (β) .0463, P < .0001] and HSI (β .0645, P = .0107). CONCLUSION: Pemafibrate had beneficial effects on hypertriglyceridemia as well as liver metabolism of patients with AGHD. However, its efficacy was attenuated by obesity.
  • Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP-ELM study.
    Maiko Miyamoto; Aika Miya; Akinobu Nakamura; Yuka Takahashi; Yuki Yamauchi; Shingo Yanagiya; Takahiro Takase; Mayuko Ono; Kiyohiko Takahashi; Kazufumi Okada; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi
    Journal of diabetes investigation, 17, 4, 627, 635, 30 Jan. 2026, [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We aimed to explore the short-term effects of tofogliflozin on the insulin secretory capacity of people with type 2 diabetes. MATERIALS AND METHODS: We performed a multicenter, prospective, randomized, active-controlled, open-label, parallel-group comparison study of people with type 2 diabetes aged 20-89 years, with hemoglobin A1c (HbA1c) 6.5%-9.0%, not previously treated with antihyperglycemic agents. The participants were randomly assigned to a group that received 20 mg tofogliflozin per day or a group that received 500 mg metformin per day for 4 weeks. Fasting blood samples were obtained and oral glucose tolerance testing was performed before and after treatment. The changes from baseline to week 4 in glucose tolerance and insulin secretory capacity were compared. RESULTS: Thirty participants in the metformin group and 35 in the tofogliflozin group completed the study. After 4 weeks, the HbA1c, glycated albumin, and fasting plasma glucose concentrations had significantly decreased in both groups, with no significant differences between the two groups. The fatty liver index improved significantly more in the tofogliflozin group. The disposition index (DI) did not significantly increase in either group, and there was no difference between the groups. However, in the tofogliflozin group, the DI improved in participants with poorer glucose tolerance at baseline or larger improvements after treatment, but not in the metformin group. CONCLUSION: Short-term tofogliflozin therapy did not improve the insulin secretory capacity of treatment-naïve people with type 2 diabetes. However, tofogliflozin may facilitate the early recovery of insulin secretory capacity in individuals with poor glucose tolerance.
  • Esaxerenone improves the blood pressure and metabolic parameters of hypertensive subjects with diabetes.
    Saki Kuwabara; Hiraku Kameda; Kei Yokozeki; Aika Miya; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Naohide Koyanagawa; Kohei Yamamoto; Jun Takeuchi; So Nagai; Arina Miyoshi; Norio Wada; Shinji Taneda; Yoshio Kurihara; Tatsuya Atsumi
    Endocrine journal, 72, 8, 947, 957, 01 Aug. 2025, [Domestic magazines]
    English, Scientific journal, Esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, may be an effective treatment for diabetes-associated mineralocorticoid receptor-related hypertension, but there have been few studies of its use in clinical practice. We aimed to determine the effects of esaxerenone on blood pressure (BP) and metabolic parameters of hypertensive subjects with diabetes in a clinical practice setting. We performed a retrospective multicenter observational study of hypertensive subjects with type 2 diabetes/prediabetes. We first compared the values of parameters at baseline and after 6 months of esaxerenone administration, then compared the changes in the parameters in propensity score-matched subjects who initiated esaxerenone or amlodipine administration. Correlation analysis was performed to identify factors associated with these changes. The single-arm analysis showed that esaxerenone caused significant reductions in systolic and diastolic BP from 155.2 ± 17.7 and 83.3 ± 12.3 mmHg at baseline to 132.9 ± 15.5 and 72.3 ± 12.9 mmHg, respectively, after 6 months of treatment (p < 0.01). In addition, body mass index (BMI), glycated hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, low-density lipoprotein-cholesterol, estimated glomerular filtration rate, and urine albumin/creatinine ratio (UACR) significantly decreased (p < 0.05). The esaxerenone group showed significantly larger reductions in systolic BP, AST, ALT, and UACR than the amlodipine group (p < 0.05). Furthermore, there was a negative correlation between the change in ALT and baseline BMI (p < 0.05). Esaxerenone has an antihypertensive effect, reduces the albuminuria, and reduces the activities of liver enzymes in hypertensive subjects with type 2 diabetes/prediabetes. The present findings suggest that esaxerenone has pleiotropic effects in such subjects.
  • Impact of preoperative NAFLD status on restoration of pancreatic β-cell function after laparoscopic sleeve gastrectomy.
    Yuki Oe; Akinobu Nakamura; Kyu Yong Cho; Takahiro Takase; Koji Ogawa; Yuma Ebihara; Masato Yoshikawa; Aika Miya; Hiroshi Nomoto; Hiraku Kameda; Goki Suda; Kohsuke Kudo; Naoya Sakamoto; Satoshi Hirano; Tatsuya Atsumi
    American journal of physiology. Endocrinology and metabolism, 328, 6, E1013-E1020, 01 Jun. 2025, [International Magazine]
    English, Scientific journal, Although pancreatic beta-cell insufficiency is ameliorated after bariatric and metabolic surgery in subjects with obesity and type 2 diabetes (T2D), the mechanism and preoperative factors related to this amelioration have been uncertain. This study investigated the effect of laparoscopic sleeve gastrectomy (LSG) on beta-cell function. The preoperative characteristics and factors associated with the degree of postoperative changes in beta-cell function in those subjects were explored as well. In this subanalysis of our prospective observational study, subjects with obesity and T2D underwent oral glucose tolerance tests (OGTTs) and magnetic resonance imaging (MRI), at the baseline and the end of the 1-year follow-up period. Beta-cell function was evaluated by the insulin secretion-sensitivity index-2 (ISSI-2) and disposition index (DI), and the preoperative factors associated with these changes were examined. In 18 eligible subjects, glucose tolerance improved, ISSI-2 increased significantly, and DI also tended to increase 1 year after LSG. The change in ISSI-2 correlated with preoperative liver fibrosis assessed by MR elastography (r = -0.49, P < 0.05). In 16 subjects without severe fibrosis, changes in DI correlated with preoperative MRI-estimated proton density fat fraction (r = -0.52, P < 0.05). Neither as glycemic control nor visceral fat was significantly associated with the degree of amelioration in beta-cell function. Pancreatic beta-cell function improved at 1-year postoperative to LSG in subjects with obesity and T2D. Preoperative liver fibrosis and steatosis were associated with a lower degree of postoperative pancreatic beta-cell improvement.NEW & NOTEWORTHY In the present study, pancreatic beta-cell function improved at 1 year postoperatively in subjects with obesity and type 2 diabetes (T2D) who underwent laparoscopic sleeve gastrectomy. Preoperative liver fibrosis and steatosis were associated with a lower degree of postoperative pancreatic beta-cell improvement. Considering that amelioration of pancreatic beta-cell function leads to better outcome of T2D, the finding of this association would be clinically significant.
  • Wnt/β-カテニン経路は成長ホルモン産生下垂体腫瘍の細胞増殖を促進する
    桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
    日本臨床分子医学会学術総会プログラム・抄録集, 60回, 47, 47, 日本臨床分子医学会, Apr. 2025
    Japanese
  • インスリンデグルデク/リラグルチド配合注を用いたインスリン頻回注射療法は,目標血糖達成率を上昇させる
    大江 悠希; 野本 博司; 曹 圭龍; 大森 高志; 涌井 理之; 高橋 由華; 宮 愛香; 亀田 啓; 古川 真; 西尾 太郎; 北川 浩彦; 中村 昭伸; 坂井 清志; 渥美 達也
    糖尿病, 68, Suppl., S, 170, (一社)日本糖尿病学会, Apr. 2025
    Japanese
  • 成人成長ホルモン分泌不全症合併脂質異常症患者におけるペマフィブラートの効果 前向き観察研究
    家坂 光; 曹 圭龍; 永井 聡; 宮 愛香; 亀田 啓; 中村 昭伸; 野本 博司; 渥美 達也
    糖尿病, 68, Suppl., S, 262, (一社)日本糖尿病学会, Apr. 2025
    Japanese
  • Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study.
    Yuki Oe; Hiroshi Nomoto; Akinobu Nakamura; Saki Kuwabara; Yuka Takahashi; Ayano Yasui; Rimi Izumihara; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi
    International journal of endocrinology, 2025, 3911323, 3911323, 2025, [International Magazine]
    English, Scientific journal, UNLABELLED: For patients with diabetes, achieving stable glucose control with minimal variability is highly significant. Incretin drugs have been shown to improve glycemic variability (GV), and we recently showed that a switch from a combination of a dipeptidyl peptidase (DPP)-4 inhibitor plus basal insulin to insulin degludec/liraglutide (IDegLira) improves GV, including the mean amplitude of glycemic excursions (MAGE), using continuous glucose monitoring in hospitalized patients with Type 2 diabetes. Here, we performed a secondary analysis to identify the factors related to an improvement in MAGE when switching to IDegLira. In patients with high MAGE, the change in C-peptide immunoreactivity during a glucagon test (ΔCPR) showed the highest correlation with the change in MAGE among the baseline patients' characteristics (ρ = -0.70; p < 0.05). Regression analysis confirmed a significant association between preserved CPR and amelioration of MAGE (R 2 = 0.45; p < 0.05). Thus, this preliminary result implies that a treatment strategy that includes a glucagon-like peptide-1 receptor agonist might be beneficial for patients being treated with a DPP-4 inhibitor plus basal insulin who show high GV but have preserved beta-cell function. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) Center Clinical Trials Registry: UMIN 000039460.
  • Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study.
    Yuki Oe; Hiroshi Nomoto; Kyu Yong Cho; Takashi Omori; Koki Nakamura; Akihiro Takahashi; Yuka Suzuki; Jyunpei Yoshikawa; Akiko Kato-Sato; Shin Furukawa; Taro Nishio; Hirohiko Kitakawa; Aika Miya; Hiraku Kameda; Daigo Nakazawa; Akinobu Nakamura; Kiyoshi Sakai; Tatsuya Atsumi
    Therapeutic advances in endocrinology and metabolism, 16, 20420188251378216, 20420188251378216, 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: Tirzepatide (TZP) has demonstrated efficacy for glycemic control and weight loss in subjects with type 2 diabetes (T2D). However, previous clinical trials were not conducted under the treatment of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a background regimen nor were they limited to subjects with chronic kidney disease (CKD). OBJECTIVES: We evaluated the glycemic control of tirzepatide switching from conventional GLP-1 receptor agonists in subjects with T2D and CKD. DESIGN: This was a prospective, two-arm, observational study performed at a single center. METHODS: Eligible subjects were individuals with T2D and CKD who had been treated with dulaglutide for more than 3 months, with glycated hemoglobin (HbA1c) ⩾7.0%, and an estimated glomerular filtration rate ⩽60 mL/min/1.73 m2. Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months. The primary outcome was a change in HbA1c over 6 months between the groups. Additional metabolic parameters, including body weight and the urine albumin-creatinine ratio (UACR), were evaluated. Adverse events in the TZP group were also investigated. RESULTS: Of the 55 participants, 48 completed the study (TZP group, n = 23; Dula group, n = 25). Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01). UACR levels remained stable in the TZP group throughout the study period and increased significantly in the Dula group (p < 0.05). Gastrointestinal events and hypoglycemia were observed in the TZP group, and those subjects who suffered hypoglycemic symptoms were mostly insulin users. CONCLUSION: Tirzepatide might be an effective alternative treatment for subjects with T2D and CKD who did not achieve sufficient glycemic control with conventional GLP-1RAs, as well as preventing the progression of nephropathy. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (registration number UMIN 000051344, date: June 16, 2023). https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058576.
  • Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
    Yuki Oe; Takashi Omori; Eriko Aimono; Shin Furukawa; Hirohiko Kitakawa; Masatoshi Tateno; Kiyoshi Sakai; Kyu Yong Cho
    Frontiers in endocrinology, 16, 1501984, 1501984, 2025, [International Magazine]
    English, Scientific journal, Metabolic dysfunction-associated steatohepatitis (MASH) has cardiometabolic risk factors, such as obesity and type 2 diabetes, and has been reported to have a potentially higher risk of mortality than conventional steatotic liver diseases. Liver fibrosis develops and can progress to cirrhosis and hepatocellular carcinoma. Although some antidiabetic agents have been reported to ameliorate the condition, no specific medical treatment has been developed to date. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) that has shown efficacy against MASH in some clinical trials. However, these trials were limited to those with mild-to-moderate fibrosis and their history of treatment was often unclear. Here, we report the case of a 50-year-old man with a 16-year history of diabetes. He demonstrated poor control of his diabetes with elevated liver enzymes. A liver biopsy was performed and he was diagnosed with steatohepatitis. Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023. The histological examination found cirrhosis and liraglutide was switched to tirzepatide. Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved. A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis. A diagnosis of steatotic liver disease was made. Although some previous studies had demonstrated an amelioration of liver fibrosis and an improvement in the prognosis of patients following GLP-1RA treatment, effective medications for patients with severe fibrosis or who are refractory to treatment with GLP-1RAs has not been identified to date. We reported a case with severe MASH whose condition had ameliorated by switching from conventional GLP-1RAs to tirzepatide.
  • チルゼパチドは慢性腎臓病合併2型糖尿病患者の収縮期血圧を低下させる
    大江 悠希; 野本 博司; 曹 圭龍; 宮 愛香; 亀田 啓; 中沢 大悟; 古川 真; 西尾 太郎; 中村 昭伸; 坂井 清志; 渥美 達也
    糖尿病, 67, 12, 511, 511, (一社)日本糖尿病学会, Dec. 2024
    Japanese
  • Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial).
    Naoko Matsuoka; Daigo Nakazawa; Saori Nishio; Kyu Yong Cho; Tomochika Maoka; Nobuharu Kaneshima; Rie Yamamoto; Junya Yamamoto; Mamiko Shimamoto; Minoru Makita; Satoko Iriuda; Kento Igarashi; Yosuke Ito; Akiko Kato; Junpei Yoshikawa; Takashi Kudo; Takahiro Nagashima; Yoichi M Ito; Tatsuya Atsumi
    BMJ open, 14, 11, e084846, 25 Nov. 2024, [International Magazine]
    English, Scientific journal, INTRODUCTION: Patients with type 2 diabetes (T2D) undergoing dialysis exhibit a higher mortality rate compared with those with other conditions, primarily due to vascular complications including coronary artery disease, heart failure and stroke. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a type of drug for T2D, have reportedly decreased cardiovascular and renal events in patients with heart failure and chronic kidney disease, irrespective of diabetes presence. Nevertheless, the evidence supporting the use of SGLT2 inhibitors in patients undergoing dialysis has been limited. Our study aims to evaluate the impact of SGLT2 inhibitors on cardiovascular disease in individuals with T2D undergoing peritoneal dialysis (PD). METHODS AND ANALYSIS: The CARD-PD study is a multicentre, prospective, randomised, open-label comparison trial of canagliflozin treatment in patients diagnosed with T2D undergoing PD. Eligible patients meeting the criteria for participation will be randomly assigned to either the canagliflozin treatment group (100 mg/day) or the control group (delayed-start canagliflozin group) for a duration of 6 months. We set a target of 18 participants in each group (a total of 36) based on sample size calculations from a previous report. Randomisation is performed using a web-based system, wherein patients are stratified by age, sex and plasma brain natriuretic peptide (BNP) concentrations at the baseline. The primary outcome measure is the plasma BNP levels after 6-month period. Following this initial phase, patients from both groups will continue to receive canagliflozin treatment (100 mg/day) in the following manner: (1) patients in the canagliflozin group will continue canagliflozin treatment for an additional 6 months, while (2) patients initially in the placebo arm will transition to canagliflozin treatment for an additional 12 months. ETHICS AND DISSEMINATION: The Ethics Review Board of Hokkaido University Hospital (CRB no. 1180001) has approved the CARD-PD study protocol. The results will be disseminated in peer-reviewed journals and summaries will be presented at scientific conferences. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials (jRCT1011210022); pre-results.
  • Normalization of impaired glucose tolerance after kidney transplantation is associated with improved β-cell function.
    Maiko Miyamoto; Akinobu Nakamura; Aika Miya; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Naoya Iwahara; Kiyohiko Hotta; Nobuo Shinohara; Tatsuya Atsumi
    American journal of physiology. Endocrinology and metabolism, 327, 2, E194-E202, 01 Aug. 2024, [International Magazine]
    English, Scientific journal, Our previous study revealed that over 50% of recipients with pretransplant impaired glucose tolerance (IGT) improved to normal glucose tolerance after kidney transplantation. However, the mechanism is unclear. We aimed to investigate whether the changes in glucose tolerance are associated with β-cell function and insulin resistance in Japanese kidney transplant recipients with pretransplant IGT. Of the 265 recipients who received kidney transplantation, 54 with pretransplant IGT were included. We divided the recipients into improvement and nonimprovement groups according to the change in the area under the curve for glucose obtained from the oral glucose tolerance test (OGTT). β-Cell function was estimated by the insulin secretion sensitivity index-2 (ISSI-2) and the disposition index (DI). Insulin resistance was estimated by the Matsuda index (MI) and the homeostasis model assessment of insulin resistance (HOMA-IR). ISSI-2 and DI increased significantly after transplantation in the improved group (P < 0.01, P < 0.05, respectively), but not in the nonimproved group. ΔISSI-2 and ΔDI were significantly and positively associated with pretransplant 60-min OGTT plasma glucose levels (both P < 0.01). There were no differences in MI or HOMA-IR between these two groups after transplantation. In recipients not on pretransplant dialysis, a significant negative association was found between Δblood urea nitrogen (BUN) and ΔDI (correlation coefficient = -0.48, P < 0.05). In pretransplant IGT recipients, improvements in glucose tolerance after kidney transplantation were linked to improvements in β-cell function. The higher the 60-min OGTT plasma glucose level, the greater the improvement in posttransplant β-cell function. Improvements in BUN after transplantation were associated with improvements in β-cell function.NEW & NOTEWORTHY In recipients with pretransplant impaired glucose tolerance, improvements in glucose tolerance after kidney transplantation were associated with improvements in β-cell function. The higher the pretransplant 60-min OGTT plasma glucose level, the greater the improvement in posttransplant β-cell function. Although glucose tolerance is known to be impaired after transplantation, the present study focused on the reason for the improvement in glucose tolerance rather than the development of posttransplantation diabetes mellitus.
  • Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).
    Yuki Oe; Hiroshi Nomoto; Kyu Yong Cho; Kei Yokozeki; Tsubasa Ono; Aika Miya; Hiraku Kameda; Akinobu Nakamura; Yoshiaki Arimura; Tatsuya Atsumi
    BMC endocrine disorders, 24, 1, 124, 124, 24 Jul. 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: Oral semaglutide in older subjects with type 2 diabetes was as effective as in younger subjects, according to phase 3 clinical trials. However, its efficacy can be limited in very aged population, due to the presence of impaired cognitive function and the complex instructions for its use. Here, we investigated its efficacy and safety by further age bracket in older subjects in real-world. METHODS: We retrospectively studied subjects > 65 years of age with type 2 diabetes who started oral semaglutide treatment. The primary outcome was the change in glycated hemoglobin (HbA1c) over 6 months. Adverse events and cognitive function were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) and the Hasegawa Dementia Rating Scale-revised (HDS-R). The achievement rate of glycemic targets was evaluated based on the age, health status of subjects and their use of anti-diabetic agents which can cause hypoglycemia, with additional analysis between two subgroups; early (65-74) versus late (≥ 75) older. Furthermore, we evaluated the relationships between their improvements in HbA1c and the baseline characteristics of the subjects, including their cognitive function and insulin secretory capacity. RESULTS: We studied the efficacy of the drug in 24 subjects. Their HbA1c and body weight significantly decreased (- 13.1 ± 7.5 mmol/mol and - 3.0 ± 2.4 kg, respectively; P < 0.01). Although cognitive function was lower in the late older group (r = -0.57, P < 0.01), changes in HbA1c showed no difference between the two subgroups (P = 0.66) and it correlated with the insulin secretory capacity rather than cognitive function (r = -0.49, P < 0.05). Glycemic targets were more likely to be achieved (P < 0.01), but HbA1c excessively decreased in late older subjects who were also using insulin or an insulin secretagogue. The frequency of adverse events was similar to that in the clinical trial, whereas discontinuation of medication were more frequent among the late older subjects (Early; n = 2, Late; n = 4). CONCLUSIONS: Oral semaglutide improves the glycemic control of older subjects, but it might be a risk for potential hypoglycemia and discontinuation because of adverse events in subjects of ≥ 75 years. Attention should be paid to insulin secretory capacity and concomitant medications rather than concern about adherence.
  • Frequency and determinants of lipid management target achievement in primary prevention of cardiovascular disease in type 2 diabetes.
    Aika Miya; Akinobu Nakamura; Yuka Suzuki; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi
    Diabetology international, 15, 3, 465, 473, Jul. 2024, [Domestic magazines]
    English, Scientific journal, AIMS: This study aimed to clarify the real-world status of lipid management in outpatients with type 2 diabetes (T2DM) following the 2022 revision of the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. It also aimed to evaluate characteristics associated with the failure to achieve management targets. MATERIALS AND METHODS: In this post-hoc analysis of a multicenter, cross-sectional study, we included Japanese outpatients with T2DM undergoing primary prevention of atherosclerotic cardiovascular diseases (ASCVD) who provided fasting blood samples. The frequency and determinants of achieving low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) targets were assessed. RESULTS: Among 223 participants with a mean age of 67 and mean HbA1c of 7.1%, 61 had no history of peripheral arterial disease, microvascular complications, or smoking. Out of the 223 participants, 64.1% (95% CI: 57.6-70.1%) achieved the LDL-C target. In multivariate logistic regression analysis, being female (odds ratio [OR] 3.139, P = 0.0011), having diabetic nephropathy (OR 2.868, P = 0.0021), smoking (OR 2.292, P = 0.0281), and non-use of statins (OR 4.857, P < 0.0001) were independently associated with non-achievement. For non-HDL-C, 65.6% (95% CI: 58.1%-70.6%) of patients met the target. Having diabetic neuropathy (OR 2.428, P = 0.0054), smoking (OR 2.008, P = 0.0478), and non-use of statins (OR 2.277, P = 0.0112) were identified as factors associated with non-achievement. CONCLUSIONS: Low achievement rate of revised lipid management targets for ASCVD primary prevention in T2DM was unveiled. Assessing comorbidities, encouraging smoking cessation, and prioritizing statin use are considered.
  • Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
    Hiroshi Nomoto; Sho Furusawa; Hiroki Yokoyama; Yuka Suzuki; Rimi Izumihara; Yuki Oe; Kiyohiko Takahashi; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Jun Takeuchi; Yoshio Kurihara; Akinobu Nakamura; Tatsuya Atsumi
    The Journal of clinical endocrinology and metabolism, 110, 3, e583-e591, 02 May 2024, [International Magazine]
    English, Scientific journal, CONTEXT: Whether continuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) or switching to oral semaglutide is more beneficial for β-cell function is unclear. OBJECTIVE: To assess the efficacy of switching from DPP-4is to oral semaglutide for β-cell function compared with DPP-4i continuation. METHODS: Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted. Changes in markers for glucose metabolism, including homeostatic model assessment (HOMA2) scores and disposition index (DI), were compared between the groups. RESULTS: A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed. In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks. Regarding indices for β-cell function, changes in HOMA2-β as well as DI, reflecting the ability of β-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-β [P = .001] and +0.09 vs 0.0 in DI [P < .001]). Improvement in DI in the semaglutide group was correlated significantly to changes in body mass index (BMI), HbA1c, and fatty liver index reflecting liver steatosis. Multiple linear regression analysis revealed that dose of semaglutide (≥ 7 mg/day), reduction in fatty liver index, and metformin nonuse were independently associated with improvement of DI. CONCLUSION: Switching to oral semaglutide ameliorated β-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and β-cells.
  • Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
    Sho Furusawa; Hiroshi Nomoto; Hiroki Yokoyama; Yuka Suzuki; Atsushi Tsuzuki; Kiyohiko Takahashi; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Jun Takeuchi; So Nagai; Shinji Taneda; Yoshio Kurihara; Akinobu Nakamura; Tatsuya Atsumi
    Diabetes, obesity & metabolism, 26, 3, 961, 970, Mar. 2024, [International Magazine]
    English, Scientific journal, AIM: To assess whether oral semaglutide provides better glycaemic control, compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) continuation, in people with type 2 diabetes. MATERIALS AND METHODS: In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is. The primary endpoint was the change in glycated haemoglobin (HbA1c) over 24 weeks. Secondary endpoints included changes in metabolic parameters and biomarkers, along with the occurrence of adverse events. Factors associated with HbA1c improvement were also explored. RESULTS: In total, 174 eligible participants were enrolled; 17 dropped out of the study. Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis. Improvement in HbA1c at week 24 was significantly greater when switching to semaglutide compared with DPP-4i continuation [-0.65 (95% confidence interval: -0.79, -0.51) vs. +0.05 (95% confidence interval: -0.07, 0.16) (p < .001)]. Body weight, lipid profiles and liver enzymes were significantly improved in the semaglutide group than in the DPP-4i continuation group. Multiple linear regression analysis revealed that baseline HbA1c and homeostasis model assessment 2-R were independently associated with HbA1c improvement after switching to semaglutide. Seven participants in the semaglutide group discontinued medication because of gastrointestinal symptoms. CONCLUSIONS: Although the potential for gastrointestinal symptoms should be carefully considered, switching from DPP-4is to oral semaglutide may be beneficial for glycaemic control and metabolic abnormalities in people with higher HbA1c and insulin resistance.
  • Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
    Rimi Izumihara; Hiroshi Nomoto; Kenichi Kito; Yuki Yamauchi; Kazuno Omori; Yui Shibayama; Shingo Yanagiya; Aika Miya; Hiraku Kameda; Kyu Yong Cho; So Nagai; Ichiro Sakuma; Akinobu Nakamura; Tatsuya Atsumi
    Diabetes & metabolism journal, 48, 3, 473, 481, 29 Feb. 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal function of diabetic subjects with or without CKD in a real-world clinical setting. METHODS: We performed a sub-analysis of data collected during a multi-center, prospective, observational study of the effects of pemafibrate on lipid metabolism in subjects with type 2 diabetes mellitus complicated by hypertriglyceridemia (the PARM-T2D study). The participants were allocated to add pemafibrate to their existing regimen (ADD-ON), switch from their existing fibrate to pemafibrate (SWITCH), or continue conventional therapy (CTRL). The changes in estimated glomerular filtration rate (eGFR) over 52 weeks were compared among these groups as well as among subgroups created according to CKD status. RESULTS: Data for 520 participants (ADD-ON, n=166; SWITCH, n=96; CTRL, n=258) were analyzed. Of them, 56.7% had CKD. The eGFR increased only in the SWITCH group, and this trend was also present in the CKD subgroup (P<0.001). On the other hand, eGFR was not affected by switching in participants with severe renal dysfunction (G3b or G4) and/or macroalbuminuria. Multivariate analysis showed that being older and a switch from fenofibrate were associated with elevation in eGFR (both P<0.05). CONCLUSION: A switch to pemafibrate may be associated with an elevation in eGFR, but to a lesser extent in patients with poor renal function.
  • Positive association between proinsulin and fatty liver index in people with type 2 diabetes.
    Akinobu Nakamura; Aika Miya; Yuka Suzuki; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; So Nagai; Tatsuya Atsumi
    Endocrine journal, 71, 2, 193, 197, 28 Feb. 2024, [Domestic magazines]
    English, Scientific journal, The post-hoc study, derived from our previous prospective observational study, investigated the association between fasting serum proinsulin levels and hepatic steatosis in people with type 2 diabetes. The severity of hepatic steatosis was assessed using the fatty liver index. A total of 268 participants were divided into three groups: low (n = 110), moderate (n = 75), and high fatty liver index (n = 83). In both the crude and age/sex-adjusted analysis, logarithm-transformed proinsulin was significantly higher in the high fatty liver index group than in the low or moderate groups (all p < 0.01). The moderate fatty liver index group showed higher logarithm-transformed proinsulin than the low group (both p < 0.01). Positive associations between proinsulin and fatty liver index shown in this study would support an involvement of hepato-pancreatic crosstalk in the pathophysiology of type 2 diabetes.
  • Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Hiroshi Iesaka; Hiraku Kameda; Aika Miya; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Takashige Abe; Nobuo Shinohara; Tatsuya Atsumi
    Medicine, 102, 51, e36664, 22 Dec. 2023, [International Magazine]
    English, Scientific journal, RATIONALE: The increasing use of immune checkpoint inhibitors (ICIs) for treating malignant tumors result in the concomitant rise of immune-related adverse events (irAEs). This case report may provide useful insight to understanding the etiology of ICI-induced hypophysitis, a severe irAE leading to potentially fatal secondary adrenal insufficiency. PATIENT CONCERNS: An 81-year-old Japanese man was hospitalized for diabetic ketoacidosis following 4 courses of ICI combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. DIAGNOSIS: Insulin secretion was depleted, leading to diagnosis of fulminant type 1 diabetes. Adrenocorticotropic hormone (ACTH) and cortisol levels were very high (60.8 pmol/L and 1575 nmol/L, respectively) upon admission. ACTH and cortisol returned to normal ranges on the 2nd day. On the 8th day, an ACTH loading test showed intact cortisol response (peak value 519 nmol/L). However, on the 14th day, there was a sharp decrease in ACTH and cortisol levels (10.5 pmol/L and 47 nmol/L, respectively) accompanied by fatigue and a drop in blood pressure to 97/63 mm Hg. As secondary adrenal insufficiency was suspected, hydrocortisone replacement was initiated. An ACTH loading test on the 17th day revealed low cortisol peak (peak value 232 nmol/L), indicating sudden disruption of adrenal function. Magnetic resonance imaging showed no abnormal findings and there was no other pituitary hormone deficiency. These findings, along with the patient clinical course, suggest that secondary adrenal insufficiency was caused by acute ACTH producing cell destruction as an irAE associated with ICI therapy. INTERVENTIONS: The patient hyperglycemia and ketoacidosis were treated using extracellular fluid and insulin therapy. After development of adrenal insufficiency, hydrocortisone 20 mg was started, and the patient symptoms improved. OUTCOMES: He was continued on insulin therapy, hydrocortisone, and reinitiated nivolumab. LESSONS: This case provides a detailed course of the fulminant onset of ACTH deficiency during ICI administration, emphasizing the importance of close monitoring.
  • 減量・代謝改善手術がNAFLDと膵β細胞機能に及ぼす効果 内科的治療対照前向き観察研究
    大江 悠希; 中村 昭伸; 曹 圭龍; 高瀬 崇宏; 小川 浩司; 海老原 裕磨; 宮 愛香; 野本 博司; 亀田 啓; 渥美 達也
    肥満研究, 29, 合同学術集会抄録集, 217, 217, (一社)日本肥満学会, Nov. 2023
    Japanese
  • Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
    Hiroshi Nomoto; Kenichi Kito; Hiroshi Iesaka; Takahisa Handa; Shingo Yanagiya; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Jun Takeuchi; So Nagai; Ichiro Sakuma; Akinobu Nakamura; Tatsuya Atsumi
    Diabetology & metabolic syndrome, 15, 1, 214, 214, 26 Oct. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear. METHODS: We conducted a sub-analysis of the PARM-T2D study where subjects with type 2 diabetes complicated by hypertriglyceridemia were prospectively treated with pemafibrate or conventional therapies for 52 weeks. From the original cohort, subjects who had metabolic-associated fatty liver disease without changing their treatment regimens for comorbidities were analyzed. Eligible subjects (n = 293) (average age 61.2 ± 11.7 years, 37.5% female) treated with pemafibrate (pemafibrate, n = 152) or controls who did not change their treatment regimens (controls, n = 141) were divided into three groups based on their alanine aminotransferase (ALT) levels: ALT ≤ upper normal limit (UNL) (pemafibrate, n = 65; controls, n = 50), UNL < ALT ≤ 2×UNL (pemafibrate, n = 58; controls, n = 54), and 2×UNL < ALT (pemafibrate, n = 29; controls, n = 27). RESULTS: Pemafibrate treatment significantly ameliorated ALT levels (from 29 to 22 U/L, p < 0.001 by Wilcoxon's signed-rank test) in the total cohort and subjects with high ALT levels (2×ULN < ALT), and improved liver fibrosis as assessed by the Fibrosis-4 index (mean change - 0.05 (95% confidence interval: -0.22 to - 0.02), p < 0.05 versus baseline by the Mann-Whitney U-test and p < 0.05 versus the ALT ≤ UNL group by the Kruskal-Wallis test followed by Dunn's post-hoc analysis). CONCLUSIONS: The hepatoprotective effects of pemafibrate were dominant in subjects with type 2 diabetes complicated with liver dysfunction. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network Center Clinical Trials Registry (UMIN000037385).
  • Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
    Tomonori Sekizaki; Hiraku Kameda; Akinobu Nakamura; Saki Kuwabara; Hiroshi Nomoto; Kyu Yong Cho; Yukitomo Ishi; Hiroaki Motegi; Hideaki Miyoshi; Tatsuya Atsumi
    Pituitary, 26, 5, 597, 610, Oct. 2023, [International Magazine]
    English, Scientific journal, PURPOSE: Cushing's disease (CD) results from autonomous adrenocorticotropic hormone (ACTH) secretion by corticotroph adenomas, leading to excessive cortisol production, ultimately affecting morbidity and mortality. Pasireotide is the only FDA approved tumor directed treatment for CD, but it is effective in only about 25% of patients, and is associated with a high rate of hyperglycemia. Neuromedin B (NMB), a member of the bombesin-like peptide family, regulates endocrine secretion and cell proliferation. Here, we assessed NMB and NMB receptor (NMBR) expression in human corticotroph adenomas and the effects of NMBR antagonist PD168368 on murine and human corticotroph tumors. METHODS: To investigate NMB and NMBR expression, real-time qPCR and immunostaining on human pathological specimens of corticotroph, non-functional and somatotroph adenomas were performed. The effects of PD168368 on hormone secretion and cell proliferation were studied in vitro, in vivo and in seven patient-derived corticotroph adenoma cells. NMB and NMBR were expressed in higher extent in human corticotroph adenomas compared with non-functional or somatotroph adenomas. RESULTS: In murine AtT-20 cells, PD168368 reduced proopiomelanocortin (Pomc) mRNA/protein expression and ACTH secretion as well as cell proliferation. In mice with tumor xenografts, tumor growth, ACTH and corticosterone were downregulated by PD168368. In patient-derived adenoma cells, PD168368 reduced POMC mRNA expression in four out of seven cases and ACTH secretion in two out of five cases. A PD168368-mediated cyclin E suppression was also identified in AtT-20 and patient-derived cells. CONCLUSION: NMBR antagonist represents a potential treatment for CD and its effect may be mediated by cyclin E suppression.
  • Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
    Hiroshi Nomoto; Yuka Takahashi; Yoshinari Takano; Hiroki Yokoyama; Kazuhisa Tsuchida; So Nagai; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Tatsuya Atsumi
    Pharmaceutics, 15, 8, 20 Aug. 2023, [International Magazine]
    English, Scientific journal, Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks. This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30]. In total, 58 participants met the criteria of this subanalysis. There were no statistical differences in baseline characteristics between the SWITCH (n = 31) and Continue groups (n = 27). FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (p < 0.01). The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (p = 0.016) and lower baseline FLI (p < 0.01). The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (p = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM.
  • Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
    Aika Miya; Akinobu Nakamura; Yuka Suzuki; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Yoichi M Ito; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
    Diabetes, obesity & metabolism, 25, 7, 1883, 1889, Jul. 2023, [International Magazine]
    English, Scientific journal, AIM: To evaluate the contribution of body fat mass and serum adiponectin concentration to glucose variability (GV) stability in people with type 2 diabetes with impaired versus preserved endogenous insulin secretion. MATERIALS AND METHODS: This multicentre prospective observational study included 193 people with type 2 diabetes who underwent ambulatory continuous glucose monitoring, abdominal computed tomography and fasting blood sampling. A fasting C-peptide (FCP) concentration >2 ng/mL was defined as preserved endogenous insulin secretion. The participants were divided into high (FCP > 2 ng/mL) and low FCP subgroups (FCP ≤ 2 ng/mL). Multivariate regression analysis was performed in each subgroup. RESULTS: In the high FCP subgroup, the coefficient of variation (CV) in GV was unrelated to abdominal fat area. In the low FCP subgroup, a high CV was significantly related to small abdominal visceral fat area (β = -0.11, standard error 0.03; P < 0.05) and to small subcutaneous fat area (β = -0.09, standard error 0.04; P < 0.05). No significant relationship between serum adiponectin concentration and continuous glucose monitoring-related variables was found. CONCLUSIONS: The contribution of body fat mass to GV depends on the endogenous insulin secretion residue. A small body fat area has independent adverse effects on GV in people with type 2 diabetes and impaired endogenous insulin secretion.
  • Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
    Hiroshi Nomoto; Kenichi Kito; Hiroshi Iesaka; Yuki Oe; Shinichiro Kawata; Kazuhisa Tsuchida; Shingo Yanagiya; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Ichiro Sakuma; Naoki Manda; Akinobu Nakamura; Tatsuya Atsumi
    Pharmaceutics, 15, 7, 27 Jun. 2023, [International Magazine]
    English, Scientific journal, Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia. The subanalysis included participants who did not change their treatment for diabetes and did not receive insulin or insulin secretagogues during the study period. Changes in glucose metabolism markers, including homeostatic model assessment (HOMA2) scores and disposition index, were assessed. A total of 279 participants (141 in the pemafibrate group; 138 in the control group) met the criteria for the subanalysis. There were no significant changes in HbA1c during the 52-week study period in both groups. However, the pemafibrate group showed significant improvements versus the control group for insulin resistance assessed by HOMA2-R (-0.15 versus 0.08; estimated treatment difference -0.23 (95% confidence interval -0.44, -0.02); p = 0.03) and maintenance of β-cell function assessed by disposition index (0.015 versus -0.023; estimated treatment difference 0.037 (95% confidence interval 0.005, 0.069); p = 0.02). Correlation analyses showed that improvements in HOMA2-R and disposition index were significantly associated with improvements in lipid abnormalities and γ-glutamyl transpeptidase. In conclusion, pemafibrate reduced insulin resistance and maintained β-cell function in subjects with T2DM and hypertriglyceridemia, presumably by improving lipid profiles and lipid-related hepatocyte stress.
  • Lipid Droplet Protein PLIN1 Regulates Inflammatory Polarity in Human Macrophages and is Involved in Atherosclerotic Plaque Development by Promoting Stable Lipid Storage.
    Kyu Yong Cho; Hideaki Miyoshi; Akinobu Nakamura; Andrew S Greenberg; Tatsuya Atsumi
    Journal of atherosclerosis and thrombosis, 30, 2, 170, 181, 01 Feb. 2023, [Domestic magazines]
    English, Scientific journal, AIM: Perilipins (PLINs), peripheral lipid droplet (LD) proteins, play important roles in lipid accumulation and maturation in adipocytes. The relationship between PLIN family proteins and macrophage polarization in atherosclerosis has not been elucidated. METHODS: The experiments used tissues from human arteries of 65 patients who had undergone a carotid endarterectomy, and cultured macrophages generated from healthy human peripheral blood mononuclear cells. RESULTS: Plaque immunohistochemistry demonstrated co-expression of PLIN1 and PLIN2 in both symptomatic (n=31) and asymptomatic patients (n=34). PLIN2 mRNA expression increased 3.38-fold in the symptomatic group compared with those from asymptomatic. PLIN1 was not expressed on small LDs at a shorter incubation but was on large LDs at longer incubation with oxidized LDL and VLDL, while PLIN2 was observed after 24 h and increased with a longer incubation in cultured M1 macrophage. In M2 macrophages, PLIN1 was seen as early as 24 h following incubation with VLDL, and LD size increased with longer incubation. PLIN1 overexpression increased the size of LDs in M1 macrophages, even after a short incubation, and reduced the RNA expression of TNFA, MMP2, ABCA1, and ABCG1 versus the M1 control. Conversely, silencing of PLIN1 in M2 macrophages had the opposite effects on LD size and RNA expression. CONCLUSION: There was a relationship between macrophage polarity, cytosolic LD size, and PLIN1/PLIN2 expression levels. PLIN2 was mainly expressed in arterial plaques in symptomatic stroke patients, and associated with the inflammatory phenotype of human macrophages, while PLIN1 expression is closely associated with plaque stability and the anti-inflammatory phenotype.
  • Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
    Yuka Takahashi; Hiroshi Nomoto; Hiroki Yokoyama; Yoshinari Takano; So Nagai; Atsushi Tsuzuki; Kyu Yong Cho; Aika Miya; Hiraku Kameda; Jun Takeuchi; Shinji Taneda; Yoshio Kurihara; Tatsuya Atsumi; Akinobu Nakamura; Hideaki Miyoshi
    Diabetes, obesity & metabolism, 25, 6, 1503, 1511, 01 Feb. 2023, [International Magazine]
    English, Scientific journal, OBJECTIVE: To investigate the effects of switching from liraglutide or dulaglutide to once-weekly semaglutide on glycemic control and treatment satisfaction in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this multicenter, open-labeled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued on current therapy. The primary endpoint was the mean change in glycated hemoglobin (HbA1c) over 24 weeks. The secondary endpoints included the changes of Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores, body weight, and metabolic indices. RESULTS: In total, 110 patients were enrolled, and 10 were excluded; therefore, 37 patients in plan A and 63 patients in plan B completed the study. HbA1c levels were significantly reduced in the semaglutide group in both plans (plan A, 7.8 ± 1.0% to 7.8 ± 0.7% [liraglutide] vs. 7.9 ± 0.7% to 7.3 ± 0.7% [semaglutide], P < 0.01; plan B, 7.8 ± 1.0% to 7.9 ± 1.2% [dulaglutide] vs. 7.8 ± 0.8% to 7.1 ± 0.6% [semaglutide], P < 0.01). Semaglutide also improved DTSQ scores in both groups (plan A, + 0.1 vs. +8.3, P < 0.01; plan B, -1.2 vs. + 3.5, P < 0.01). Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters. CONCLUSIONS: Once-weekly semaglutide administration improved glycemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite GLP-1 receptor agonist treatment. This article is protected by copyright. All rights reserved.
  • Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
    Yuki Oe; Hiroshi Nomoto; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Tatsuya Atsumi
    Advances in therapy, 40, 1, 383, 386, Jan. 2023, [International Magazine]
    English
  • Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
    Yuki Yamauchi; Akinobu Nakamura; Takashi Yokota; Kiyohiko Takahashi; Shinichiro Kawata; Kazuhisa Tsuchida; Kazuno Omori; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Toshihisa Anzai; Shinya Tanaka; Yasuo Terauchi; Hideaki Miyoshi; Tatsuya Atsumi
    Scientific Reports, 12, 1, 9740, 9740, Springer Science and Business Media LLC, Dec. 2022, [International Magazine]
    English, Scientific journal, Abstract

    We aimed to determine the mechanism by which the sodium glucose co-transporter 2 inhibitor, luseogliflozin, preserves pancreatic beta-cell mass and function in db/db mice. Six-week-old db/db mice were fed to standard chow or standard chow containing 0.01% luseogliflozin. After 4 weeks, DNA microarray analysis, real-time PCR analysis, and measurement of mitochondrial respiratory capacity and reactive oxygen species (ROS) generation were performed using isolated islets. Immunohistochemistry and electron microscopic analysis were performed using pancreatic tissues. Metabolites extracted from the islets were measured by capillary electrophoresis mass spectrometry. The expression of genes involved in the tricarboxylic acid (TCA) cycle and electron transport chain was upregulated by luseogliflozin. Luseogliflozin improved the mitochondrial complex II-linked oxidative phosphorylation capacity and reduced ROS generation. Mitochondrial morphology was normally maintained by luseogliflozin. Luseogliflozin increased NK6 homeobox 1 (NKX6.1) expression and TCA cycle metabolites. Relief of glucotoxicity by luseogliflozin may involve lower mitochondrial ROS generation and an improvement in complex II-linked mitochondrial respiration. Reducing ROS generation through preventing complex II damage likely increases NKX6.1 expression and ameliorate glucose metabolism in the TCA cycle, contributing to the protection of pancreatic beta-cells. Protection of complex II in pancreatic beta-cells represents a novel therapeutic target for type 2 diabetes.
  • Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Hiroshi Nomoto; Akihiro Takahashi; Akinobu Nakamura; Hiroyoshi Kurihara; Jun Takeuchi; So Nagai; Shinji Taneda; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Hideaki Miyoshi; Tatsuya Atsumi
    BMJ open diabetes research & care, 10, 6, Nov. 2022, [International Magazine]
    English, Scientific journal, INTRODUCTION: Imeglimin is a novel anti-hyperglycemic drug that improves both insulin resistance and insulin secretion. The effects of imeglimin on glycemic control were confirmed in phase III clinical trials, but little is known about its effectiveness in daily clinical practice settings, especially compared with metformin. Therefore, we aim to clarify the efficacy of imeglimin in patients with type 2 diabetes (T2D) being treated with a dipeptidyl peptidase-4 (DPP-4) inhibitor plus low-dose metformin. RESEARCH DESIGN AND METHODS: This is a multicenter, randomized, prospective, open-label, parallel-group trial. Seventy participants with T2D treated with a DPP-4 inhibitor plus metformin (500-1000 mg/day) for more than 12 weeks and a glycated hemoglobin (HbA1c) level of 52-85 mmol/mol (7.0%-9.9%) will be randomized to receive add-on imeglimin 1000 mg two times per day or metformin dose escalation for 24 weeks. Biochemical analyses and physical assessments will be performed at baseline and at the end of the study, and adverse events will be recorded. The primary endpoint is the change in HbA1c after 24 weeks. The secondary endpoints comprise the changes in blood pressure, pulse rate, body weight, abdominal circumference, and other laboratory parameters; the relationship between improvements of biological parameters including glycemic control and patient background characteristics; and side effects. RESULTS: This study will reveal new insights into the incorporation of imeglimin into the diabetes treatment strategy. CONCLUSIONS: This will be the first randomized controlled trial to compare the efficacy of adding imeglimin versus metformin dose escalation on glycemic control in patients with T2D. TRIAL REGISTRATION NUMBER: jRCT1011220005.
  • COVID-19肺炎治療中に冠攣縮性狭心症を発症した褐色細胞腫の一例
    宮本 麻唯子; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 中久保 祥; 佐藤 琢真; 松本 隆児; 大塚 拓也; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, 98, 2, 597, 597, (一社)日本内分泌学会, Oct. 2022
    Japanese
  • Urethral injury related to peri‐urethral abscess as a complication of self‐catheterization in an older patient with type 2 diabetes
    Yuri Ofuji; Hiroshi Nomoto; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Tatsuya Atsumi
    Geriatrics & Gerontology International, 22, 10, 894, 895, Wiley, Oct. 2022, [Domestic magazines]
    English, Scientific journal
  • Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study
    Kenichi Kito; Hiroshi Nomoto; Ichiro Sakuma; Akinobu Nakamura; Kyu Yong Cho; Hiraku Kameda; Aika Miya; Kazuno Omori; Shingo Yanagiya; Takahisa Handa; Shinji Taneda; Jun Takeuchi; So Nagai; Kumiko Yamashita; Yoshio Kurihara; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes Research and Clinical Practice, 192, 110091, 110091, Elsevier BV, Oct. 2022, [International Magazine]
    English, Scientific journal, AIMS: Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, was shown to ameliorate lipid abnormalities in a phase III clinical trial of patients with type 2 diabetes mellitus (T2DM). However, its efficacy has not been demonstrated in real-world clinical practice in patients with T2DM. METHODS: We performed a multi-center prospective observational study of the use of pemafibrate in patients with T2DM and hypertriglyceridemia versus conventional therapy, with or without a fibrate. The primary outcomes were the changes from baseline in fasting serum triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C) concentrations at week 52. RESULTS: We recruited 650 patients, and data from 504 (252 per group) were analyzed after propensity score matching. In the pemafibrate group, both TG and HDL-C showed significant improvements (p < 0.001), and several indices reflecting TG-rich lipoproteins, low-density lipoprotein-cholesterol particle size, and liver enzyme elevations were significantly ameliorated compared with the control group, but there was no difference in glycemic control markers. One of the key secondary endpoints showed that switching from conventional fibrates to pemafibrate improved eGFR but increased uric acid concentration. CONCLUSIONS: In patients with T2DM, pemafibrate has superior effects on lipid profile as well as liver and renal dysfunction to conventional fibrates.
  • 腹腔鏡下スリーブ状胃切除術は肥満2型糖尿病患者の治療薬剤を減量し得る
    高橋 由華; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 野本 博司; 亀田 啓; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 65, 8, 473, 473, (一社)日本糖尿病学会, Aug. 2022
    Japanese
  • 肥満合併2型糖尿病患者において、術前骨格筋量が肥満手術の減量効果を予測する
    大江 悠希; 高瀬 崇宏; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 65, 8, 474, 474, (一社)日本糖尿病学会, Aug. 2022
    Japanese
  • 腹腔鏡下スリーブ状胃切除術は脂質代謝および脂肪肝を改善させる
    安井 彩乃; 高瀬 崇宏; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 65, 8, 474, 474, (一社)日本糖尿病学会, Aug. 2022
    Japanese
  • The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8): A cross-sectional study of elderly patients with diabetes.
    Aika Miya; Akinobu Nakamura; Isao Yokota; Kyu Yong Cho; Hiraku Kameda; Hiroshi Nomoto; Takahiro Takase; Kazuno Omori; Mayuko Ono; So Nagai; Shinji Taneda; Hideaki Miyoshi; Tatsuya Atsumi
    Geriatrics & gerontology international, 22, 8, 560, 567, 30 Jun. 2022, [Domestic magazines]
    English, Scientific journal, AIM: To investigate the achievement of individualized target HbA1c based on the Japanese guideline after geriatric assessment with the Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8) and to evaluate patient characteristics acting as barriers to achieving the target HbA1c in elderly outpatients with diabetes. METHODS: This cross-sectional study enrolled 303 Japanese outpatients aged ≥65 years with diabetes. Their health status was measured using the DASC-8. The target HbA1c was optimized for each patient by the guideline based on the DASC-8 score and use of drugs potentially associated with severe hypoglycemia. Patient characteristics related to the agreement between measured HbA1c and target HbA1c were extracted by multivariate logistic regression analysis. RESULTS: The mean age was 73.0 years and the mean body mass index (BMI) was 24.2 kg/m2 . The agreement between measured HbA1c and target HbA1c was 43.9% (95% confidence interval: 38.4%-50.0%). In multivariate logistic regression analysis, the agreement in patients with drugs potentially associated with severe hypoglycemia was significantly lower than in those without these drugs (37.8% vs. 60.5%, P = 0.0004). In patients with these drugs, higher BMI (P = 0.0271) and higher fasting plasma glucose (P = 0.0034) were independent related factors for measured HbA1c being higher than target HbA1c. Vulnerable elderly patients (P = 0.0116) and not taking sodium glucose co-transporter-2 (SGLT2) inhibitor (P = 0.0186) were independent related factors for inappropriately lower HbA1c. CONCLUSIONS: The agreement between measured HbA1c and target HbA1c was low in elderly patients with diabetes. Geriatr Gerontol Int 2022; ••: ••-••.
  • Metabolic Remodeling in Pancreatic Beta Cells in Japanese Patients with Type 2 Diabetes
    Rimi Izumihara; Hiroshi Nomoto; Koki Chiba; Hiraku Kameda; Kyuyong Cho; Akinobu Nakamura; Hideaki Miyoshi; Hiroki Mizukami; Tatsuya Atsumi
    DIABETES, 71, Jun. 2022
    English
  • Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
    Hiroshi Nomoto; Sho Furusawa; Akinobu Nakamura; Jun Takeuchi; So Nagai; Hiroki Yokoyama; Ichiro Sakuma; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi; Hideaki Miyoshi
    BMJ open, 12, 5, e056885, 18 May 2022, [International Magazine]
    English, Scientific journal, INTRODUCTION: Incretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion. The first-in-class oral glucagon-like peptide-1 receptor agonist semaglutide has potent effects on glycaemic and weight control, but little evidence has been published for the superiority of semaglutide for glycaemic control in patients after switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor. Therefore, we aim to verify the efficacy of oral semaglutide in patients with T2D being treated with a DPP-4 inhibitor. METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, parallel-group trial. In total, 172 participants with T2D who have been treated with a DPP-4 inhibitor for more than 12 weeks and who have a glycated haemoglobin (HbA1c) level of 7.0%-9.9% will be randomised to continue using their existing DPP-4 inhibitor or switch to oral semaglutide for 24 weeks. Biochemical analyses and physical assessment will be performed, and adverse events will be recorded at baseline and at the end of the study. The primary endpoint will be the effect of oral semaglutide on the change in HbA1c. The secondary endpoints will be the mean changes in body weight, abdominal circumference, systolic and diastolic blood pressure (BP), pulse rate, the relationship between improvement of metabolic parameters including HbA1c and patient background characteristics, side effects and other laboratory parameters. ETHICS AND DISSEMINATION: This will be the first study to compare the effects of switching from a DPP-4 inhibitor to oral semaglutide on glycaemic control in patients with T2D. The results will be disseminated in peer-reviewed journals and at scientific conferences. Hokkaido University Certified Review Board (CRB no.1180001) has approved the protocol (no. 020-013). TRIAL REGISTRATION NUMBER: UMIN000045270 in the University Hospital Medical Information Network; jRCT1011210032 in the Japan Registry of Clinical Trials.
  • SGLT2阻害薬はミトコンドリア機能の改善を介し膵β細胞量・機能を保護する
    山内 裕貴; 中村 昭伸; 横田 卓; 高橋 清彦; 川田 晋一朗; 土田 和久; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 安斉 俊久; 田中 伸哉; 寺内 康夫; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, 98, 1, 361, 361, (一社)日本内分泌学会, Apr. 2022
    Japanese
  • 日本人肥満症合併2型糖尿病患者への減量・代謝改善手術により代謝疾患は改善し治療薬を減量し得る
    大藤 悠理; 曹 圭龍; 海老原 裕磨; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 65, Suppl.1, S, 288, (一社)日本糖尿病学会, Apr. 2022
    Japanese
  • 日本人肥満2型糖尿病における腹腔鏡下スリーブ状胃切除術が脂肪肝に及ぼす効果 前向きコホート研究
    大江 悠希; 高瀬 崇宏; 曹 圭龍; 小川 浩司; 海老原 裕磨; 吉川 仁人; 西田 睦; 宮 愛香; 野本 博司; 亀田 啓; 荘 拓也; 須田 剛生; 中村 昭伸; 倉島 庸; 阿保 大介; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 65, Suppl.1, S, 139, (一社)日本糖尿病学会, Apr. 2022
    Japanese
  • Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis.
    Yuka Takahashi; Hiraku Kameda; Aika Miya; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Hiroki Nishimura; Hirokazu Kimura; Masaru Suzuki; Satoshi Konno; Ai Shimizu; Yoshihiro Matsuno; Michinari Okamoto; Hiroaki Motegi; Naoko Iwata; Haruki Fujisawa; Atsushi Suzuki; Yoshihisa Sugimura; Hideaki Miyoshi; Tatsuya Atsumi
    Pituitary, 25, 2, 321, 327, Apr. 2022, [International Magazine]
    English, Scientific journal, PURPOSE: To explore the clinical significance of anti-rabphillin-3A antibody for the differential diagnosis of lymphocytic panhypophysitis. METHODS AND RESULTS: A 58-year-old Japanese man developed uveitis of unknown cause in 2017. In 2019, he became aware of polyuria. In August 2020, he noticed transient diplopia and was diagnosed with right abducens nerve palsy. At the same time, he complained of fatigue and loss of appetite. Head magnetic resonance imaging demonstrated enlargement of the pituitary stalk and pituitary gland, corresponding to hypophysitis. Hormone stimulation tests showed blunted responses with respect to all anterior pituitary hormones. Central diabetes insipidus was diagnosed on the basis of a hypertonic saline loading test. Taking these findings together, a diagnosis of panhypopituitarism was made. Computed tomography showed enlargement of hilar lymph nodes. Biopsies of the hilar lymph nodes revealed non-caseating epithelioid cell granulomas that were consistent with sarcoidosis. Biopsy of the anterior pituitary revealed mild lymphocyte infiltration in the absence of IgG4-positive cells, non-caseating granulomas, or neoplasia. Western blotting revealed the presence of anti-rabphilin-3A antibody, supporting a diagnosis of lymphocytic panhypophysitis. Because the patient had no visual impairment or severe uveitis, we continued physiological hormone replacement therapy and topical steroid therapy for the uveitis. CONCLUSION: To the best of our knowledge, this is the first case of anti-rabphilin 3A antibody positive lymphocytic panhypophysitis comorbid with sarcoidosis, diagnosed by both pituitary and hilar lymph node biopsy. The utility of anti-rabphilin-3A antibody for the differential diagnosis of hypophysitis like this case should be clarified with further case studies.
  • Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.
    Shinichiro Kawata; Akinobu Nakamura; Hideaki Miyoshi; Kelaier Yang; Ikumi Shigesawa; Yuki Yamauchi; Kazuhisa Tsuchida; Kazuno Omori; Kiyohiko Takahashi; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Yasuo Terauchi; Tatsuya Atsumi
    Diabetes, obesity & metabolism, 24, 3, 391, 401, Mar. 2022, [International Magazine]
    English, Scientific journal, AIM: To investigate how subchronic administration of a glucokinase activator (GKA) results in attenuation of the hypoglycaemic effect in the diabetic condition. MATERIALS AND METHODS: Six-week-old db/db mice were fed standard chow containing a GKA or the sodium-glucose cotransporter 2 inhibitor ipragliflozin for 1, 6, 14 or 28 days. We performed histological evaluation and gene expression analysis of the pancreatic islets and liver after each treatment and compared the results to those in untreated mice. RESULTS: The unsustained hypoglycaemic effect of GKAs was reproduced in db/db mice in conjunction with significant hepatic fat accumulation. The initial reactions to treatment with the GKA in the liver were upregulation of the gene expression of carbohydrate response element-binding protein beta (Chrebp-b) and downregulation of phosphoenolpyruvate carboxykinase (Pepck) on day 1. Subsequently, the initial changes in Chrebp-b and Pepck disappeared and increases in the expression of genes involved in lipogenesis, including acetyl-CoA carboxylase and fatty acid synthase, were observed. There were no significant changes in the pancreatic β cells nor in hepatic insulin signalling. CONCLUSIONS: The GKA showed an unsustained hypoglycaemic effect and promoted hepatic fat accumulation in db/db mice. Dynamic changes in the expression of hepatic genes involved in lipogenesis and gluconeogenesis could affect the unsustained hypoglycaemic effect of the GKA despite no changes in pancreatic β-cell function and mass.
  • Impact of low-starch high-fiber pasta on postprandial blood glucose.
    Chiho Oba-Yamamoto; Jun Takeuchi; Akinobu Nakamura; Hiroshi Nomoto; Hiraku Kameda; Kyu Y Cho; Tatsuya Atsumi; Hideaki Miyoshi
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 32, 2, 487, 493, Feb. 2022, [International Magazine]
    English, Scientific journal, BACKGROUND AND AIMS: Almost all of the energy in noodle dishes is derived from carbohydrates, particularly starch. Recently, we invented a pasta with reduced starch content to about 50% and increased dietary fiber content, designated low-starch high-fiber pasta (LSHFP). In this study, we investigated the ingestion of LSHFP on the postprandial glucose response as a breakfast meal. METHODS AND RESULT: This was a randomized, single-blinded, crossover study. The postprandial glucose area under the curve for 4 h (4h-gluAUC), as the primary outcome, and the extent of postprandial glucose elevation (maxΔBG) were evaluated using a continuous glucose monitoring system in healthy volunteers and patients with type 2 diabetes (T2DM) after intake of LSHFP, standard pasta (SP), and rice. The amount of total carbohydrate was matched between LSHFP and SP. Ten individuals with T2DM and 10 individuals who did not have T2DM and were otherwise healthy were enrolled in this crossover study. The 4h-gluAUC for LSHFP (137.6 ± 42.2 mg/dL・h) was significantly smaller than the 4h-gluAUC for rice (201.7 ± 38.7 mg/dL・h) (p = 0.001) and SP (178.5 ± 59.2 mg/dL・h) (p = 0.020). The maxΔBG for rice (118.6 ± 24.2 mg/dL) was significantly higher than those for SP (87.5 ± 19.9 mg/dL) (p < 0.001) and LSHFP (72.7 ± 26.2 mg/dL) (p = 0.001), while the maxΔBG for LSHFP (p = 0.047) was significantly lower than that for SP, in T2DM patients as well as in healthy participants. CONCLUSIONS: This study demonstrated that LSHFP can reduce postprandial glucose elevation compared with SP in both healthy participants and patients with T2DM.
  • Letter to the Editor: False Hypercortisolemia Due to Abnormal Albumin-Cortisol Binding in a Patient with Familial Dysalbuminemic Hyperthyroxinemia.
    Koki Chiba; Hiraku Kameda; Aika Miya; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Shigeki Jin; Kotaro Matoba; Hideaki Miyoshi; Tatsuya Atsumi
    Thyroid : official journal of the American Thyroid Association, 32, 2, 219, 220, Feb. 2022, [International Magazine]
    English
  • 患者・市民参画(PPI)ワークショップトライアルの検討
    堀江 奈穂; 渡邊 祐介; 曹 圭龍; 豊田 有希; 菊池 ちひろ; 佐藤 典宏
    日本臨床薬理学会学術総会抄録集, 43, 3-C-O10-4, 一般社団法人 日本臨床薬理学会, 2022
    Japanese, 【目的】患者・市民参画(PPI: patient and public involvement)は1980年代から欧米で始まり、日本においても患者中心(Patient-centricity)の概念と併せ、診療のみならず研究開発の領域にも取り入れられつつある。日本医療研究開発機構(AMED)は、PPIを「医学研究・臨床試験プロセスの一環として、研究者が患者・市民の知見を参考とすること」と定義し、患者・市民参画(PPI)ガイドブック(以下、ガイドブック)を公開し、啓発を行っている。北海道大学病院医療・ヘルスサイエンス研究開発機構(以下、機構)では、2021年に機構職員と学外有識者・一般の立場の方から成るPPIプロジェクトチームを立ち上げ、「臨床研究のプロセスにおいて、患者・市民と研究者等が協働・共創する社会の構築」を目標に取り組みを始めた。患者・市民の立場に近い非医療従事者を対象にワークショップ (以下、WS)を試験的に実施し、参加者評価に基づきWSについて検討を行った。【方法】ガイドブックを参考に「説明同意文書」に対する意見収集をテーマとし、治験・臨床研究に関する基礎知識習得を目標とするレクチャーと、説明同意書を題材に意見交換を行うグループワークで編成される半日型WSを計画した。非医療従事者を中心とした機構職員を対象にWSを2回試行し、選択回答式(ネットプロモータースコア(NPS)形式を含む)および自由回答形式設問からなる参加者アンケートを実施した。結果は全体NPS(第1回;第2回)で記載した。【結果・考察】WSの参加者は計23名(第1回13名、第2回10名)であった。第1回の振り返りとアンケート結果から、レクチャーの重複内容の削除やグループワーク時間の延長を含むWSの変改を行った。アンケート結果の満足度NPSは67%(55%;80%)、推奨度NPSは14%(-9%;20%)で、いずれも第2回に改善を認めた。少数だが「内容が難しかった」という意見も認め、質問や意見を出し易い雰囲気づくり、発言の少ない参加者へ意見を求めるスキル、さらに意見調整や時間管理などの課題も明確となった。【結論】WSの試行経験と参加者からのフィードバックを踏まえ、WSの最適化と実施体制の強化に継続的に取り組んで行きたい。学内外の研究者、研究支援者へのさらなるPPI啓発に加え、実際の患者・市民や学生を対象としたWSの実施へと活動を発展させたい。
  • Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
    Yuki Oe; Hiroshi Nomoto; Akinobu Nakamura; Saki Kuwabara; Yuka Takahashi; Ayano Yasui; Rimi Izumihara; Aika Miya; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes research, 2022, 5603864, 5603864, 2022, [International Magazine]
    English, Scientific journal, Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare the effect of IDegLira and the combination on GV. We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor. GV was analyzed using continuous glucose monitoring (CGM) before and after switching the medication to IDegLira. The principal endpoint was the change in mean amplitude of glycemic excursions (MAGE). Other indices of GV and CGM parameters were analyzed as the secondary endpoints. Fifteen participants were enrolled and 12 completed the study. In these participants, the DPP-4 inhibitor and insulin degludec were discontinued, and the equivalent dose of IDegLira was commenced. Switching to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration. Analysis of the ambulatory glucose profile showed marked reductions in postprandial glucose concentration. Nocturnal glucose concentration was similar under the two treatment regimens. IDegLira improved GV as well as the mean and the postprandial glucose concentration by switching from insulin degludec plus DPP-4 inhibitor combination. IDegLira might be beneficial for patients being treated with low-dose basal insulin.
  • Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
    Hikaru Kamoshima; Hiroshi Nomoto; Kumiko Yamashita; Yuka Takahashi; Kazuhisa Tsuchida; Saki Kuwabara; Aika Miya; Kyu Yong Cho; Hiraku Kameda; Akinobu Nakamura; Tatsuya Atsumi; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Yuri Ono; Hideaki Miyoshi
    Endocrine journal, 69, 5, 495, 509, 25 Nov. 2021, [Domestic magazines]
    English, Scientific journal, Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are well-established means of improving glycemia and preventing cardio-renal events in patients with type 2 diabetes. However, their efficacy and safety have yet to be fully characterized in patients with type 1 diabetes (T1D). We studied patients with T1D who regularly attended one of five diabetes centers and treated with an SGLT2i (ipragliflozin or dapagliflozin) for >52 weeks, and the changes in HbA1c, body mass, insulin dose, and laboratory data were retrospectively evaluated and adverse events (AEs) recorded during December 2018 to April 2021. A total of 216 patients with T1D were enrolled during the period. Of these, 42 were excluded owing to short treatment periods and 15 discontinued their SGLT2i. The mean changes in glycated hemoglobin (HbA1c), body mass, and insulin dose were -0.4%, -2.1 kg, and -9.0%, respectively. The change in HbA1c was closely associated with the baseline HbA1c (p < 0.001), but not with the baseline body mass or renal function. The basal and bolus insulin doses decreased by 18.2% and 12.6%, respectively, in participants with a baseline HbA1c <8%. The most frequent AE was genital infection (2.8%), followed by diabetic ketoacidosis (DKA; 1.4%). None of the participants experienced severe hypoglycemic events. In conclusion, the administration of an SGLT2i in addition to intensive insulin treatment in patients with T1D improves glycemic control and body mass, without increasing the incidence of hypoglycemia or DKA.
  • Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report.
    Yuki Oe; Hiraku Kameda; Hiroshi Nomoto; Keita Sakamoto; Takeshi Soyama; Kyu Yong Cho; Akinobu Nakamura; Koji Iwasaki; Daisuke Abo; Kohsuke Kudo; Hideaki Miyoshi; Tatsuya Atsumi
    Medicine, 100, 46, e27895, 19 Nov. 2021, [International Magazine]
    English, Scientific journal, RATIONALE: Tumor-induced osteomalacia (TIO) is curable by tumor resection, but detection of the tumor can be challenging. Overproduction of fibroblast growth factor 23 (FGF23) by the tumor causes hypophosphatemia and consequently induces inappropriate bone turnover. Conventionally oral phosphate supplementation was the only treatment for TIO, but had risks of hypercalciuria and nephrocalcinosis. Burosumab, a human monoclonal anti-FGF23 antibody, was recently post-marketed in Japan against for FGF23-related hypophosphatemia. Herein, we present a case of TIO with undetectable tumor that was successfully treated with burosumab. PATIENT CONCERNS: A 47-year-old woman was forced to use a wheelchair because of pain in both feet. DIAGNOSIS: Laboratory findings showed hypophosphatemia, elevated bone markers, and high serum FGF23 without renal tubular defects. Imaging studies revealed bone atrophy in the feet, decreased bone density, and multiple pseudofractures in the talar, sacral, and L5 vertebral regions. After excluding drug-induced and hereditary osteomalacia, we diagnosed her as TIO. INTERVENTIONS: Comprehensive imaging studies and stepwise venous sampling failed to localize the tumor, and we started to administer subcutaneous burosumab. OUTCOMES: After administration of burosumab, her serum phosphate was normalized without phosphate supplementation within 2 months. Improvement of pseudofractures, relief of pain evaluated by a visual analog scale, and normalization of bone biomarkers were observed. The patient was able to stand by herself after 6 months administration of burosumab. LESSONS: This is the first report in clinical practice to demonstrate favorable effects of burosumab, including not only normalization of serum phosphate but also improvements of pseudofractures and subjective pain, in a patient with TIO and undetectable tumor.
  • Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
    Reina Hashimoto-Kameda; Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Kazuno Omori; So Nagai; Sachiko Edagawa; Shinichiro Kawata; Jun Takeuchi; Hiraku Kameda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes research and clinical practice, 180, 109069, 109069, 23 Sep. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, AIMS: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces clinic blood pressure (BP), but the effects on BP circadian rhythm remain unclear. The present study aimed to determine the nighttime antihypertensive effect of SGLT2i compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) in patients with type 2 diabetes and hypertension. MATERIALS AND METHODS: In this randomized, open-label, parallel-group trial, patients treated with DPP-4i were either switched to luseogliflozin 2.5 mg/day (Luseo group;n = 30) or continued DPP-4i (DPP-4i group;n = 26). The patients undertook 24-h ambulatory BP monitoring before and 8 weeks after the group allocation. The primary endpoint was mean change in nighttime systolic BP (SBP). RESULTS: Nighttime SBP, as well as daytime SBP, was significantly reduced in the Luseo group compared with the DPP-4i group (nighttime, -4.0 ± 11.4 vs. 3.6 ± 10.7 mmHg,P = 0.01; daytime, -4.4 ± 10.9 vs. 3.7 ± 11.9 mmHg,P = 0.01). Similarly, nighttimepulse rate(PR) was significantly reduced in the Luseo group (-2.0 ± 4.8 vs. 0.9 ± 4.8 bpm,P = 0.03). The proportion of patients with abnormal BP circadian rhythms (non-dipper pattern plus riser pattern) was significantly lower in the Luseo group (36.6% vs. 56.7%,P < 0.05). CONCLUSIONS: Switching from DPP-4i to luseogliflozin decreased nighttime SBP and PR; moreover, BP circadian rhythm was improved.
  • Improved Mitochondria! Function by Luseogliflozin Prevents Pancreatic Beta-Cell Damage
    Yuki Yamauchi; Akinobu Nakamura; Takashi Yokota; Kiyohiko Takahashi; Shinichiro Kawata; Kazuhisa Tsuchida; Kazuno Omori; Hiroshi Nomoto; Hiraku Kameda; Kyuyong Cho; Toshihisa Anzai; Shinya Tanaka; Yasuo Terauchi; Hideaki Miyoshi; Tatsuya Atsumi
    DIABETES, 70, Jun. 2021
    English
  • Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study.
    Tomonori Sekizaki; Hiraku Kameda; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Kiyohiko Takahashi; Arina Miyoshi; Norio Wada; Jun Takeuchi; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
    Journal of diabetes investigation, 12, 11, 1978, 1982, 17 May 2021, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, Dipeptidyl peptidase-4 (DPP-4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP-4 might affect the immune system. The current multicenter observational case-control study was carried out to investigate the effects of DPP-4 inhibitor (DPP-4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP-4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non-exacerbation group. The frequency of DPP-4i administration was significantly higher in the exacerbation group (88%) than that in the non-exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP-4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP-4i administration is associated with GD exacerbation.
  • Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
    Yuki Oe; Hiraku Kameda; Hiroshi Nomoto; Keita Sakamoto; Takeshi Soyama; Kyu Yong Cho; Akinobu Nakamura; Daisuke Abo; Kohsuke Kudo; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of the Endocrine Society, 5, Supplement_1, A194, A194, The Endocrine Society, 03 May 2021
    Scientific journal, Abstract
    Background: Fibroblast growth factor 23 (FGF23) decreases serum phosphate levels by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption by decreasing serum 1,25-dihydroxyvitamin D level, thereby regulating phosphate metabolism. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by FGF23 overproduction by tumor tissue. Resecting the responsible tumor is a radical treatment for TIO. When the responsible tumor is undetectable, phosphate and active vitamin D administration is recommended. However, supplementation alone is frequently insufficient to maintain phosphate levels and it is difficult to prevent the complications associated with medical therapy, including hypercalciuria and nephrocalcinosis. Recently, burosumab, a human monoclonal anti-FGF23 antibody, has been approved in Japan as a therapeutic agent for FGF23-related hypophosphatemia. Here, we present a patient with TIO effectively treated with burosumab in the absence of identification of tumour location. Clinical case: A 47-year-old female developed pain and edema of the feet; however, the cause could not be determined at local hospitals. Afterwards, she developed marked bone atrophy in the feet and was referred to our hospital. Her age at symptom onset, hypophosphatemia (serum P, 1.9 mg/dl, 2.7 mg/dl &lt; n &lt; 4.6 mg/dl), high serum FGF23 level (630 pg/ml, 16 pg/ml &lt; n &lt; 69 pg/ml), and decreased 1,25-dihydroxyvitamin D level (12.9 pg/ml, 20 pg/ml &lt; n &lt; 60 pg/ml) indicated FGF23-related osteomalacia. She was not having any medication at the time of diagnosis, including saccharified iron oxide or iron polymaltose. Urinary phosphate excretion increased without renal tubular defect; therefore, hypophosphatemic osteomalacia was diagnosed. MRI showed high signal intensity in the talus, sacral, and L5 vertebral regions, indicating multiple pseudofractures. Comprehensive imaging studies, including systemic CT scan and 111In-pentetreotide scintigraphy, did not reveal any tumors despite the suspicion of TIO. Next, we performed systemic venous sampling, which revealed high FGF23 level in the left external iliac vein. Second venous sampling limited to the left lower limb exhibited high FGF23 level in the posterior tibial vein. However, an additional imaging study limited to the left foot could not identify any tumors. Genetic variation was negative for potentially responsible genes, including PHEX and FGF23. We decided to administer burosumab to normalize serum phosphate level without phosphate supplementation. Within 2 months, pain was relieved and the visual analog scale scores also improved from 10 to 6. Moreover, bone MRI showed improved pseudofractures. Conclusion: Burosumab administration was effective for TIO of unknown origin, and it improved not only laboratory findings but also clinical symptoms in this case.
  • 膵特異的グルコキナーゼの抑制が2型糖尿病病態下の膵β細胞量を保持する
    大森 一乃; 中村 昭伸; 三好 秀明; 川田 晋一朗; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, 64, Suppl.1, I, 3, (一社)日本糖尿病学会, May 2021
    Japanese
  • db/dbマウスを用いたグルコキナーゼ活性化薬の血糖降下作用消失機序の解明
    川田 晋一朗; 中村 昭伸; 三好 秀明; 重沢 郁美; 山内 裕貴; 土田 和久; 大森 一乃; 高橋 清彦; 北尾 直之; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, 64, Suppl.1, P, 1, (一社)日本糖尿病学会, May 2021
    Japanese
  • SGLT2阻害薬はミトコンドリア機能の改善を介し膵β細胞を保護する
    山内 裕貴; 中村 昭伸; 横田 卓; 高橋 清彦; 川田 晋一朗; 土田 和久; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 安斉 俊久; 田中 伸哉; 寺内 康夫; 三好 秀明; 渥美 達也
    糖尿病, 64, Suppl.1, III, 6, (一社)日本糖尿病学会, May 2021
    Japanese
  • 糖代謝障害を伴った高度肥満症患者における腹腔鏡下スリーブ状胃切除術による糖・脂質代謝および肝臓への好影響
    安井 彩乃; 曹 圭龍; 大江 悠希; 野本 博司; 亀田 啓; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 64, Suppl.1, I, 4, (一社)日本糖尿病学会, May 2021
    Japanese
  • 耐糖能異常合併肥満症患者における腹腔鏡下スリーブ状胃切除後の骨密度低下
    上垣 里紗; 大江 悠希; 亀田 啓; 高瀬 崇宏; 野本 博司; 曹 圭龍; 中村 昭伸; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, 64, Suppl.1, P, 6, (一社)日本糖尿病学会, May 2021
    Japanese
  • Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report.
    Yuki Yamauchi; Hiraku Kameda; Kazuno Omori; Michio Tani; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Shinya Tanaka; Tatsuya Atsumi
    BMC endocrine disorders, 21, 1, 84, 84, 27 Apr. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Subclinical Cushing's disease (SCD) is defined by corticotroph adenoma-induced mild hypercortisolism without typical physical features of Cushing's disease. Infection is an important complication associated with mortality in Cushing's disease, while no reports on infection in SCD are available. To make clinicians aware of the risk of infection in SCD, we report a case of SCD with disseminated herpes zoster (DHZ) with the mortal outcome. CASE PRESENTATION: An 83-year-old Japanese woman was diagnosed with SCD, treated with cabergoline in the outpatient. She was hospitalized for acute pyelonephritis, and her fever gradually resolved with antibiotics. However, herpes zoster appeared on her chest, and the eruptions rapidly spread over the body. She suddenly went into cardiopulmonary arrest and died. Autopsy demonstrated adrenocorticotropic hormone-positive pituitary adenoma, renal abscess, and DHZ. CONCLUSIONS: As immunosuppression caused by SCD may be one of the triggers of severe infection, the patients with SCD should be assessed not only for the metabolic but also for the immunodeficient status.
  • Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring.
    Aika Miya; Akinobu Nakamura; Takahisa Handa; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; So Nagai; Yoichi M Ito; Hideaki Miyoshi; Tatsuya Atsumi
    Scientific reports, 11, 1, 9057, 9057, 27 Apr. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, The contribution of endogenous insulin secretion to glycemic variability (GV) may differ between patients with impaired insulin secretion and those with preserved secretion. Our objective was to determine the linearity of the relationship between fasting C-peptide (CPR) as a marker of endogenous insulin secretion and GV in type 2 diabetes (T2DM), regardless of the type of antidiabetic treatment. We conducted a prospective observational study using continuous glucose monitoring obtained from 284 Japanese outpatients with T2DM with various HbA1c values and antidiabetic treatment. We constructed a prediction curve of base-line CPR versus coefficient of variation (CV) and identified the clinical factors associated with CV using multiple regression analysis. Fasting CPR showed a significant negative log-linear relationship with CV (P < 0.0001), and the latter being strikingly high in the low-CPR group. The multiple regression analysis showed that low CPR was an independent predictor of high CV (P < 0.0001). The significant correlations were sustained in both patients with/without insulin treatment. The contribution of endogenous insulin secretion to GV depends on the extent of insulin secretion impairment. Fasting CPR may represent a useful indicator of GV instability in T2DM.
  • The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study.
    Takahisa Handa; Akinobu Nakamura; Aika Miya; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; So Nagai; Narihito Yoshioka; Hideaki Miyoshi; Tatsuya Atsumi
    Diabetology & metabolic syndrome, 13, 1, 37, 37, 01 Apr. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: This study aimed to explore predictive factors of time below target glucose range (TBR) ≥ 1% among patients' characteristics and glycemic variability (GV) indices using continuous glucose monitoring data in elderly patients with type 2 diabetes. METHODS: We conducted a prospective observational study on 179 (71 female) Japanese outpatients with type 2 diabetes aged ≥ 65 years. The characteristics of the participants with TBR ≥ 1% were evaluated by multivariate logistic regression analysis. Receiver-operating characteristic (ROC) curve analyses of GV indices, comprising coefficient of variation (CV), standard deviation, and mean amplitude of glycemic excursions, were performed to identify the optimal index for the identification of patients with TBR ≥ 1%. RESULTS: In the multivariate logistic regression analysis, none of the clinical characteristics, including HbA1c and C-peptide index, were independent markers for TBR ≥ 1%, while all three GV indices showed significant associations with TBR ≥ 1%. Among the three GV indices, CV showed the best performance based on the area under the curve in the ROC curve analyses. CONCLUSIONS: Among elderly patients with type 2 diabetes, CV reflected TBR ≥ 1% most appropriately among the GV indices examined. Trial registration UMIN-CTR: UMIN000029993. Registered 16 November 2017.
  • Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Hiroshi Nomoto; Chiho Oba-Yamamoto; Yuka Takahashi; Jun Takeuchi; So Nagai; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes therapy : research, treatment and education of diabetes and related disorders, 12, 3, 955, 964, Mar. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, INTRODUCTION: Glucagon-like peptide (GLP)-1 receptor agonists exert potent hypoglycemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent manner. Once-weekly subcutaneous administration of the GLP-1 receptor agonist semaglutide has beneficial effects on glycemic and body weight control, but it is currently unclear if semaglutide provides superior glycemic control compared to conventional GLP-1 receptor agonists in the Japanese population. We aim to compare the effects of once-weekly subcutaneous semaglutide with those of liraglutide or dulaglutide administration in Japanese patients with T2D. METHODS: This study is a multicenter, prospective, randomized, open-label, blinded-endpoint, parallel-group trial. In total, 100 participants with T2D who have been treated with liraglutide (0.9-1.8 mg/day in plan A) or dulaglutide (0.75 mg/week in plan B) for more than 12 weeks and have a glycated hemoglobin (HbA1c) level of 6.0-9.9% and a body mass index (BMI) of ≥ 22 kg/m2 will be randomized to either continue using their existing GLP-1 receptor agonist or switch to subcutaneous semaglutide once weekly for 24 weeks. Biochemical analysis, physical assessment, and a quality-of-life questionnaire (DTSQ) will be completed at baseline and at the end of the study. The primary endpoint is the effect of semaglutide on the change in HbA1c. The secondary endpoints are the mean changes in total DTSQ score, body mass, abdominal circumference, systolic and diastolic blood pressure, pulse rate, factors associated with improvement in HbA1c and secondary endpoints, side effects, and other laboratory parameters. PLANNED OUTCOMES: The results of the study will provide useful information regarding the effects of switching to semaglutide from other GLP-1 receptor agonists on glycemic control in patients with T2D. ETHICS AND DISSEMINATION: The Hokkaido University Certified Review Board (CRB no. 1180001) has approved the protocol (no. 018-005). The results will be disseminated in peer-reviewed journals and at scientific conferences. TRIAL REGISTRATION: UMIN000042369 in the University Hospital Medical Information Network (UMIN); jRCT1011200008 in the Japan Registry of Clinical Trials (jRCT); pre-results.
  • Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia.
    Natsuki Baba; Hiraku Kameda; Akinobu Nakamura; Kyu Yong Cho; Hiroshi Nomoto; Tomoko Mitsuhashi; Hideaki Miyoshi; Tatsuya Atsumi
    Endocrine journal, 68, 2, 195, 200, 28 Feb. 2021, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, A silent pituitary adenoma (SPA) is characterized by the expression of pituitary hormones, detected by immunohistochemical staining, in the absence of clinical signs or symptoms of hormonal excess. Compared with functional pituitary adenomas, little is known regarding the involvement of SPAs in metabolic disorders. This study aimed to examine the correlations between SPAs and metabolic disorders, including obesity, abnormal glucose tolerance, hypertension and dyslipidemia. Seventy-four patients with nonfunctional pituitary adenomas who underwent a pituitary adenomectomy in Hokkaido University Hospital from 2008 to 2016 were retrospectively examined. Pituitary adenomas were immunohistochemically classified into pituitary hormone positive or negative groups. Twenty whole hormone-negative pituitary adenomas were excluded because we couldn't identify pituitary transcription factors which is necessary for the diagnosis of a null cell adenoma. The preoperative rates of obesity, abnormal glucose tolerance, hypertension and dyslipidemia were compared between each group. Twenty-seven GH positive adenomas (50.0%), 32 gonadotroph positive adenomas (59.3%), 28 TSH positive adenomas (51.9%) and 21 ACTH positive adenomas (38.9%) were identified. Evaluation of the preoperative clinical data showed 25 cases of obesity (46.2%), 16 cases of abnormal glucose tolerance (29.6%), 29 cases of hypertension (53.7%) and 35 cases of dyslipidemia (64.8%). The rate of hypertension was significantly lower in the GH positive group (37.0%) than the GH negative group (70.4%) (p = 0.0140). In the GH negative group, postoperative systolic and diastolic blood pressure levels were significantly lower than preoperative values. GH positive SPAs may affect the homeostasis of blood pressure.
  • Glucokinase is required for high-starch diet-induced beta cell mass expansion in mice.
    Kazuhisa Tsuchida; Akinobu Nakamura; Hideaki Miyoshi; Kelaier Yang; Yuki Yamauchi; Shinichiro Kawata; Kazuno Omori; Kiyohiko Takahashi; Naoyuki Kitao; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Yusuke Seino; Yasuo Terauchi; Tatsuya Atsumi
    Journal of diabetes investigation, 12, 9, 1545, 1554, 27 Feb. 2021, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We aimed to determine whether glucokinase is required for beta cell mass expansion induced by high-starch diet (HSTD)-feeding, as has been shown in its high-fat diet-induced expansion. MATERIALS AND METHODS: Eight-week-old male wild-type (Gck+/+ ) or glucokinase haploinsufficient (Gck+/- ) mice were fed either a normal chow (NC) or an HSTD for 15 weeks. The body weight, glucose tolerance, insulin sensitivity, insulin secretion, and beta-cell mass were assessed. RESULTS: Both HSTD-fed Gck+/+ and Gck+/- mice had significantly higher body weight than NC-fed mice. Insulin and oral glucose tolerance tests revealed that HSTD-feeding did not affect insulin sensitivity nor glucose tolerance in either the Gck+/+ or Gck+/- mice. However, during the oral glucose tolerance test, the 15 minutes' plasma insulin concentration after glucose loading was significantly higher in the HSTD group than that in the NC group for Gck+/+ , but not for Gck+/- mice. Beta cell mass was significantly larger in HSTD-fed Gck+/+ mice than that in NC-fed Gck+/+ mice. In contrast, the beta cell mass of the HSTD-fed Gck+/- mice was not different from that of the NC-fed Gck+/- mice. CONCLUSIONS: The results indicated that HSTD-feeding would increase pancreatic beta-cell mass and insulin secretion in Gck+/+ , but not Gck+/- mice. This observation implies that glucokinase in beta-cells would be required for the increase in beta cell mass induced by HSTD-feeding.
  • Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing Beta-Cell Mass in db/db Mice.
    Kazuno Omori; Akinobu Nakamura; Hideaki Miyoshi; Yuki Yamauchi; Shinichiro Kawata; Kiyohiko Takahashi; Naoyuki Kitao; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Yasuo Terauchi; Tatsuya Atsumi
    Diabetes, 70, 4, 917, 931, 18 Feb. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Efficacy of glucokinase activation on glycemic control is limited to a short-term period. One reason might be related with the excess glucose signalling by glucokinase activation towards beta-cells. In this study, we investigated the effect of glucokinase haploinsufficiency on glucose tolerance as well as beta-cell function and mass using a mouse model of type 2 diabetes. Our results showed that db/db mice with glucokinase haploinsufficiency presented amelioration of glucose tolerance by augmented insulin secretion associated with the increase in beta-cell mass when compared with db/db mice. Gene expression profiling, and immunohistochemical and metabolomic analyses revealed that glucokinase haploinsufficiency in the islets of db/db mice was associated with lower expression of stress-related genes, higher expression of transcription factors involved in the maintenance and maturation of beta-cell function, less mitochondrial damage, and a superior metabolic pattern. These effects of glucokinase haploinsufficiency could preserve beta-cell mass under diabetic conditions. These findings verified our hypothesis that optimizing excess glucose signalling in beta-cells by inhibiting glucokinase could prevent beta-cell insufficiency, leading to improving glucose tolerance in diabetes status by preserving beta-cell mass. Therefore, glucokinase inactivation in beta-cells could, paradoxically, be a potential strategy for the treatment of type 2 diabetes.
  • Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.
    Koki Chiba; Hiroshi Nomoto; Akinobu Nakamura; Kyu Yong Cho; Kumiko Yamashita; Yui Shibayama; Aika Miya; Hiraku Kameda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 12, 2, 176, 183, Feb. 2021, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. MATERIALS AND METHODS: Patients with type 1 diabetes who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day-to-day glucose variability, as the primary end-point, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring. RESULTS: A total of 51 patients (37 women; mean age 52.7 years) were included. Glycated hemoglobin and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6-38.7 ± 24.3 units/day). Continuous glucose monitoring data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P < 0.001). The percentage of time per day within the target glucose range of 70-180 mg/dL significantly increased (from 42.2 to 55.5%, P < 0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. CONCLUSIONS: SGLT2i improved day-to-day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with type 1 diabetes, and reduced glycated hemoglobin, body mass and the required insulin dose.
  • Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
    Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuno Omori; Kazuhisa Tsuchida; Aika Miya; Ikumi Shigesawa; Kenichi Tsuchida; Shingo Yanagiya; Hiraku Kameda; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Naoki Nishimoto; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 12, 8, 1417, 1424, 09 Jan. 2021, [Peer-reviewed], [Lead author], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We recently reported the beneficial effect of the combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Additional favorable effects of combination therapy were explored in this secondary analysis. MATERIALS AND METHODS: The CALMER study was a multicenter, open-label, prospective, randomized, parallel-group comparison trial for type 2 diabetes mellitus involving continuous glucose monitoring under meal tolerance tests. Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The continuous glucose monitoring metrics, including time in target range, were investigated. RESULTS: All 99 participants (mean age 62.3 years; mean glycated hemoglobin 7.4%) completed the trial. The time in target range was increased in the COMB group (71.2-82.7%, P < 0.001). The extent of the reduction in time above target range was significantly larger in the COMB group compared with the SWITCH group (-14.8% vs -7.5%, P < 0.01). Area under the curve values for glucose at 120 min after all meal tolerance tests were significantly decreased in the COMB group compared with the SWITCH group (P < 0.05). CONCLUSIONS: Sodium-glucose cotransporter 2 inhibitor combined with dipeptidyl peptidase-4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy.
  • Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
    Chiho Oba-Yamamoto; Hiraku Kameda; Hideaki Miyoshi; Tomonori Sekizaki; Takahiro Takase; Tsuyoshi Yanagimachi; Yukihiro Fujita; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; So Nagai; Tatsuya Atsumi
    Internal medicine (Tokyo, Japan), 60, 15, 2375, 2383, 2021, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, Objective Glucose-dependent insulinotropic polypeptide (GIP) is speculated to worsen growth hormone (GH) hypersecretion in acromegaly and to be a cause of paradoxical increases in GH (PI-GH) during 75-g oral glucose tolerance testing (75-g OGTT). Dipeptidyl peptidase-4 inhibitors (DPP4is), which increase the circulating concentration of active GIP, are frequently administered to diabetic patients, including those with acromegaly. We aimed to determine whether or not the administration of a DPP4i increases GH concentration, especially in patients demonstrating PI-GH during a DPP4i-OGTT, in which a DPP4i was administered immediately before 75-g OGTT. Methods This prospective cross-sectional study was carried out on acromegalic patients admitted to Hokkaido University hospital between June 2011 and May 2018. The participants underwent both 75-g OGTT and DPP4i-OGTT. For those who underwent surgery, immunohistochemical staining and quantitative polymerase chain reaction (PCR) for the GIP receptor (GIPR) were performed on the resected pituitary adenomas. Results Twenty-five percent of the participants had PI-GH confirmed (3 of 12 cases). Two of the three participants who demonstrated PI-GH exhibited higher circulating GH concentrations during DPP4i-OGTT than during OGTT. The increase in plasma glucose was reduced during DPP4i-OGTT compared to during 75-g OGTT, suggesting that the increase in GH during DPP4i-OGTT was due not to high glucose concentrations but instead increased GIP caused by the administration of DPP4i. The adenoma from one participant with PI-GH displayed positive immunostaining for GIPR and a higher GIPR messenger ribonucleic acid (mRNA) expression than the others. Conclusion DPP4i may enhance the GH secretion response during glucose loading, especially in individuals with PI-GH.
  • Successful management of a patient with active Cushing‍'‍s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
    Akiko Yuno; Yoshiyuki Kenmotsu; Yuka Takahashi; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Yu Yamashita; Junichi Nakamura; Sho Nakakubo; Keisuke Kamada; Masaru Suzuki; Hirokazu Sugino; Naoko Inoshita; Satoshi Konno; Hideaki Miyoshi; Tatsuya Atsumi; Yutaka Sawamura; Akira Shimatsu
    Endocrine journal, 68, 4, 477, 484, 24 Dec. 2020, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, We provide the details of the successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient was a 27-year-old Japanese female healthcare worker who was scheduled to undergo pituitary surgery for Cushing's disease. She had been in close contact with an undiagnosed patient infected with COVID-19 and then developed COVID-19 pneumonia. Despite a lack of known risk factors associated with severe COVID-19 infection, the patient's dyspnea worsened and her respiratory condition deteriorated, as indicated by the need for 7 L/min oxygen supply by mask to maintain her oxygen saturation at >90%. Medical treatment was initiated to control hypercortisolism by the 'block and replace' regimen using steroidogenesis inhibitors and hydrocortisone. The COVID-19 pneumonia improved with multi-modal treatment including antiviral therapy. One month later, after a negative severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) test result and with appropriate protection against virus transmission to medical staff in the operating room and daily medical care nurses, trans-sphenoidal surgery was performed by our highly experienced pituitary surgeon. One month after the surgery, the patient's basal ACTH and cortisol levels and urinary free cortisol were all under the detection limit. Surgical remission was expected. Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases.
  • Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Aika Miya; Akinobu Nakamura; Kyu Yong Cho; Shinichiro Kawata; Hiroshi Nomoto; So Nagai; Hajime Sugawara; Shinji Taneda; Kazuhisa Tsuchida; Kazuno Omori; Hiroki Yokoyama; Jun Takeuchi; Shin Aoki; Yoshio Kurihara; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 12, 8, 1395, 1399, 16 Dec. 2020, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase-4 inhibitor and a sodium-glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase-4 inhibitor to a sodium-glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS: A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel-group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C-peptide (CPR) divided at baseline by the median. RESULTS: ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2 ± 28.3 vs -20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS: COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.
  • Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Kyu Yong Cho; Akinobu Nakamura; Kazuno Omori; Takahiro Takase; Aika Miya; Kohei Yamamoto; Hiroshi Nomoto; Hiraku Kameda; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 12, 7, 1272, 1277, 01 Nov. 2020, [Peer-reviewed], [Lead author], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non-inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium-glucose cotransporter inhibitors for NAFLD. MATERIALS AND METHODS: In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ-glutamyl transpeptidase, was used for the evaluation of NAFLD. RESULTS: A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. CONCLUSION: Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.
  • Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment.
    Aika Miya; Akinobu Nakamura; Takahisa Handa; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
    Journal of diabetes investigation, 12, 5, 738, 746, 06 Oct. 2020, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: To identify the coefficient of variation (CV) threshold for unstable glucose variability (GV) and hypoglycemia, and to characterize a patient population with unstable GV and hypoglycemia. MATERIALS AND METHODS: This was an observational study that enrolled 284 Japanese outpatients with type 2 diabetes who underwent continuous glucose monitoring. The C-peptide index (CPI =  × 100) was used as a marker of endogenous insulin secretion. The CV threshold between stable and unstable GV was defined as the upper limit of the CV distribution in the subgroup of patients who did not receive insulin nor insulin secretagogues (relatively stable GV subgroup, n = 104). The optimal CV range corresponding to time below target range ≥4% was determined for all patients using receiver operating characteristic curve analysis. Various characteristics of patients with unstable GV and hypoglycemia were extracted using multivariate logistic regression analysis. RESULTS: The upper limit of the CV in the relatively stable GV subgroup was 40. The optimal CV range corresponding to time below target range ≥4% was also defined as CV ≥40 (area under the curve 0.85) for all patients. The CPI was an independent risk for CV ≥40 (odds ratio 0.17, 95% confidence interval 0.04-0.50, P < 0.01). The optimal cut-off point for CPI to predict a CV cut-off value of 40 was equivalent to 0.81 (area under the curve 0.80). CONCLUSIONS: A CV of 40 discriminates unstable GV and hypoglycemia from stable GV in Japanese outpatients with type 2 diabetes. Impaired insulin secretion might affect the stability of GV.
  • SGLT2阻害薬ルセオグリフロジンによる膵β細胞保護作用の機序の解明
    山内 裕貴; 中村 昭伸; 三好 秀明; 関崎 知紀; 川田 晋一朗; 土田 和久; 柴山 惟; 大森 一乃; 高橋 清彦; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, 63, Suppl.1, S, 239, (一社)日本糖尿病学会, Aug. 2020
    Japanese
  • 高炭水化物食長期摂取による膵β細胞量増加作用におけるグルコキナーゼの役割
    土田 和久; 中村 昭伸; 三好 秀明; Kelaier Yang; 関崎 知紀; 山内 裕貴; 川田 晋一朗; 柴山 惟; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 清野 祐介; 寺内 康夫; 渥美 達也
    糖尿病, 63, Suppl.1, S, 260, (一社)日本糖尿病学会, Aug. 2020
    Japanese
  • Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
    Kyu Yong Cho; Akinobu Nakamura; Chiho Oba-Yamamoto; Kazuhisa Tsuchida; Shingo Yanagiya; Naoki Manda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes & metabolism journal, 44, 4, 532, 541, Aug. 2020, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal, BACKGROUND: To explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes mellitus (T2DM). METHODS: In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, participants on basal insulin therapy were switched to IDegAsp (IDegAsp group; n=30) or continued basal insulin (Basal group; n=29). The primary endpoint was the superiority of IDegAsp in causing changes in the daily blood glucose profile, especially post-prandial blood glucose concentration after 12 weeks. RESULTS: Blood glucose concentrations after dinner and before bedtime were lower in the IDegAsp group, and the improvement in blood glucose before bedtime was significantly greater in the IDegAsp group than in the Basal group at 12 weeks (-1.7±3.0 mmol/L vs. 0.3±2.1 mmol/L, P<0.05). Intriguingly, glycemic control after breakfast was not improved by IDegAsp injection before breakfast, in contrast to the favorable effect of injection before dinner on blood glucose after dinner. Glycosylated hemoglobin significantly decreased only in the IDegAsp group (58 to 55 mmol/mol, P<0.05). Changes in daily insulin dose, body mass, and recorded adverse effects, including hypoglycemia, were comparable between groups. CONCLUSION: IDegAsp was more effective than basal insulin at reducing blood glucose after dinner and before bedtime, but did not increase the incidence of hypoglycemia. Switching from basal insulin to IDegAsp does not increase the burden on the patient and positively impacts glycemic control in patients with T2DM.
  • Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia.
    Chiho Oba-Yamamoto; Jun Takeuchi; Akinobu Nakamura; Ryoko Takikawa; Ayano Ozaki; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 12, 4, 651, 657, 29 Jul. 2020, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: Alcohol consumption has been reported to cause hypoglycemia. However, the mechanism involved has not been unequivocally established. This study comprised healthy volunteers. We carried out a prospective trial to compare the effects of glucose and alcohol consumption, alone or in combination, on glucose and lipid metabolism. MATERIALS AND METHODS: A 75-g oral glucose tolerance test (OGTT), a combined 75-g glucose plus 20-g alcohol tolerance test (OGATT) and a 20-g alcohol tolerance test (OATT) were carried out in the participants. Plasma glucose, insulin, triglyceride and ethanol concentrations during each test were compared. RESULTS: We studied 10 participants. Their plasma glucose concentrations 15 and 30 min after the intake of 75 g of glucose were significantly higher during the OGATT than the OGTT. Hypoglycemia occurred in five participants after the OGATT, which was significantly more frequently than after the OGTT (P = 0.046). Hypoglycemia did not occur after the OATT, and the ethanol concentration was significantly lower after the OGATT than the OATT. The changes in triglyceride concentration from 30 min after the consumption of 75 g of glucose were significantly greater during the OGATT than the OGTT. The plasma insulin concentrations peaked after 60 min during both the OGTT and OGATT, and were significantly higher during the OGATT (P = 0.047). There were no differences between the two interventions in the Matsuda or disposition indexes. CONCLUSIONS: Hypoglycemia occurred more frequently after the simultaneous consumption of alcohol plus glucose than after the consumption of glucose alone, suggesting that alcohol in the combination of glucose induces reactive hypoglycemia.
  • 糖尿病合併肥満症患者に対する腹腔鏡下スリーブ状胃切除術への術前寛解予測スコアの検討
    小野 渉; 中村 昭伸; 海老原 裕磨; 曹 圭龍; 亀田 玲奈; 亀田 啓; 野本 博司; 渥美 達也; 三好 秀明; 平野 聡
    糖尿病, 63, 5, 354, 354, (一社)日本糖尿病学会, May 2020
    Japanese
  • Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
    Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuhisa Tsuchida; Kazuno Omori; Hiroki Yokoyama; Naoki Manda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes, obesity & metabolism, 22, 3, 458, 462, Mar. 2020, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal, This multicentre, prospective, randomized, open-label, blinded-endpoint, parallel-group, short-term (4-5 weeks) controlled trial was conducted to investigate the superiority of the effect of reducing mean amplitude of glycaemic excursions (MAGE) during meal tolerance tests (MTTs) for the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor compared with SGLT2 inhibitor monotherapy. Ninety-nine patients with type 2 diabetes who were taking teneligliptin (20 mg/d) were randomized to one of the following two groups: those who switched to 100 mg/d of canagliflozin (SWITCH group) or those who added 100 mg/d of canagliflozin (COMB group). MAGE in the COMB group was significantly decreased compared with that in the SWITCH group (COMB 117.5 ± 39.8 to 92.2 ± 28.0 mg/dL vs SWITCH 110.7 ± 29.8 to 104.2 ± 27.6 mg/dL; P<0.01). Mean blood glucose decreased significantly during MTTs in both groups, although the extent of the reduction was significantly greater in the COMB group (COMB 142.3 ± 28.7 to 119.5 ± 25.1 mg/dL vs SWITCH 146.4 ± 25.5 to 135.5 ± 22.4 mg/dL; P < 0.01). SGLT2 inhibitor combined with DPP-4 inhibitor therapy strongly reduced glycaemic fluctuation compared with SGLT2 inhibitor monotherapy.
  • Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
    Reina Kameda; Hiroshi Nomoto; Kyu Yong Cho; Shinichiro Kawata; Kazuno Omori; Jun Takeuchi; So Nagai; Yoshio Kurihara; Shin Aoki; Akinobu Nakamura; Tatsuya Atsumi; Hideaki Miyoshi
    BMJ open, 10, 2, e034883, 06 Feb. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, INTRODUCTION: Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension more effectively than a dipeptidyl peptidase (DPP)-4 inhibitor in patients with T2D. METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group trial. Sixty participants with T2D and hypertension who have been treated with a DPP-4 inhibitor for more than 4 weeks and who have a glycated haemoglobin A1c (HbA1c) level of 6.0%-9.0% will be randomised based on age, body mass index (BMI) and HbA1c to continue taking their DPP-4 inhibitor or to switch to luseogliflozin 2.5 mg once daily for 8 weeks. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) will be performed twice at baseline and at the end of the study. All participants will continue their diet and exercise therapy, and the doses of concomitant medications will not be adjusted during the study. The primary endpoint is the effect of luseogliflozin on the mean change in systolic blood pressure (SBP) during the night, as measured by ABPM. The secondary endpoints are mean change in diastolic blood pressure (DBP) during the night, 24 hours of SBP and DBP, daytime SBP and DBP, pulse rate, BP M-value, trough SBP and DBP for 1 hour before the next dose, and other laboratory parameters. The sample size was calculated for a two-sided test at 90% power for the detection of a difference between treatments. ETHICS AND DISSEMINATION: The Ethics Review Board of Hokkaido University Hospital has approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences. TRIAL REGISTRATION NUMBERS: The University Hospital Medical Information Network (UMIN000031451); Japan Registry of Clinical Trials (jRCTs011180019); Pre-results.
  • Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Tomonori Sekizaki; Hiraku Kameda; Chiho Oba; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Takahiro Osawa; Nobuo Shinohara; Tatsuya Atsumi
    Endocrine journal, 66, 10, 937, 941, 28 Oct. 2019, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, A 62-year-old man was referred to our department for elevation of plasma ACTH and cortisol levels during nivolumab administration for renal cell carcinoma. Although his ACTH and cortisol levels had been maintained within their reference ranges, they were elevated to 232.7 pg/mL and 21.9 μg/dL, respectively, after eight courses of nivolumab without any subjective symptoms or Cushing's sign. He was hospitalized for endocrinological investigation. ACTH and cortisol returned to their normal ranges (29.18 pg/mL and 11.4 μg/dL, respectively) in the early morning on day 1, but fell down sharply to 3.7 pg/mL and 1.6 μg/dL, respectively, in the early morning on day 2 without subjective symptoms or vital sign changes. Brain magnetic resonance imaging showed no abnormality in his pituitary gland. ACTH response to CRH was apparently normal, but cortisol did not respond to increased ACTH. A rapid ACTH stimulation test showed slightly reduced response of cortisol to exogenous ACTH (1-24). These findings and his clinical course suggested secondary adrenal insufficiency arising from nivolumab-induced hypophysitis. In previous reports, most cases of immune checkpoint inhibitor (ICI)-induced hypophysitis were diagnosed based on adrenal insufficiency symptoms or hyponatremia with low ACTH and cortisol. The ACTH elevation observed in the present case may reflect destruction of the pituitary gland, suggesting that this finding may be important for early detection of ICI-induced hypophysitis. Our case underlines the necessity of close monitoring for subsequent onset of adrenal insufficiency when ACTH elevation is observed during ICI administration.
  • Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
    Kazuno Omori; Akinobu Nakamura; Hideaki Miyoshi; Kiyohiko Takahashi; Naoyuki Kitao; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Ryo Takagi; Kanako C Hatanaka; Yasuo Terauchi; Tatsuya Atsumi
    Metabolism: clinical and experimental, 98, 27, 36, Sep. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: To explore the beneficial effects of dapagliflozin and/or insulin glargine on the pancreatic beta cell mass and hepatic steatosis in db/db mice. METHODS: Six-week-old db/db mice were assigned to one of four groups: untreated (Placebo), treated with dapagliflozin (Dapa), treated with insulin glargine (Gla), or treated with dapagliflozin and insulin glargine (Dapa+Gla). After 8 weeks of treatment, we determined glucose tolerance, beta cell mass, hepatic lipid content and gene expression. RESULTS: Glucose tolerance was significantly ameliorated in the three treated groups to the same degree compared with the Placebo group. Immunohistochemical analysis revealed that the pancreatic beta cell mass was significantly maintained in the Dapa and Dapa+Gla groups, but not in the Gla group, compared with the Placebo group (Placebo 2.25 ± 1.44 mg, Dapa 5.01 ± 1.63 mg, Gla 3.79 ± 0.96 mg, Dapa+Gla 5.19 ± 1.78 mg). However, the triglyceride content of the liver was markedly elevated in the Gla group compared with that in the other three groups (Placebo 24.1 ± 11.5 mg, Dapa 30.6 ± 12.9 mg, Gla 128 ± 49.7 mg, Dapa+Gla 54.4 ± 14.1 mg per gram liver). The expression levels of genes related to fatty acid synthesis and lipid storage were significantly upregulated in the Gla group. CONCLUSIONS: Our results showed that beta cell mass was sustained and hepatic steatosis was prevented, after 8 weeks of treatment with either dapagliflozin or dapagliflozin plus insulin glargine, but not with insulin glargine alone, in db/db mice.
  • Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.
    Yui Shibayama; Hiraku Kameda; Shoichiro Ota; Kazuhisa Tsuchida; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Tatsuya Atsumi
    Journal of diabetes investigation, 10, 5, 1385, 1387, Sep. 2019, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, With the expansive use of immune checkpoint inhibitors, the frequency of immune-related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti-programmed death-ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma therapy. Here, we report a patient that developed fulminant type 1 diabetes during avelumab treatment. An 81-year-old woman with no history of diabetes received avelumab for metastatic Merkel cell carcinoma. Elevated plasma glucose level (483 mg/dL), hemoglobin A1c level (7.5%) and ketosis were observed after 10 courses of avelumab without any symptoms related to hyperglycemia. As the laboratory tests showed insulin depletion, we diagnosed her with fulminant type 1 diabetes induced by avelumab. This is the first reported case of avelumab-induced type 1 diabetes, illustrating the necessity for close monitoring of glycemic control during avelumab therapy, as well as other immune checkpoint inhibitors.
  • Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
    Takahiro Takase; Akinobu Nakamura; Chiho Yamamoto; Hiroshi Nomoto; Aika Miya; Midori Dannoura; Kyu Yong Cho; Yoshio Kurihara; Naoki Manda; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 10, 3, 699, 705, May 2019, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon-like peptide-1 receptor agonists. MATERIALS AND METHODS: The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial. The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months. Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group). The primary outcome was the change in the Diabetes Treatment Satisfaction Questionnaire score from baseline to week 12 in the two groups. The secondary outcomes comprised changes in the Diabetes Therapy-Related Quality of Life score, body mass and glycemic control. RESULTS: A total of 33 participants were initially enrolled in the trial, and 31 participants completed the protocol. The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 ± 4.7 in the Lira group vs +4.9 ± 5.2 in the Dula group; P = 0.013). The change in Diabetes Therapy-Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (-3.7 ± 6.9 vs +8.9 ± 15.1; P = 0.007). There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin. CONCLUSIONS: Weekly administration of dulaglutide was superior to liraglutide with regard to treatment satisfaction in patients with type 2 diabetes, in the absence of any negative effect on glycemic control.
  • Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
    Kazuno Omori; Hiroshi Nomoto; Akinobu Nakamura; Takahiro Takase; Kyu Yong Cho; Kota Ono; Naoki Manda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 10, 2, 367, 374, Mar. 2019, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: Glinides are antidiabetic drugs that enhance the early phase of insulin secretion, but have been considered to be less effective at lowering blood glucose than sulfonylureas. However, glinides show a lower risk of hypoglycemia and a greater effect on postprandial hyperglycemia, and are particularly recommended for use in elderly patients with type 2 diabetes. We investigated the efficacy and safety of repaglinide compared with sulfonylurea for the treatment of elderly patients. MATERIALS AND METHODS: In the present multicenter, prospective, randomized, open-label, controlled trial, 57 elderly lean patients with type 2 diabetes who were being treated with sulfonylureas were studied. They were either switched to repaglinide (Repa group) or continued a sulfonylurea (SU group) for 12 weeks. The primary outcome comprised the change in glycemic control, and among the secondary outcomes was the presence of hypoglycemia and drug compliance. RESULTS: Although glycated hemoglobin (HbA1c) was not significantly different between the two groups (SU +0.02% vs Repa -0.07%), greater improvements in the glycated albumin (GA) and GA to HbA1c ratio (GA/HbA1c) were observed in the Repa group (ΔGA, SU +0.12% vs Repa -1.15%; ΔGA/HbA1c, SU +0.01 vs Repa -0.13; each P < 0.01) without increasing hypoglycemia. When the Repa group was subdivided according to whether GA improved, the SU dose before switching to repaglinide was significantly smaller and the homeostatic model assessment of β-cell function was significantly higher in the GA improvement subgroup. CONCLUSIONS: Switching from SU to Repa improved GA and GA/HbA1c, and had favorable effects on glucose fluctuation in elderly patients with type 2 diabetes.
  • Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
    Kiyohiko Takahashi; Kyu Yong Cho; Akinobu Nakamura; Aika Miya; Arina Miyoshi; Chiho Yamamoto; Hiroshi Nomoto; Hirokatsu Niwa; Kiyohito Takahashi; Naoki Manda; Yoshio Kurihara; Shin Aoki; Yoichi M Ito; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of diabetes investigation, 10, 2, 429, 438, Mar. 2019, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We investigated the difference in efficacy and safety between discontinuation and maintaining of sulfonylurea when adding a sodium-glucose cotransporter 2 inhibitor. MATERIALS AND METHODS: In the present multicenter, prospective observational study, 200 patients with type 2 diabetes treated with sulfonylurea and with a need to add ipragliflozin were enrolled and divided into two groups: discontinued sulfonylurea (Discontinuation group) or maintained sulfonylurea, but at the lowest dose (Low-dose group) when adding ipragliflozin. We compared the two groups after 24 weeks using propensity score matching to adjust for differences between the groups. RESULTS: In the matched cohort (58 patients in each group), baseline characteristics of both groups were balanced. The primary outcome of the proportion of patients with non-exacerbation in glycated hemoglobin after 24 weeks was 91.4% in the Low-dose group and 75.9% in the Discontinuation group, a significant difference (P = 0.024). However, bodyweight was significantly decreased in the Discontinuation group compared with the Low-dose group (-4.4 ± 2.1 kg vs -2.9 ± 1.9 kg, P < 0.01). Similarly, liver enzyme improvement was more predominant in the Discontinuation group. A logistic regression analysis showed that high-density lipoprotein cholesterol, age and sulfonylurea dose were independent factors associated with non-exacerbation of glycated hemoglobin in the Discontinuation group. CONCLUSIONS: The purpose of using ipragliflozin should be considered when making the decision to discontinue or maintain sulfonylurea at the lowest dose. Furthermore, low high-density lipoprotein cholesterol level, low dose of sulfonylurea and younger age were possible markers to not show worsening of glycemic control by discontinuing sulfonylurea.
  • Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
    Kyu Yong Cho; Akinobu Nakamura; Kazuno Omori; Takahiro Takase; Aika Miya; Naoki Manda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi; Hideaki Miyoshi
    Diabetes, obesity & metabolism, 21, 3, 710, 714, Mar. 2019, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal, The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy-one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non-inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT-proBNP, P < 0.01; ACR, P = 0.02), and the change in NT-proBNP correlated negatively with baseline NT-proBNP level (ρ = -0.68, P < 0.01) and log-converted ACR (ρ = -0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events.
  • The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring.
    Shingo Yanagiya; Kyu Yong Cho; Akinobu Nakamura; Hiroshi Nomoto; Yasuyuki Kawamoto; Kazumichi Kawakubo; Yoshito Komatsu; Tomoko Mitsuhashi; Hideaki Miyoshi; Tatsuya Atsumi
    Internal medicine (Tokyo, Japan), 57, 17, 2527, 2531, 01 Sep. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM.
  • The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice.
    Naoyuki Kitao; Akinobu Nakamura; Hideaki Miyoshi; Hiroshi Nomoto; Kiyohiko Takahashi; Kazuno Omori; Kohei Yamamoto; Kyu Yong Cho; Yasuo Terauchi; Tatsuya Atsumi
    Metabolism: clinical and experimental, 85, 48, 58, Aug. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: We investigated whether glucokinase and insulin receptor substrate-2 were required for beta cell proliferation induced by short-term high-fat (HF) diet feeding, as has been shown for long-term HF diet. METHODS: Eight-week-old C57BL/6J mice were exposed to either a standard chow (SC) or HF diet. After 1 week on the diet, histopathological beta cell proliferation and gene expression in isolated islets were examined. Additionally, 8-week-old beta cell-specific glucokinase haploinsufficient (Gck+/-) and Irs2 knockout (Irs2-/-) mice were exposed to either an SC or HF diet. RESULTS: Immunohistochemical analysis revealed that short-term HF diet feeding resulted in a significant increase in BrdU incorporation rate compared with SC consumption in wild-type mice. Western blot analysis demonstrated that Irs2 expression levels did not differ between the two diets. Moreover, there was a significant increase in the BrdU incorporation rate in the HF diet group compared with the SC group in both Gck+/- and Irs2-/- mice. Gene expression profiling of isolated islets from mice fed an HF diet for 1 week revealed that the expression levels of downstream genes of Foxm1 were coordinately upregulated. One week of HF diet feeding stimulated beta cell proliferation with Foxm1 upregulation in 48-week-old mice as well as in 8-week-old. CONCLUSIONS: The mechanism of pancreatic beta cell proliferation induced by short-term HF diet feeding in mice could involve a glucokinase- and Irs2-independent pathway. Our results suggest that the pathways that induce beta cell proliferation in response to short-term HF diet feeding may differ from those in response to sustained HF diet feeding.
  • The data of change in macrophage gene expression which induced by perilipin 1 overexpression.
    Kohei Yamamoto; Hideaki Miyoshi; Kyu Yong Cho; Akinobu Nakamura; Andrew S Greenberg; Tatsuya Atsumi
    Data in brief, 19, 179, 182, Aug. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, The data presented here are related to the research article entitled "Overexpression of Perilipin1 protects against atheroma progression in apolipoprotein E knockout mice" [1]. This paper describes data that were obtained from perilipin 1 (PLIN1) transgenic mice (Plin1Tg) regarding atherosclerosis. The main aim of collecting the data was to clarify the role of PLIN1 in the pathophysiology of atherosclerosis. The data were collected from C57BL/6J mice, apolipoprotein E knockout mice (ApoeKO) and Plin1Tg/ApoeKO. The atherosclerotic lesion areas of aorta were 3.3 ± 1.2% in C57BL/6J mice, 14.2 ± 3.2% in ApoeKO, and 5.6 ± 1.9% in Plin1Tg/ApoeKO. Body weight, gonadal adipose mass and plasma triglyceride concentrations were comparable among the three groups [1]. Furthermore, PLIN1 overexpression did not affect the gene expressions related to cholesterol influx and efflux in macrophage.
  • HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.
    Hideyuki Ujiie; Ken Muramatsu; Taisei Mushiroda; Takeshi Ozeki; Hideaki Miyoshi; Hiroaki Iwata; Akinobu Nakamura; Hiroshi Nomoto; Kyu Yong Cho; Norihiro Sato; Machiko Nishimura; Takamasa Ito; Kentaro Izumi; Wataru Nishie; Hiroshi Shimizu
    The Journal of investigative dermatology, 138, 5, 1201, 1204, May 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages.
    Kiyohiko Takahashi; Akinobu Nakamura; Hideaki Miyoshi; Hiroshi Nomoto; Naoyuki Kitao; Kazuno Omori; Kohei Yamamoto; Kyu Yong Cho; Yasuo Terauchi; Tatsuya Atsumi
    Scientific reports, 8, 1, 6864, 6864, 01 May 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, To examine the effects of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, on pancreatic beta cell mass in db/db mice of different ages. db/db mice aged 6, 10, 14 and 24 weeks old were fed either standard chow (control group) or standard chow containing 0.01% luseogliflozin (luseo group). After 4 weeks, immunohistochemistry and gene expression tests were conducted. In 6-week-old db/db mice, immunohistochemistry revealed a significant increase in beta cell mass in the luseo group compared with the control group after 4 weeks of treatment. Gene expression profiling of isolated islets showed upregulation Mafa, Pdx1, Ki67 and Ccnd2 in the luseo group. Beta cell mass decreased with age in db/db mice in the control group. Beta cell mass in the luseo group significantly increased compared with the control group regardless of age, although beta cell mass in the 28-week-old luseo group (4 weeks of treatment in 24-week-old db/db mice) was significantly lower than in the 10-week-old luseo group (4 weeks of treatment in 6-week-old db/db mice). Luseogliflozin preserved beta cell mass in db/db mice. The protective effect was more evident in the earlier phase of diabetes.
  • Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
    Mayuko Oita; Hideaki Miyoshi; Kota Ono; Akinobu Nakamura; Kyu Yong Cho; Hiroshi Nomoto; Kohei Yamamoto; Kazuno Omori; Naoki Manda; Yoshio Kurihara; Shin Aoki; Tatsuya Atsumi
    Endocrine journal, 65, 2, 141, 150, 26 Feb. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, We compared treatment satisfaction between daily dipeptidyl peptidase-4 (DPP-4) inhibitors and a weekly DPP-4 inhibitor in patients with type 2 diabetes. The study was a 12-week, open-label, randomized, multicenter, controlled trial. Participants were Japanese patients with type 2 diabetes who had received daily DPP-4 inhibitors for more than 3 months. Patients were randomly assigned to a treatment cohort: (1) a group that continued taking daily DPP-4 inhibitors (daily group); or (2) a group that switched from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin (weekly group). The primary outcome was the change in treatment satisfaction levels from baseline to 12 weeks between the two groups, according to Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire scores. The changes in glycemic control and body weight were also assessed. Of 49 patients initially enrolled in the study, 47 completed the study. The change in DTSQ scores in the weekly group was not significantly different from that in the daily group. However, the improvements in total score and subscale domains 1 and 2 in the DTR-QOL analysis, which relate to burden on social/daily activities and anxiety/dissatisfaction with treatment, were significantly greater in the weekly group than the daily group (p = 0.048, 0.013 and 0.045, respectively). Mean changes in glycated hemoglobin levels and body weight were comparable between the groups. Switching from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin, could partially improve treatment satisfaction levels in patients with type 2 diabetes without affecting glycemic control.
  • Overexpression of perilipin1 protects against atheroma progression in apolipoprotein E knockout mice.
    Kohei Yamamoto; Hideaki Miyoshi; Kyu Yong Cho; Akinobu Nakamura; Andrew S Greenberg; Tatsuya Atsumi
    Atherosclerosis, 269, 192, 196, Feb. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND AND AIMS: Perilipin1 (PLIN1), a lipid droplet-associated protein, plays an important role in the regulation of lipolysis and lipid storage in adipocytes. PLIN1 has recently been reported to be expressed in macrophages within atheroma plaques, suggesting PLIN1 may play a role in the accumulation of lipids at the arterial wall and in the development of atherosclerosis. To clarify the role of PLIN1 in the pathophysiology of atherosclerosis, we assessed the progression of atherosclerosis in PLIN1 transgenic mice (Plin1Tg). METHODS: Plin1Tg were crossed with apolipoprotein E knockout mice (ApoeKO). C57BL/6J mice, ApoeKO and Plin1Tg/ApoeKO received a normal chow diet for 20 weeks. Body weight, gonadal fat mass and plasma lipid concentrations were measured. Aortas were collected for quantification of atheroma lesions and histological analysis by Oil Red O staining. RESULTS: Body weight, gonadal adipose mass and plasma triglyceride concentrations were not significantly different among the three groups. In contrast, the atherosclerotic lesion area was significantly increased in ApoeKO (14.2 ± 3.2%; p < .01) compared with C57BL/6J mice (3.3 ± 1.2%) and Plin1Tg/ApoeKO (5.6 ± 1.9%). CONCLUSIONS: Overexpressed PLIN1 in macrophages had a protected role against atheroma progression in ApoeKO in the absence of changes in gonadal fat mass or plasma lipid levels, presumably due to modification of the stability and/or inflammatory profile of macrophages.
  • Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.
    Aika Miya; Akinobu Nakamura; Hideaki Miyoshi; Kyu Yong Cho; So Nagai; Yoshio Kurihara; Shin Aoki; Masataka Taguri; Yasuo Terauchi; Tatsuya Atsumi
    Journal of diabetes investigation, 9, 1, 119, 126, Jan. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, AIMS/INTRODUCTION: We compared the satisfaction levels of patients with type 2 diabetes undergoing combination therapy with lixisenatide (LIX) and basal insulin with that of patients undergoing multiple daily insulin injection (MDI) therapy. MATERIALS AND METHODS: The study was a 12-week open-label, randomized, multicenter, controlled trial. Participants were Japanese patients with type 2 diabetes receiving MDI for >3 months. Patients were randomly assigned to each treatment cohort: (i) a group that continued MDI (MDI group); and (ii) a group that switched from MDI to combination therapy with LIX and basal insulin (LIX group). The primary outcome was change in Diabetes Treatment Satisfaction Questionnaire scores from baseline to 12 weeks between these two groups. Key secondary outcomes were glycated hemoglobin and body weight changes. RESULTS: A total of 31 patients were initially enrolled in the study, and 26 of them completed the study. The change in Diabetes Treatment Satisfaction Questionnaire scores in the LIX group was significantly greater compared with that in the MDI group. Mean changes in glycated hemoglobin levels were -0.05 ± 0.37% in the MDI group and 0.04 ± 0.38% in the LIX group (P = 0.36). Mean changes in body weight were +0.6 ± 1.8 kg in the MDI group and -2.5 ± 1.8 kg in the LIX group (P < 0.01). CONCLUSIONS: Switching from MDI to combination therapy with LIX and basal insulin improved satisfaction levels while maintaining glycemic control in Japanese patients with type 2 diabetes.
  • Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial.
    Shinsuke Otagiri; Shunsuke Ohnishi; Arisa Miura; Hiroshi Hayashi; Izumi Kumagai; Yoichi M Ito; Takehiko Katsurada; Shiro Nakamura; Rika Okamoto; Kenichi Yamahara; Kyu Yong Cho; Toshiyuki Isoe; Norihiro Sato; Naoya Sakamoto
    BMJ open gastroenterology, 5, 1, e000206, 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Introduction: The medical treatment options for patients with Crohn's disease (CD) are limited and patients resistant to those therapies are left requiring surgical operations that usually only achieve some symptomatic relief. Mesenchymal stem cells (MSC) have been shown to be effective for the treatment of CD, and we have demonstrated in animal experiments that human amnion-derived MSCs (AMSC) are a potential new therapeutic strategy. Therefore, we designed this study to investigate the safety and efficacy of AMSCs in patients with treatment-resistant CD. Methods and analysis: This is the protocol for an ongoing phase I/II, dual-centre, open-label, uncontrolled, dose-response study. The estimated enrolment is 6-12 patients with treatment-resistant, moderate CD. A dose of 1.0×106 cells/kg will be administered intravenously in the low-dose group at days 0 and 7. After confirming the safety of low-dose administration, a dose of 4.0×106 cells/kg will be administered intravenously in the high-dose group on days 0 and 7. The primary endpoint will measure the occurrence of adverse events related to acute infusion toxicity, and secondary endpoints will include long-term adverse events and efficacy of AMSC administration. Ethics and dissemination: The Institutional Review Board of Hokkaido University Hospital approved this study protocol (approval number H29-6). A report releasing study results will be submitted to an appropriate journal. Discussion: This study is the first to investigate the safety and efficacy of AMSC use for CD treatment. Our results will advance studies on more efficient and convenient methods to overcome the limits of available CD treatments. Trial registration number: UMIN000029841.
  • Factors associated with an inadequate hypoglycemia in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism.
    Kiyohiko Takahashi; Akinobu Nakamura; Hideaki Miyoshi; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; So Nagai; Chikara Shimizu; Masataka Taguri; Yasuo Terauchi; Tatsuya Atsumi
    Endocrine journal, 64, 4, 387, 392, 29 Apr. 2017, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, We attempted to identify the predictors of an inadequate hypoglycemia in insulin tolerance test (ITT), defined as a blood glucose level higher than 2.8 mmol/L after insulin injection, in Japanese patients with suspected or proven hypopituitarism. A total of 78 patients who had undergone ITT were divided into adequate and inadequate hypoglycemia groups. The relationships between the subjects' clinical parameters and inadequate hypoglycemia in ITT were analyzed. Stepwise logistic regression analysis identified high systolic blood pressure (SBP) and high homeostasis model assessment of insulin resistance (HOMA-IR) as being independent factors associated with inadequate hypoglycemia in ITT. Receiver operating characteristic (ROC) curve analysis revealed the cutoff value for inadequate hypoglycemia was 109 mmHg for SBP and 1.4 for HOMA-IR. The areas under ROC curve for SBP and HOMA-IR were 0.72 and 0.86, respectively. We confirmed that high values of SBP and HOMA-IR were associated with inadequate hypoglycemia in ITT, regardless of the degree of reduction of pituitary hormone levels. Furthermore, the strongest predictor of inadequate hypoglycemia was obtained by using the cutoff value of HOMA-IR. Our results suggest that HOMA-IR is a useful pre-screening tool for ITT in these populations.
  • Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Hiroshi Nomoto; Kimihiko Kimachi; Hideaki Miyoshi; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; So Nagai; Takuma Kondo; Tatsuya Atsumi
    Endocrine journal, 64, 4, 417, 424, 29 Apr. 2017, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, To date, several clinical trials have compared differences in glucose fluctuation observed with dipeptidyl peptidase-4 inhibitor treatment in patients with type 2 diabetes mellitus. However, most patients were assessed for limited periods or during hospitalization. The aim of the present study was to evaluate the effects of switching from sitagliptin to vildagliptin, or vice versa, on 12-week glucose fluctuations using self-monitoring of blood glucose in the standard care setting. We conducted a multicenter, prospective, open-label controlled trial in Japanese patients with type 2 diabetes. Thirty-two patients were treated with vildagliptin (50 mg) twice daily or sitagliptin (50 mg) once daily and were allocated to one of two groups: vildagliptin treatment for 12 weeks before switching to sitagliptin for 12 weeks, or vice versa. Daily profiles of blood glucose were assessed several times during each treatment period, and the mean amplitude of glycemic excursions and M-value were calculated. Metabolic biomarkers such as hemoglobin A1c (HbA1c), glycated albumin, and 1,5-anhydroglucitol were also assessed. With vildagliptin treatment, mean amplitude of glycemic excursions was significantly improved compared with sitagliptin treatment (57.9 ± 22.2 vs. 68.9 ± 33.0 mg/dL; p=0.0045). M-value (p=0.019) and mean blood glucose (p=0.0021) were also lower with vildagliptin, as were HbA1c, glycated albumin, and 1,5-anhydroglucitol. There were no significant differences in other metabolic parameters evaluated. Reduction of daily blood glucose profile fluctuations by vildagliptin was superior to that of sitagliptin in Japanese patients with type 2 diabetes.
  • 短期高脂肪食負荷誘導性膵β細胞増殖メカニズムの検討
    北尾 直之; 中村 昭伸; 山本 浩平; 野本 博司; 曹 圭龍; 三好 秀明; 寺内 康夫; 渥美 達也
    日本臨床分子医学会学術総会プログラム・抄録集, 54回, 75, 75, 日本臨床分子医学会, Apr. 2017
    Japanese
  • Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy.
    Atsushi Narahira; Teruki Yanagi; Kyu Yong Cho; Akinobu Nakamura; Hideaki Miyoshi; Hiroo Hata; Keisuke Imafuku; Shinya Kitamura; Hiroshi Shimizu
    The Journal of dermatology, 44, 4, e70, Apr. 2017, [Peer-reviewed], [International Magazine]
    English
  • Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor].
    Kyu Yong Cho; Hideaki Miyoshi; Akinobu Nakamura; Takashi Kurita; Tatsuya Atsumi
    Endocrine journal, 64, 2, 235, 236, 27 Feb. 2017, [Peer-reviewed], [Lead author], [Domestic magazines]
    English
  • A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo athero-incretin study 1 (SAIS1)
    Hiroshi Nomoto; Hideaki Miyoshi; Tomoo Furumoto; Koji Oba; Hiroyuki Tsutsui; Atsushi Inoue; Tatsuya Atsumi; Naoki Manda; Yoshio Kurihara; Shin Aoki; Y. Takano; N. Koyanagawa; A. Miyoshi; K. Yamamoto; C. Yamamoto; N. Tajima; H. Kameda; K. Y. Cho; O. Nakagaki; S. Nagai; T. Kondo; H. Miyoshi; T. Atsumi; C. Takashina; T. Watanabe; H. Ohira; K. Y. Cho; M. Endo; H. Kamoshima; Y. Ono; S. Hagiwara; K. Misawa; K. Tsuchida; S. Aoki; James W. Perfield; on behalf of SAIS Study Group
    PLoS ONE, 11, 10, Public Library of Science, 01 Oct. 2016
    English, Scientific journal
  • Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Naohide Koyanagawa; Hideaki Miyoshi; Kota Ono; Akinobu Nakamura; Kyu Yong Cho; Kohei Yamamoto; Yoshinari Takano; Midori Dan-Noura; Tatsuya Atsumi
    Endocrine journal, 63, 8, 747, 53, 31 Aug. 2016, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, The dipeptidyl peptidase-4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus. Patients receiving standard doses of sitagliptin plus insulin may require increased doses of sitagliptin or switching to vildagliptin to improve blood glucose control. This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin. This prospective, randomized, parallel-group comparison trial enrolled 33 type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin. Seventeen patients were randomized to 50 mg vildagliptin twice daily, and 16 to 100 mg sitagliptin once daily, and evaluated by continuous glucose monitoring at baseline and after 8 weeks. The primary end-point was the change in mean amplitude of glycemic excursions (MAGE). MAGE decreased from baseline in both the vildagliptin (-13.4 ± 35.7 mg/dL) and sitagliptin (-8.4 ± 24.3 mg/dL) groups, but neither within- nor between-group changes were statistically significant. Similarly, the areas under the curve for blood glucose levels ≥180 mg/dL and <70 mg/dL tended to improve in both groups, but these differences were not statistically significant. In contrast, HbA1c was significantly reduced only in the vildagliptin group, from 7.1 ± 0.6% at baseline to 6.8 ± 0.6% at 8 weeks (p=0.006). Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin.
  • Clipping of incidental aneurysm of middle cerebral artery through small temporal craniotomy and linear skin incision.
    Jong Hyun Mun; Kyu Yong Cho; Rae Seop Lee; Byung Chan Lim; Tai Min Choi; Jun Seob Lim
    Journal of cerebrovascular and endovascular neurosurgery, 16, 1, 32, 8, Mar. 2014, [International Magazine]
    English, The authors introduced a new approach for clipping of the incidental aneurysm of the middle cerebral artery (MCA) and reported the clinical results. We retrospectively reviewed 26 patients with 27 incidental MCA aneurysms who were treated from January 2010 to December 2012. All clippings were performed through a small temporal craniotomy and linear skin incision. Follow-up imaging showed complete occlusion of 26 aneurysms (96.3%), residual neck in one (3.7%). In one case, residual neck of the aneurysm did not grow on serial follow up. In one of 26 cases (3.8%), approach-related complication was retraction injury of the temporal cortex. Two patients developed postoperative infarction on the MCA territories due to vasospasm and on the cerebellum due to unknown causes. These were not approach-related complications. Operation time was 95 min-250 min (mean 143 min). There were no complications of temporal muscle atrophy, scar deformity, paresthesia, or pain around the scalp incision and frontalis palsy. This approach offers good surgical possibilities and little approach related morbidity in the clipping of incidental MCA aneurysms.
  • The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
    Yuri Ono; Akinobu Nakamura; Kyu Yong Cho; Hiroshi Nomoto
    Expert opinion on pharmacotherapy, 15, 3, 311, 24, Feb. 2014, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Meal tolerance tests (MTTs) are usually conducted at breakfast after overnight fasting in type 2 diabetes mellitus (T2DM) patients, but differences in postprandial glycemic responses between meals have been reported. OBJECTIVE: We conducted MTTs at breakfast, lunch, and dinner to examine the effects of a fixed combination of 10 mg mitiglinide/0.2 mg voglibose (the combination) on glycemic/metabolic responses to meals during the day in T2DM patients. MTTs with unified meals were conducted in 11 T2DM patients before and after 4 weeks of treatment with the combination administered thrice daily before meals. Glycemic/metabolic profiles measured before and at 30, 60, and 120 min after each meal were compared between each meal and between the baseline and treatment periods. RESULTS AND CONCLUSION: The combination significantly reduced postprandial hyperglycemia after each meal. Postprandial AUC0 - 120 min for insulin significantly decreased after lunch and dinner compared with after breakfast, while insulin levels significantly increased at only 30 min after breakfast and dinner. The combination also significantly increased postprandial C-peptide and active glucagon-like peptide-1 levels, and reduced free fatty acid and triglyceride levels, but did not significantly affect glucagon levels compared with baseline, confirming that treatment with the combination improves postprandial responses in Japanese T2DM patients.
  • The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery.
    Kyu Yong Cho; Hideaki Miyoshi; Satoshi Kuroda; Hiroshi Yasuda; Kenji Kamiyama; Joji Nakagawara; Masayoshi Takigami; Takuma Kondo; Tatsuya Atsumi
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 22, 7, 910, 8, Oct. 2013, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal, BACKGROUND: Proinflammatory (M1) macrophages and anti-inflammatory (M2) macrophages have been identified in atherosclerotic plaques. While these macrophages have been speculated to be related to plaque vulnerability, there are limited studies investigating this relationship. Therefore, we examined the association between macrophage phenotype (M1 versus M2) and plaque vulnerability and clinical events. METHODS: Patients undergoing carotid endarterectomy received an ultrasound of the carotid artery before surgery. Plaques were processed for analysis by immunohistochemistry, Western blotting, and real-time polymerase chain reaction studies. Medical history and clinical data were obtained from medical records. RESULTS: Patients were divided into 2 groups: those suffering from acute ischemic attack (symptomatic, n = 31) and those that did not present with symptoms (asymptomatic, n = 34). Ultrasound analysis revealed that plaque vulnerability was greater in the symptomatic group (P= .033; Chi-square test). Immunohistochemistry revealed that plaques from the symptomatic group had a greater concentration of M1 macrophages (CD68-, CD11c-positive) while plaques from the asymptomatic group had more M2 macrophages (CD163-positive). This observation was confirmed by Western blotting. Characterization by real-time polymerase chain reaction studies revealed that plaques from the symptomatic group had increased expression of the M1 markers CD68 and CD11c, as well as monocyte chemoattractive protein-1, interleukin-6, and matrix metalloproteinase-9. In addition, more M1 macrophages expressed in unstable plaques were defined by ultrasound analysis, while more M2 macrophages were expressed in stable plaques. CONCLUSIONS: Our data show that M1 macrophage content of atherosclerotic plaques is associated with clinical incidence of ischemic stroke and increased inflammation or fibrinolysis. We also show the benefits of using ultrasound to evaluate vulnerability in the plaques.
  • Evaluation of thrice-daily injections of insulin Lispro Mix 50/50 versus basal-bolus therapy in perioperative patients with type 2 diabetes
    Kyu Yong Cho; Osamu Nakagaki; Hideaki Miyoshi; Kazumasa Akikawa; Tatsuya Astumi
    Diabetology International, 5, 117, 121, May 2013, [Peer-reviewed], [Lead author]
    English, Scientific journal, Purpose: The purpose of this study was to compare two perioperative insulin therapies [thrice-daily injections of insulin Lispro Mix 50/50 (3X-Mix50) versus basal-bolus injections (BBT)] in type 2 diabetic patients who were judged by attending endocrinologists to require intensive insulin treatment before surgery.
    Materials and methods: A retrospective analysis was performed on data collected from 47 surgical patients hospitalized at Obihiro-Kosei General Hospital and treated with BBT (n = 27) or 3X-Mix50 (n = 20) for 1 year.
    Results: Patient baseline characteristics (age, duration of diabetes, BMI, FPG and HbA1c) were similar between therapeutic groups. Both therapies achieved target glycemic control for surgery in 9 days on average. There was no significant difference in average pre-meal or bedtime blood glucose levels. The total daily insulin dose before surgery was similar (28.3 U in BBT vs. 24.8 U in 3X-Mix50, p = 0.1146). No episodes of severe hypoglycemia occurred, and the number of episodes of mild hypoglycemia during the perioperative period was similar. No surgical complications such as infection occurred, and one orthopedic surgery-related issue occurred in each therapeutic group.
    Conclusion: We showed 3X-Mix50 and BBT were comparable in terms of glycemic control, total insulin dose, and incidence of hypoglycemia and perioperative complications. While comparable to classical BBT therapy, the 3X-Mix50 provides a convenient alternative method for maintaining glycemic control in patients with type 2 diabetes during the perioperative period.
  • Ovarian morphology and prevalence of polycystic ovary syndrome in japanese women with type 1 diabetes mellitus
    Arina Miyoshi; So Nagai; Masamitsu Takeda; Takuma Kondo; Hiroshi Nomoto; Hiraku Kameda; Amiko Hirai; Kyuyong Cho; Kimihiko Kimachi; Chikara Shimizu; Tatsuya Atsumi; Hideaki Miyoshi
    Journal of Diabetes Investigation, 4, 3, 326, 329, May 2013, [Peer-reviewed]
    English, Scientific journal
  • Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
    Yuri Ono; Hiraku Kameda; Kyu Yong Cho
    Expert opinion on pharmacotherapy, 14, 4, 361, 70, Mar. 2013, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: We examined the effects of a fixed-dose combination of 10 mg mitiglinide and 0.2 mg voglibose on postprandial glycemic excursions in Japanese type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS: After a 2-week baseline period, 11 T2DM patients were treated with mitiglinide alone for 2 weeks and with the mitiglinide/voglibose combination for 6 weeks. MAIN OUTCOME MEASURES: Self-monitoring of blood glucose (SMBG) at home before and after unified meals, metabolic parameters during meal tolerance tests, and overall glycemic control parameters. RESULTS: Postprandial glycemic excursions after all three meals, as assessed by SMBG, were significantly lower in the combination period than in the baseline period, and after lunch and dinner in the combination period than in the mitiglinide period. The meal tolerance test confirmed that the magnitude of postprandial hyperglycemia was significantly lower, with significantly greater early-phase serum insulin secretion and sustained GLP-1 production, in the combination period compared with the baseline period. Overall glycemic control parameters also improved significantly in the combination period compared with the baseline period. These profiles suggest the combination is superior to mitiglinide alone, and may spare insulin secretion. CONCLUSION: The mitiglinide/voglibose combination significantly reduced postprandial glycemic excursions in Japanese T2DM patients. This trial was registered with the University Hospital Medical Information Network clinical trials database (no. UMIN000007202).
■ Other Activities and Achievements
■ Lectures, oral presentations, etc.
  • 成長ホルモン産生下垂体腫瘍におけるβ-カテニンの細胞内局在と病理型・臨床経過との関連
    桑原咲; 亀田啓; 野本博司; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也
    日本内分泌学会雑誌, 2025
    2025 - 2025
  • 成長ホルモン産生下垂体腫瘍におけるWnt/β-カテニン経路と細胞増殖ならびにsparsely granulated typeとの関連
    桑原咲; 亀田啓; 野本博司; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也
    日本間脳下垂体腫瘍学会プログラム・抄録集, 2025
    2025 - 2025
  • チルゼパチドは慢性腎臓病合併2型糖尿病患者の収縮期血圧を低下させる
    大江 悠希; 野本 博司; 曹 圭龍; 宮 愛香; 亀田 啓; 中沢 大悟; 古川 真; 西尾 太郎; 中村 昭伸; 坂井 清志; 渥美 達也
    糖尿病, Dec. 2024, (一社)日本糖尿病学会, Japanese
    Dec. 2024 - Dec. 2024
  • 薬物療法1 慢性腎臓病合併2型糖尿病患者に対するデュラグルチドからチルゼパチドへの切替えとその有効性:非盲検2群前向き観察研究
    大江 悠希; 野本 博司; 曹 圭龍; 大森 高志; 中村 昂生; 吉川 純平; 宮 愛香; 加藤 亜樹子; 亀田 啓; 中沢 大悟; 古川 真; 西尾 太郎; 北川 浩彦; 中村 昭伸; 坂井 清志; 渥美 達也
    糖尿病合併症, Sep. 2024, (一社)日本糖尿病合併症学会, Japanese
    Sep. 2024 - Sep. 2024
  • 薬物療法1 2型糖尿病または耐糖能異常合併高血圧患者におけるエサキセレノンの効果 Ca拮抗薬アムロジピンとの比較
    桑原 咲; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 小梁川 直秀; 山本 浩平; 竹内 淳; 永井 聡; 三次 有奈; 和田 典男; 種田 紳二; 栗原 義夫; 渥美 達也
    糖尿病合併症, Sep. 2024, (一社)日本糖尿病合併症学会, Japanese
    Sep. 2024 - Sep. 2024
  • DPP-4阻害薬から経口セマグルチドへの切替えによる肝脂肪化・線維化指標の改善効果 SWITCH-SEMA2 study post-hoc解析
    古澤 翔; 野本 博司; 横山 宏樹; 鈴木 柚香; 横関 恵; 安井 彩乃; 大江 悠希; 泉原 里美; 宮 愛香; 亀田 啓; 曹 圭龍; 中村 昭伸; 渥美 達也
    糖尿病, Apr. 2024, (一社)日本糖尿病学会, Japanese
    Apr. 2024 - Apr. 2024
  • DPP-4阻害薬から経口セマグルチドへの切替えは膵β細胞機能を改善させる SWITCH-SEMA2 post-hoc解析
    野本 博司; 古澤 翔; 横山 宏樹; 鈴木 柚香; 横関 圭; 安井 彩乃; 泉原 里実; 大江 悠希; 高橋 清彦; 宮 愛香; 亀田 啓; 曹 圭龍; 中村 昭伸; 渥美 達也
    糖尿病, Apr. 2024, (一社)日本糖尿病学会, Japanese
    Apr. 2024 - Apr. 2024
  • DPP-4阻害薬から経口セマグルチドへの切替えは膵β細胞機能を改善させる:SWITCH-SEMA2 post-hoc解析
    野本博司; 古澤翔; 横山宏樹; 鈴木柚香; 横関圭; 安井彩乃; 泉原里実; 大江悠希; 高橋清彦; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 渥美達也
    糖尿病(Web), 2024
    2024 - 2024
  • DPP-4阻害薬から経口セマグルチドへの切替えによる肝脂肪化・線維化指標の改善効果:SWITCH-SEMA2study post-hoc解析
    古澤翔; 野本博司; 横山宏樹; 鈴木柚香; 横関恵; 安井彩乃; 大江悠希; 泉原里美; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 渥美達也
    糖尿病(Web), 2024
    2024 - 2024
  • 成長ホルモン産生下垂体腫瘍においてWnt/β-カテニン経路は細胞増殖に関連する
    桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也
    日本内分泌学会雑誌, 2024
    2024 - 2024
  • 減量・代謝改善手術がNAFLDと膵β細胞機能に及ぼす効果 内科的治療対照前向き観察研究
    大江 悠希; 中村 昭伸; 曹 圭龍; 高瀬 崇宏; 小川 浩司; 海老原 裕磨; 宮 愛香; 野本 博司; 亀田 啓; 渥美 達也
    肥満研究, Nov. 2023, (一社)日本肥満学会, Japanese
    Nov. 2023 - Nov. 2023
  • 2型糖尿病における血清プロインスリンと肝脂肪化との関連
    中村 昭伸; 宮 愛香; 鈴木 柚香; 野本 博司; 亀田 啓; 曹 圭龍; 永井 聡; 渥美 達也
    肥満研究, Nov. 2023, (一社)日本肥満学会, Japanese
    Nov. 2023 - Nov. 2023
  • 薬物療法(4) 2型糖尿病におけるDPP-4阻害薬から経口セマグルチドへの切り替えによる血糖マネジメントへの影響 SWITCH-SEMA2 study
    古澤 翔; 野本 博司; 鈴木 柚香; 横関 恵; 安井 彩乃; 大江 悠希; 泉原 里美; 続木 惇; 高橋 清彦; 宮 愛香; 亀田 啓; 曹 圭龍; 竹内 じゅん; 永井 聡; 種田 紳二; 横山 宏樹; 栗原 義夫; 青木 伸; 中村 昭伸; 渥美 達也
    糖尿病合併症, Sep. 2023, (一社)日本糖尿病合併症学会, Japanese
    Sep. 2023 - Sep. 2023
  • 第1子妊娠中に一過性の尿崩症を呈し,第2子妊娠中に再び尿崩症が出現した1例
    小野 翼; 亀田 啓; 横関 恵; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 渥美 達也
    日本内分泌学会雑誌, May 2023, (一社)日本内分泌学会, Japanese
    May 2023 - May 2023
  • COVID-19感染症を契機に多彩な電解質異常を呈し尿細管機能障害が疑われた一例
    高橋 明広; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 渥美 達也
    日本内分泌学会雑誌, May 2023, (一社)日本内分泌学会, Japanese
    May 2023 - May 2023
  • SGLT2阻害薬投与による尿中L-FABPの変化
    曹圭龍; 家坂光; 大場知穂; 野本博司; 亀田啓; 中村昭伸; 竹内淳; 渥美達也
    糖尿病(Web), 2023
    2023 - 2023
  • 腹腔鏡下スリーブ状胃切除術が肥満2型糖尿病の脂肪肝と膵β細胞機能に及ぼす効果
    大江悠希; 曹圭龍; 曹圭龍; 中村昭伸; 小川浩司; 海老原裕磨; 宮愛香; 野本博司; 亀田啓; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2023
    2023 - 2023
  • 認知機能低下を伴う高齢2型糖尿病患者における経口セマグルチドの有効性
    大江悠希; 大江悠希; 野本博司; 曹圭龍; 曹圭龍; 小野翼; 小野翼; 横関恵; 横関恵; 宮愛香; 亀田啓; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2023
    2023 - 2023
  • 腎移植後の耐糖能改善は移植前の維持透析療法の有無に影響されない
    宮本麻唯子; 中村昭伸; 宮愛香; 野本博司; 亀田啓; 曹圭龍; 堀田記世彦; 篠原信雄; 三好秀明; 渥美達也
    糖尿病(Web), 2023
    2023 - 2023
  • DPP-4阻害薬からSGLT2阻害薬への切替による脈拍日内変動の改善
    亀田玲奈; 曹圭龍; 野本博司; 宮愛香; 亀田啓; 中村昭伸; 竹内淳; 永井聡; 栗原義夫; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2023
    2023 - 2023
  • ペマフィブラートは高中性脂肪血症合併2型糖尿病のインスリン抵抗性を改善させる
    家坂光; 野本博司; 鬼頭健一; 佐久間一郎; 萬田直紀; 川田晋一朗; 亀田啓; 曹圭龍; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2023
    2023 - 2023
  • 高中性脂肪血症合併2型糖尿病におけるペマフィブラートの脂質改善効果
    鬼頭健一; 野本博司; 佐久間一郎; 曹圭龍; 山下久美子; 半田喬久; 永井聡; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2023
    2023 - 2023
  • 高度肥満症患者における減量・代謝改善手術後の栄養アセスメント蛋白と微量元素の変化
    横関恵; 曹圭龍; 大江悠希; 宮愛香; 野本博司; 亀田啓; 中村昭伸; 渥美達也; 三好秀明
    糖尿病(Web), 2023
    2023 - 2023
  • GH産生下垂体腺腫におけるβ-カテニンの細胞内局在と腫瘍径および術後寛解率
    桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也
    日本間脳下垂体腫瘍学会プログラム・抄録集, 2023
    2023 - 2023
  • 糖尿病と感染症
    曹圭龍
    日本糖尿病眼学会総会講演抄録集, 2023
    2023 - 2023
  • 高中性脂肪血症合併2型糖尿病患者へのペマフィブラート投与が肝機能・脂肪肝へ与える影響:多施設共同観察研究PARM-T2Dサブ解析
    野本博司; 鬼頭健一; 家坂光; 半田喬久; 柳谷真悟; 宮愛香; 亀田啓; 曹圭龍; 竹内淳; 永井聡; 佐久間一郎; 中村昭伸; 渥美達也
    糖尿病合併症, 2023
    2023 - 2023
  • 糖尿病性腎臓病患者における従来のフィブラートからペマフィブラートへの切替えが腎機能に及ぼす効果:PARM-T2D studyサブ解析
    泉原里美; 野本博司; 鬼頭健一; 山内裕貴; 大森一乃; 柴山惟; 柳谷真吾; 宮愛香; 亀田啓; 曹圭龍; 永井聡; 佐久間一郎; 中村昭伸; 渥美達也
    糖尿病合併症, 2023
    2023 - 2023
  • 成長ホルモン産生下垂体腫瘍におけるWnt/β-カテニン経路の細胞増殖への影響
    桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也
    日本神経内分泌学会学術集会プログラム・抄録集, 2023
    2023 - 2023
  • 2型糖尿病患者の高血糖に対する認識と実際の高血糖時間との不一致に関連する背景因子
    濱谷柚香; 宮愛香; 野本博司; 亀田啓; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2023
    2023 - 2023
  • COVID-19肺炎治療中に冠攣縮性狭心症を発症した褐色細胞腫の一例
    宮本 麻唯子; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 中久保 祥; 佐藤 琢真; 松本 隆児; 大塚 拓也; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2022, (一社)日本内分泌学会, Japanese
    Oct. 2022 - Oct. 2022
  • リラグルチドおよびデュラグルチドからセマグルチド切り替えによる血糖コントロール及びQOLへの影響 SWITCH-SEMA1 study
    高橋 由華; 野本 博司; 横山 宏樹; 続木 惇; 宮 愛香; 亀田 啓; 曹 圭龍; 大場 知穂; 竹内 淳; 永井 聡; 土田 和久; 種田 紳二; 高野 善成; 木島 弘道; 山下 久美子; 栗原 義夫; 青木 伸; 中村 昭伸; 渥美 達也; 三好 秀明
    糖尿病合併症, Sep. 2022, (一社)日本糖尿病合併症学会, Japanese
    Sep. 2022 - Sep. 2022
  • 2型糖尿病経過中に劇症1型糖尿病が発症した1例
    大西 錦之介; 野田 学; 増田 創; 高橋 由華; 川田 晋一朗; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 免疫チェックポイント阻害薬投与中に早期に発見・治療し得た劇症1型糖尿病の1例
    桑原 咲; 野本 博司; 高橋 由華; 安井 彩乃; 泉原 里美; 大江 悠希; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 酸塩基平衡異常が遷延したSGLT2阻害薬服用下の糖尿病性ケトアシドーシスの2例
    上垣 里紗; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • canagliflozinとteneligliptinの併用はTime Rangeと食後高血糖を改善する
    曹 圭龍; 野本 博司; 中村 昭伸; 川田 晋一朗; 亀田 啓; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 持効型インスリン/GLP-1アナログ配合注の導入により血糖変動が改善した3例
    泉原 里美; 野本 博司; 桑原 咲; 高橋 由華; 安井 彩乃; 大江 悠希; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 腹腔鏡下スリーブ状胃切除術は肥満2型糖尿病患者の治療薬剤を減量し得る
    高橋 由華; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 野本 博司; 亀田 啓; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 肥満合併2型糖尿病患者において、術前骨格筋量が肥満手術の減量効果を予測する
    大江 悠希; 高瀬 崇宏; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 腹腔鏡下スリーブ状胃切除術は脂質代謝および脂肪肝を改善させる
    安井 彩乃; 高瀬 崇宏; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 高中性脂肪血症合併2型糖尿病におけるペマフィブラートの肝機能改善効果
    鬼頭 健一; 野本 博司; 佐久間 一郎; 山下 久美子; 柳谷 真吾; 曹 圭龍; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2022, (一社)日本糖尿病学会, Japanese
    Aug. 2022 - Aug. 2022
  • 本邦における腹腔鏡下スリーブ状胃切除術後の骨密度変化と関連因子 前向きコホート研究
    大江 悠希; 曹 圭龍; 小川 浩司; 海老原 裕磨; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
    日本骨粗鬆症学会雑誌, Aug. 2022, (一社)日本骨粗鬆症学会, Japanese
    Aug. 2022 - Aug. 2022
  • Metabolic Remodeling in Pancreatic Beta Cells in Japanese Patients with Type 2 Diabetes
    Rimi Izumihara; Hiroshi Nomoto; Koki Chiba; Hiraku Kameda; Kyuyong Cho; Akinobu Nakamura; Hideaki Miyoshi; Hiroki Mizukami; Tatsuya Atsumi
    DIABETES, Jun. 2022, English
    Jun. 2022 - Jun. 2022
  • COVID-19ワクチン接種後に脳炎・副腎不全を呈した汎下垂体機能低下症の一例
    濱谷 柚香; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 穴田 麻眞子; 矢部 一郎; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 高齢で診断され、skewed X inactivationが確認されたAVPR2遺伝子変異を有する腎性尿崩症の女性例
    中田 健人; 亀田 啓; 桑原 咲; 安井 彩乃; 高橋 由華; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 岡田 絵里; 野津 寛大; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 細胞株、マウス、患者由来腺腫細胞を用いた、クッシング病に対するニューロメジンB受容体拮抗薬の増殖・ホルモン分泌抑制効果の検討
    関崎 知紀; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 茂木 洋晃; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 2型糖尿病または耐糖能異常合併高血圧患者におけるエサキセレノンの効果
    桑原 咲; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 小梁川 直秀; 竹内 淳; 永井 聡; 三次 有奈; 和田 典男; 種田 紳二; 栗原 義夫; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 減量・代謝改善手術による骨代謝の変化
    大江 悠希; 高瀬 崇宏; 曹 圭龍; 海老原 裕磨; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 平野 聡; 渥美 達也; 三好 秀明
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • COVID-19ワクチン接種後に脳炎・副腎不全を呈した汎下垂体機能低下症の一例
    濱谷 柚香; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 穴田 麻眞子; 矢部 一郎; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • SGLT2阻害薬はミトコンドリア機能の改善を介し膵β細胞量・機能を保護する
    山内 裕貴; 中村 昭伸; 横田 卓; 高橋 清彦; 川田 晋一朗; 土田 和久; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 安斉 俊久; 田中 伸哉; 寺内 康夫; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • グルコキナーゼ活性化薬の長期投与に伴う血糖降下作用の消失機序の解明
    川田 晋一朗; 中村 昭伸; 三好 秀明; 山内 裕貴; 土田 和久; 大森 一乃; 高橋 清彦; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 2型糖尿病における副腎ステロイドホルモン合成亢進機序の解明とDHCR24阻害薬の効果の検討
    上垣 里紗; 亀田 啓; 柴山 惟; 野本 博司; 曹 圭龍; 中村 昭伸; 神 茂樹; 的場 光太郎; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • 高齢で診断され、skewed X inactivationが確認されたAVPR2遺伝子変異を有する腎性尿崩症の女性例
    中田 健人; 亀田 啓; 桑原 咲; 安井 彩乃; 高橋 由華; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 岡田 絵里; 野津 寛大; 渥美 達也
    日本内分泌学会雑誌, Apr. 2022, (一社)日本内分泌学会, Japanese
    Apr. 2022 - Apr. 2022
  • インスリンデグルデクとDPP-4阻害薬の併用からデグルデク/リラグルチド配合注への切替えは血糖変動とQOLを改善させる
    野本 博司; 大江 悠希; 中村 昭伸; 桑原 咲; 高橋 由華; 安井 彩乃; 宮 愛香; 亀田 啓; 曹 圭龍; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 日本人肥満2型糖尿病における腹腔鏡下スリーブ状胃切除術が脂肪肝に及ぼす効果 前向きコホート研究
    大江 悠希; 高瀬 崇宏; 曹 圭龍; 小川 浩司; 海老原 裕磨; 吉川 仁人; 西田 睦; 宮 愛香; 野本 博司; 亀田 啓; 荘 拓也; 須田 剛生; 中村 昭伸; 倉島 庸; 阿保 大介; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 内臓脂肪面積は内因性インスリン分泌低下型の2型糖尿病において血糖変動の安定性を予測する
    宮 愛香; 中村 昭伸; 半田 喬久; 野本 博司; 亀田 啓; 曹 圭龍; 伊藤 陽一; 永井 聡; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 肥満糖尿病病態への介入による膵β細胞の細胞内代謝変化
    千葉 幸輝; 野本 博司; 泉原 里美; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 高中性脂肪血症合併2型糖尿病におけるペマフィブラートの効果 前向きコホート研究
    鬼頭 健一; 野本 博司; 佐久間 一郎; 曹 圭龍; 山下 久美子; 家坂 光; 大江 悠希; 山内 裕貴; 半田 喬久; 川田 晋一郎; 土田 和久; 柴山 唯; 大森 一乃; 大場 知穂; 宮 愛香; 亀田 啓; 竹内 淳; 永井 聡; 種田 紳二; 沖 一郎; 栗原 義夫; 青木 伸; 中村 昭伸; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 2型糖尿病におけるDPP-4阻害薬から経口セマグルチド切り替えによる血糖コントロールへの影響 SWITCH SEMA-2 studyプロトコール
    古澤 翔; 野本 博司; 宮 愛香; 亀田 啓; 曹 圭龍; 中村 昭伸; 竹内 淳; 永井 聡; 種田 紳二; 横山 宏樹; 佐久間 一郎; 栗原 義夫; 青木 伸; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 剖検膵を用いた日本人2型糖尿病膵β細胞における代謝リモデリングの検討
    泉原 里美; 野本 博司; 千葉 幸輝; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 水上 浩哉; 渥美 達也
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 日本人肥満症合併2型糖尿病患者への減量・代謝改善手術により代謝疾患は改善し治療薬を減量し得る
    大藤 悠理; 曹 圭龍; 海老原 裕磨; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 耐糖能異常患者における腎移植後の耐糖能変化及びその関連因子
    久住 麻唯子; 中村 昭伸; 宮 愛香; 野本 博司; 亀田 啓; 曹 圭龍; 堀田 記世彦; 篠原 信雄; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 左上下肢の不随意運動を契機に診断された糖尿病性舞踏病の一例
    横関 恵; 野本 博司; 桑原 咲; 宮 愛香; 亀田 啓; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • リラグルチドおよびデュラグルチドからセマグルチド切り替えによる血糖コントロール及びQOLへの影響 SWITCH-SEMA1 study
    高橋 由華; 野本 博司; 横山 宏樹; 濱谷 柚香; 宮崎 あすか; 中田 健人; 泉原 里美; 上垣 里紗; 続木 惇; 宮 愛香; 亀田 啓; 曹 圭龍; 大場 知穂; 竹内 淳; 永井 聡; 土田 和久; 種田 紳二; 高野 善成; 木島 弘道; 山下 久美子; 栗原 義夫; 青木 伸; 中村 昭伸; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する
    中村 昭伸; 大江 悠希; 久住 麻唯子; 宮 愛香; 野本 博司; 亀田 啓; 曹 圭龍; 小川 浩司; 荘 拓也; 須田 剛生; 吉川 仁人; 阿保 大介; 西田 睦; 海老原 裕磨; 倉島 庸; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2022, (一社)日本糖尿病学会, Japanese
    Apr. 2022 - Apr. 2022
  • 減量代謝改善手術後の甲状腺機能の変化
    大江 悠希; 亀田 啓; 関崎 知紀; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 渥美 達也; 三好 秀明
    日本内分泌学会雑誌, Mar. 2022, (一社)日本内分泌学会, Japanese
    Mar. 2022 - Mar. 2022
  • ニューロメジンB受容体を標的としたACTH産生下垂体腺腫の新規治療法の探索
    関崎 知紀; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 岡本 迪成; 茂木 洋晃; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Mar. 2022, (一社)日本内分泌学会, Japanese
    Mar. 2022 - Mar. 2022
  • 減量・代謝改善手術による代謝疾患治療薬の減量と総体重減少率の関連
    大藤 悠理; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    肥満研究, Mar. 2022, (一社)日本肥満学会, Japanese
    Mar. 2022 - Mar. 2022
  • 減量・代謝改善手術によるインスリン抵抗性と分泌能の変化
    久住 麻唯子; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    肥満研究, Mar. 2022, (一社)日本肥満学会, Japanese
    Mar. 2022 - Mar. 2022
  • 減量・代謝改善手術後の栄養動態変化
    横関 恵; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    肥満研究, Mar. 2022, (一社)日本肥満学会, Japanese
    Mar. 2022 - Mar. 2022
  • 耐糖能異常を伴う肥満患者の腹腔鏡下スリーブ状胃切除術の肝脂肪化および肝線維化に対する効果
    古澤 翔; 曹 圭龍; 大江 悠希; 高橋 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    肥満研究, Mar. 2022, (一社)日本肥満学会, Japanese
    Mar. 2022 - Mar. 2022
  • 腹腔鏡下スリーブ状胃切除術後の骨密度の変化
    濱谷 柚香; 曹 圭龍; 大江 悠希; 高瀬 崇宏; 宮 愛香; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    肥満研究, Mar. 2022, (一社)日本肥満学会, Japanese
    Mar. 2022 - Mar. 2022
  • SGLT2阻害薬による膵β細胞保護作用の機序の解明
    山内裕貴; 中村昭伸; 横田卓; 高橋清彦; 川田晋一朗; 土田和久; 大森一乃; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 安斉俊久; 田中伸哉; 田中伸哉; 寺内康夫; 三好秀明; 三好秀明; 渥美達也
    日本糖尿病・肥満動物学会年次学術集会プログラム・講演抄録集, 2022
    2022 - 2022
  • グルコキナーゼの抑制が2型糖尿病病態下の膵β細胞量を保持する
    大森一乃; 中村昭伸; 三好秀明; 三好秀明; 山内裕貴; 川田晋一朗; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 寺内康夫; 渥美達也
    日本糖尿病・肥満動物学会年次学術集会プログラム・講演抄録集, 2022
    2022 - 2022
  • 肥満合併2型糖尿病患者において,術前骨格筋量が肥満手術の減量効果を予測する
    大江悠希; 高瀬崇宏; 野本博司; 亀田啓; 曹圭龍; 中村昭伸; 海老原裕磨; 平野聡; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 糖尿病合併肥満患者に対する腹腔鏡下スリーブ状胃切除術後の骨密度への影響
    濱谷柚香; 曹圭龍; 大江悠希; 高瀬崇宏; 宮愛香; 野本博司; 亀田啓; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 神経性やせ症の治療経過中に1型糖尿病を発症し治療に難渋した1例
    宮崎あすか; 野本博司; 桑原咲; 山内裕貴; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2022
    2022 - 2022
  • ペマフィブラートは高中性脂肪血症合併2型糖尿病患者の肝機能・肝脂肪化を改善する
    古澤翔; 鬼頭健一; 鬼頭健一; 野本博司; 佐久間一郎; 山下久美子; 柳谷真悟; 曹圭龍; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 減量・代謝改善手術1年後総体重減少率が18.2%を超えると糖尿病治療薬を中止し得る
    大藤悠理; 曹圭龍; 大江悠希; 高瀬崇宏; 宮愛香; 野本博司; 亀田啓; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 札幌糖尿病療養指導士認定機構の活動と今後について
    亀田啓; 中村昭伸; 大場知穂; 曹圭龍; 川崎てるみ; 中野玲子; 福岡由紀; 坂田祐樹; 小林元子; 関口雅友; 三好秀明; 亀田啓; 中村昭伸; 大場知穂; 曹圭龍; 川崎てるみ; 中野玲子; 福岡由紀; 坂田祐樹; 小林元子; 関口雅友; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 糖尿病性ケトアシドーシスに高度脂肪肝を合併した2例
    横関恵; 野本博司; 濱谷柚香; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2022
    2022 - 2022
  • 2型糖尿病における減量・代謝改善手術はインスリン抵抗性と分泌能を改善させる
    久住麻唯子; 曹圭龍; 大江悠希; 高瀬崇宏; 宮愛香; 野本博司; 亀田啓; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 週3回デグルデク投与の効果を持続血糖モニターにて評価した高齢者2型糖尿病の1例
    中田健人; 野本博司; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2022
    2022 - 2022
  • 高中性脂肪血症合併2型糖尿病におけるペマフィブラートの効果-前向きコホート研究-
    鬼頭健一; 野本博司; 佐久間一郎; 山下久美子; 曹圭龍; 中村昭伸; 柳谷真悟; 半田喬久; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • デグルデク/リラグルチド配合注は血糖変動を改善しQOLを向上させ得る
    大江悠希; 野本博司; 中村昭伸; 桑原咲; 高橋由華; 安井彩乃; 宮愛香; 亀田啓; 曹圭龍; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2022
    2022 - 2022
  • 患者・市民参画(PPI)ワークショップトライアルの検討
    堀江奈穂; 渡邊祐介; 曹圭龍; 豊田有希; 菊池ちひろ; 佐藤典宏
    日本臨床薬理学会学術総会抄録集(Web), 2022
    2022 - 2022
  • 腹腔鏡下スリーブ状胃切除術は2型糖尿病における糖代謝および脂肪肝を改善する-前向き観察研究-
    大江悠希; 曹圭龍; 高瀬崇宏; 高瀬崇宏; 海老原裕磨; 宮愛香; 野本博司; 亀田啓; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2022
    2022 - 2022
  • 内臓脂肪面積はインスリン分泌低下型の2型糖尿病において血糖変動の安定性を予測する
    宮愛香; 中村昭伸; 半田喬久; 野本博司; 亀田啓; 曹圭龍; 伊藤陽一; 永井聡; 三好秀明; 渥美達也
    日本内科学会雑誌, 2022
    2022 - 2022
  • パシレオチド投与後に著明な高血糖を呈した先端巨大症の1例
    大藤 悠理; 亀田 啓; 桑原 咲; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • IgG4関連疾患治療中に尿崩症を呈しIgG4関連漏斗下垂体炎を発症した1例
    中田 健人; 亀田 啓; 桑原 咲; 安井 彩乃; 高橋 由華; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • 原発性アルドステロン症を合併した中枢性尿崩症の1例
    宮崎 あすか; 亀田 啓; 亀田 玲奈; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • 対側病変の原発性アルドステロン症を合併した副腎性Cushing症候群に対して副腎部分切除を施行した1例
    横関 恵; 亀田 啓; 千葉 幸輝; 桑原 咲; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 安倍 崇重; 篠原 信雄; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • 慢性心房細動に対する抗凝固療法中に指摘された両側副腎血腫の1例
    濱谷 柚香; 亀田 啓; 安井 彩乃; 大江 悠希; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • 悪性腹膜中皮腫の治療中に著しい高LDLコレステロール血症を指摘された1例
    久住 麻唯子; 亀田 啓; 千葉 幸輝; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 大原 克仁; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2021, (一社)日本内分泌学会, Japanese
    Dec. 2021 - Dec. 2021
  • 妊娠中の高血圧緊急症から診断されたパラガングリオーマの一例
    中田 健人; 亀田 啓; 桑原 咲; 安井 彩乃; 高橋 由華; 高瀬 崇宏; 西尾 太郎; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 安部 崇重; 篠原 信雄; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2021, (一社)日本内分泌学会, Japanese
    Oct. 2021 - Oct. 2021
  • 常染色体優性多発性嚢胞腎を合併した嚢胞性GH産生下垂体腺腫
    桑原 咲; 亀田 啓; 関崎 知紀; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 岡本 迪成; 茂木 洋晃; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2021, (一社)日本内分泌学会, Japanese
    Oct. 2021 - Oct. 2021
  • ライム病を契機に診断されたACTH単独欠損症の一例
    各務 萌; 亀田 啓; 古澤 翔; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2021, (一社)日本内分泌学会, Japanese
    Oct. 2021 - Oct. 2021
  • 抗rabphilin-3A抗体が陽性であったリンパ球性汎下垂体炎の一例
    高橋 由華; 亀田 啓; 曹 圭龍; 中村 昭伸; 西村 弘基; 木村 孔一; 清水 亜衣; 岡本 迪成; 茂木 洋晃; 岩田 尚子; 藤沢 治樹; 鈴木 敦詞; 椙村 益久; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2021, (一社)日本内分泌学会, Japanese
    Oct. 2021 - Oct. 2021
  • 腫瘍性骨軟化症に対してブロスマブを使用した3例
    宮崎 あすか; 亀田 啓; 大江 悠希; 泉原 里美; 重沢 郁美; 野本 博司; 曹 圭龍; 中村 昭伸; 坂本 圭太; 森田 亮; 曽山 武士; 阿保 大介; 工藤 與亮; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2021, (一社)日本内分泌学会, Japanese
    Oct. 2021 - Oct. 2021
  • 肥満糖尿病病態におけるHPA軸の活動性亢進機序
    関崎 知紀; 亀田 啓; 柴山 惟; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    ACTH RELATED PEPTIDES, Sep. 2021, 間脳・下垂体・副腎系研究会, Japanese
    Sep. 2021 - Sep. 2021
  • 認知・生活機能質問票(DASC-8)を用いた目標HbA1cの達成に関連する患者背景因子の特定
    宮 愛香; 中村 昭伸; 横田 勲; 曹 圭龍; 亀田 啓; 野本 博司; 高瀬 崇宏; 大森 一乃; 永井 聡; 種田 紳二; 小野 真佑子; 渥美 達也; 三好 秀明
    糖尿病合併症, Sep. 2021, (一社)日本糖尿病合併症学会, Japanese
    Sep. 2021 - Sep. 2021
  • Improved Mitochondria! Function by Luseogliflozin Prevents Pancreatic Beta-Cell Damage
    Yuki Yamauchi; Akinobu Nakamura; Takashi Yokota; Kiyohiko Takahashi; Shinichiro Kawata; Kazuhisa Tsuchida; Kazuno Omori; Hiroshi Nomoto; Hiraku Kameda; Kyuyong Cho; Toshihisa Anzai; Shinya Tanaka; Yasuo Terauchi; Hideaki Miyoshi; Tatsuya Atsumi
    DIABETES, Jun. 2021, English
    Jun. 2021 - Jun. 2021
  • 膵特異的グルコキナーゼの抑制が2型糖尿病病態下の膵β細胞量を保持する
    大森 一乃; 中村 昭伸; 三好 秀明; 川田 晋一朗; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 肥満外科治療は糖尿病治療薬の減量・中止および2型糖尿病寛解の期待ができる
    千葉 幸輝; 大江 悠希; 高瀬 崇宏; 曹 圭龍; 野本 博司; 亀田 啓; 中村 昭伸; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 糖代謝障害を伴った高度肥満症患者における腹腔鏡下スリーブ状胃切除術による糖・脂質代謝および肝臓への好影響
    安井 彩乃; 曹 圭龍; 大江 悠希; 野本 博司; 亀田 啓; 中村 昭伸; 海老原 裕磨; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • リラグルチドおよびデュラグルチドからセマグルチド切り替えによる血糖コントロール及びQOLへの影響 SWITCH-SEMA1プロトコール
    高橋 由華; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 竹内 淳; 永井 聡; 種田 紳二; 横山 宏樹; 栗原 義夫; 青木 伸; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 2型糖尿病または耐糖能異常合併高血圧患者におけるエサキセレノンの効果
    桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 山本 浩平; 種田 紳二; 三次 有奈; 和田 典男; 小梁川 直秀; 竹内 淳; 永井 聡; 栗原 義夫; 三好 秀明; 渥美 達也
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • DPP-4阻害薬からSGLT2阻害薬への切替は、高血圧症を合併する2型糖尿病患者の夜間血圧・脈拍を低下させる
    亀田 玲奈; 曹 圭龍; 川田 晋一朗; 大森 一乃; 野本 博司; 亀田 啓; 竹内 淳; 永井 聡; 中村 昭伸; 栗原 義夫; 青木 伸; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 空腹時内因性インスリン分泌は不安定な血糖変動・低血糖の予測に役立つだけでなく血糖降下薬の選択においても有用である
    宮 愛香; 中村 昭伸; 半田 喬久; 野本 博司; 亀田 啓; 曹 圭龍; 永井 聡; 伊藤 陽一; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • インスリンデグルデクとDPP-4阻害薬の併用からデグルデク/リラグルチド配合注への切り替えは血糖変動を改善する
    大江 悠希; 野本 博司; 中村 昭伸; 桑原 咲; 高橋 由華; 安井 彩乃; 亀田 啓; 曹 圭龍; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 耐糖能異常合併肥満症患者における腹腔鏡下スリーブ状胃切除後の骨密度低下
    上垣 里紗; 大江 悠希; 亀田 啓; 高瀬 崇宏; 野本 博司; 曹 圭龍; 中村 昭伸; 平野 聡; 渥美 達也; 三好 秀明
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • db/dbマウスを用いたグルコキナーゼ活性化薬の血糖降下作用消失機序の解明
    川田 晋一朗; 中村 昭伸; 三好 秀明; 重沢 郁美; 山内 裕貴; 土田 和久; 大森 一乃; 高橋 清彦; 北尾 直之; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • SGLT2阻害薬はミトコンドリア機能の改善を介し膵β細胞を保護する
    山内 裕貴; 中村 昭伸; 横田 卓; 高橋 清彦; 川田 晋一朗; 土田 和久; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 安斉 俊久; 田中 伸哉; 寺内 康夫; 三好 秀明; 渥美 達也
    糖尿病, May 2021, (一社)日本糖尿病学会, Japanese
    May 2021 - May 2021
  • 高コルチゾール血症を呈したFamilial Dysalbuminemic Hyperthyroxinemiaの一例
    千葉 幸輝; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 神 繁樹; 的場 光太郎; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2021, (一社)日本内分泌学会, Japanese
    Apr. 2021 - Apr. 2021
  • ニューロメジンB受容体はACTH産生下垂体腺腫の治療ターゲットとなりうる
    関崎 知紀; 亀田 啓; 中村 昭伸; 野本 博司; 曹 圭龍; 伊師 雪友; 茂木 洋晃; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2021, (一社)日本内分泌学会, Japanese
    Apr. 2021 - Apr. 2021
  • グルコキナーゼの抑制が2型糖尿病病態下の膵β細胞量に与える影響
    大森 一乃; 中村 昭伸; 三好 秀明; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    日本内分泌学会雑誌, Apr. 2021, (一社)日本内分泌学会, Japanese
    Apr. 2021 - Apr. 2021
  • COVID-19肺炎を合併し、ブロック&リプレースにより高コルチゾール血症のコントロールを行った活動性クッシング病の1例
    湯野 暁子; 高橋 由華; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 山下 優; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 井下 尚子; 今野 哲; 三好 秀明; 渥美 達也; 澤村 豊; 島津 章
    日本内分泌学会雑誌, Apr. 2021, (一社)日本内分泌学会, Japanese
    Apr. 2021 - Apr. 2021
  • 腹腔鏡下スリーブ状胃切除後の大腿骨頸部骨密度低下に関連する因子
    亀田啓; 大江悠希; 高瀬崇宏; 高瀬崇宏; 野本博司; 曹圭龍; 曹圭龍; 中村昭伸; 平野聡; 渥美達也; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • 膵β細胞グルコキナーゼの抑制が肥満2型糖尿病モデルマウスの膵β細胞機能・量を保持する
    中村昭伸; 大森一乃; 三好秀明; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 寺内康夫; 渥美達也
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • 肥満を伴う2型糖尿病患者に対する腹腔鏡下スリーブ状胃切除術の薬剤減量効果
    高橋由華; 高瀬崇宏; 高瀬崇宏; 大江悠希; 野本博司; 亀田啓; 曹圭龍; 中村昭伸; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • 肥満患者に対する腹腔鏡下スリーブ状胃切除術の脂肪肝および脂肪代謝の改善効果
    安井彩乃; 曹圭龍; 大江悠希; 高瀬崇宏; 野本博司; 亀田啓; 中村昭伸; 海老原裕磨; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • 当院における肥満外科手術の治療効果と減量不良因子についての検討
    大江悠希; 高瀬崇宏; 高瀬崇宏; 野本博司; 亀田啓; 曹圭龍; 中村昭伸; 海老原裕磨; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • SGLT2阻害薬はミトコンドリア機能の改善を介し膵β細胞を保護する
    山内裕貴; 中村昭伸; 横田卓; 高橋清彦; 川田晋一朗; 土田和久; 大森一乃; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 安斉俊久; 田中伸哉; 田中伸哉; 寺内康夫; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2021
    2021 - 2021
  • DPP-4阻害薬からSGLT2阻害薬への切替は,高血圧症を合併する2型糖尿病患者の夜間血圧・脈拍を低下させる
    亀田玲奈; 曹圭龍; 曹圭龍; 川田晋一朗; 大森一乃; 野本博司; 亀田啓; 竹内淳; 永井聡; 中村昭伸; 栗原義夫; 青木伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2021
    2021 - 2021
  • リラグルチドおよびデュラグルチドからセマグルチド切り替えによる血糖コントロール及びQOLへの影響:SWITCH-SEMA1プロトコール
    高橋由華; 野本博司; 亀田啓; 曹圭龍; 中村昭伸; 竹内淳; 永井聡; 種田紳二; 横山宏樹; 栗原義夫; 青木伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2021
    2021 - 2021
  • メドロキシプロゲステロンにより副腎皮質機能低下を呈した1例
    安井 彩乃; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Jan. 2021, (一社)日本内分泌学会, Japanese
    Jan. 2021 - Jan. 2021
  • 悪性リンパ腫の両側副腎転移により副腎不全を呈した1例
    桑原 咲; 亀田 啓; 家坂 光; 泉原 里美; 大江 悠希; 上垣 里紗; 千葉 幸輝; 宮 愛華; 野本 博司; 曹 圭龍; 中村 昭伸; 安部 崇重; 篠原 信雄; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Jan. 2021, (一社)日本内分泌学会, Japanese
    Jan. 2021 - Jan. 2021
  • 肥満外科手術後に妊娠・出産に至った肥満2型糖尿病の1例
    高瀬崇宏; 高瀬崇宏; 亀田玲奈; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 海老原裕磨; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2021
    2021 - 2021
  • 持続血糖モニタリングにおける2型糖尿病患者の血糖変動と内因性インスリン分泌の関係性
    宮愛香; 中村昭伸; 半田喬久; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 永井聡; 伊藤陽一; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2021
    2021 - 2021
  • COVID-19肺炎を合併したCushing病の一例
    高橋 由華; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 湯野 暁子; 澤村 豊; 島津 章; 山下 優; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 今野 哲; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2020, (一社)日本内分泌学会, Japanese
    Oct. 2020 - Oct. 2020
  • 副甲状腺切除26年後に多発性内分泌腫瘍症1型と診断された1例
    泉原 里美; 亀田 啓; 家坂 光; 大江 悠希; 千葉 幸輝; 上垣 里紗; 重沢 郁美; 亀田 玲奈; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2020, (一社)日本内分泌学会, Japanese
    Oct. 2020 - Oct. 2020
  • 病理所見から原発性色素性結節状副腎皮質病変が疑われた一例
    上垣 里紗; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 清水 亜衣; 笹野 公伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2020, (一社)日本内分泌学会, Japanese
    Oct. 2020 - Oct. 2020
  • 抗FGF23抗体が奏功したFGF23関連低リン血症性骨軟化症の一例
    大江 悠希; 亀田 啓; 家坂 光; 泉原 里美; 上垣 里紗; 亀田 玲奈; 野本 博司; 坂本 圭太; 曽山 武士; 曹 圭龍; 中村 昭伸; 阿保 大介; 工藤 與亮; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2020, (一社)日本内分泌学会, Japanese
    Oct. 2020 - Oct. 2020
  • 転移性腎癌に対するニボルマブとイピリムマブの併用療法により破壊性甲状腺炎に続いて劇症1型糖尿病を発症した1例
    家坂 光; 亀田 啓; 安部 崇重; 亀田 玲奈; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 篠原 信雄; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • 1型糖尿病患者へのSGLT2阻害薬の投与は血糖変動を改善する
    泉原 里美; 亀田 啓; 千葉 幸輝; 野本 博司; 曹 圭龍; 中村 昭伸; 山下 久美子; 栗原 義夫; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • 肥満外科治療は薬剤の減量・中止および糖尿病寛解を期待できる
    大江 悠希; 高瀬 崇宏; 曹 圭龍; 野本 博司; 亀田 啓; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • SGLT2阻害薬ルセオグリフロジンによる膵β細胞保護作用の機序の解明
    山内 裕貴; 中村 昭伸; 三好 秀明; 関崎 知紀; 川田 晋一朗; 土田 和久; 柴山 惟; 大森 一乃; 高橋 清彦; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • グルコキナーゼ活性化薬の長期投与に伴う血糖降下作用の消失機序の解明
    川田 晋一朗; 中村 昭伸; 山内 裕貴; 関崎 知紀; 土田 和久; 柴山 惟; 大森 一乃; 高橋 清彦; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 三好 秀明; 渥美 達也
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • 高血圧症合併2型糖尿病患者におけるDPP-4阻害薬からSGLT2阻害薬への切替による血圧・脈拍への影響に関する検討(プロトコール)
    曹 圭龍; 亀田 玲奈; 野本 博司; 中村 昭伸; 竹内 淳; 永井 聡; 栗原 義夫; 青木 伸; 渥美 達也; 三好 秀明
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • 高炭水化物食長期摂取による膵β細胞量増加作用におけるグルコキナーゼの役割
    土田 和久; 中村 昭伸; 三好 秀明; Kelaier Yang; 関崎 知紀; 山内 裕貴; 川田 晋一朗; 柴山 惟; 大森 一乃; 野本 博司; 亀田 啓; 曹 圭龍; 清野 祐介; 寺内 康夫; 渥美 達也
    糖尿病, Aug. 2020, (一社)日本糖尿病学会, Japanese
    Aug. 2020 - Aug. 2020
  • メチラポンの投与で自覚症状が改善した再発周期性クッシング病の一例
    上垣 里紗; 亀田 啓; 家坂 光; 泉原 里美; 大江 悠希; 千葉 幸輝; 小野 渉; 重沢 郁美; 亀田 玲奈; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Aug. 2020, (一社)日本内分泌学会, Japanese
    Aug. 2020 - Aug. 2020
  • 新規TRβ遺伝子変遺を認め、心房細動と脳梗塞を発症した甲状腺ホルモン不応症の一例
    小野 渉; 亀田 啓; 家坂 光; 泉原 里美; 大江 悠希; 上垣 里紗; 千葉 幸輝; 亀田 玲奈; 野本 博司; 曹 圭龍; 中村 昭伸; 林 良敬; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Aug. 2020, (一社)日本内分泌学会, Japanese
    Aug. 2020 - Aug. 2020
  • 高コルチゾール血症を呈したFamilial Dysalbuminemic Hyperthyroxinemiaの一例
    千葉 幸輝; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 神 繁樹; 的場 光太郎; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Aug. 2020, (一社)日本内分泌学会, Japanese
    Aug. 2020 - Aug. 2020
  • 1型糖尿病患者へのSGLT-2阻害薬投与の有効性と安全性
    千葉 幸輝; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 山下 久美子; 栗原 義夫; 渥美 達也; 三好 秀明
    糖尿病, May 2020, (一社)日本糖尿病学会, Japanese
    May 2020 - May 2020
  • 1型糖尿病患者におけるSensor Augmented Pump療法(SAP)への変更の効果
    川田 晋一朗; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, May 2020, (一社)日本糖尿病学会, Japanese
    May 2020 - May 2020
  • 糖尿病合併肥満症患者に対する腹腔鏡下スリーブ状胃切除術への術前寛解予測スコアの検討
    小野 渉; 中村 昭伸; 海老原 裕磨; 曹 圭龍; 亀田 玲奈; 亀田 啓; 野本 博司; 渥美 達也; 三好 秀明; 平野 聡
    糖尿病, May 2020, (一社)日本糖尿病学会, Japanese
    May 2020 - May 2020
  • グルコキナーゼ活性化薬の長期投与に伴う血糖降下作用の消失機序の解明
    川田 晋一朗; 中村 昭伸; 三好 秀明; 山内 裕貴; 土田 和久; 大森 一乃; 高橋 清彦; 野本 博司; 亀田 啓; 曹 圭龍; 寺内 康夫; 渥美 達也
    日本臨床分子医学会学術総会プログラム・抄録集, Apr. 2020, 日本臨床分子医学会, Japanese
    Apr. 2020 - Apr. 2020
  • 当院における免疫チェックポイント阻害薬による下垂体機能低下症の臨床的特徴
    泉原里美; 亀田啓; 家坂光; 大江悠希; 千葉幸輝; 小野渉; 上垣里紗; 重沢郁美; 亀田玲奈; 野本博司; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2020
    2020 - 2020
  • 肥満糖尿病病態におけるアルドステロン合成亢進機構の解明
    柴山惟; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本糖尿病・肥満動物学会年次学術集会プログラム・講演抄録集, 2020
    2020 - 2020
  • 1型糖尿病患者におけるSensor Augmented Pump療法(SAP)への変更の効果
    川田晋一朗; 亀田啓; 野本博司; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2020
    2020 - 2020
  • 糖尿病合併肥満症患者に対する腹腔鏡下スリーブ状胃切除術への術前寛解予測スコアの検討
    小野渉; 中村昭伸; 海老原裕磨; 海老原裕磨; 曹圭龍; 亀田玲奈; 亀田啓; 野本博司; 渥美達也; 三好秀明; 平野聡; 平野聡
    糖尿病(Web), 2020
    2020 - 2020
  • 肥満を伴う2型糖尿病患者に対する腹腔鏡下スリーブ状胃切除術の治療効果
    大江悠希; 中村昭伸; 海老原裕磨; 亀田玲奈; 曹圭龍; 平野聡; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2020
    2020 - 2020
  • フラッシュグルコースモニタリングの導入が血糖コントロールに及ぼす影響の検討
    泉原里美; 亀田啓; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2020
    2020 - 2020
  • 高炭水化物食長期摂取による膵β細胞量増加作用におけるグルコキナーゼの役割
    土田和久; 中村昭伸; 三好秀明; YANG Kelaier; 関崎知紀; 山内裕貴; 川田晋一朗; 柴山惟; 大森一乃; 野本博司; 亀田啓; 曹圭龍; 清野祐介; 寺内康夫; 渥美達也
    糖尿病(Web), 2020
    2020 - 2020
  • 食道癌の治療中に横紋筋融解症を発症したことを契機に診断された甲状腺機能低下症の一例
    大江悠希; 亀田啓; 関崎知紀; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 原田一顕; 結城敏志; 小松嘉人; 坂本直哉; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2020
    2020 - 2020
  • 下垂体全摘後に寛解と増悪を呈し周期性が疑われたクッシング病
    桑原咲; 亀田啓; 高橋由華; 安井彩乃; 泉原里美; 大江悠希; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2020
    2020 - 2020
  • 分娩直後に尿崩症を呈し血管攣縮による下垂体壊死が疑われた一例
    安井彩乃; 亀田啓; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 茂木洋晃; 藤沢治樹; 鈴木敦詞; 三好秀明; 三好秀明; 椙村益久; 渥美達也
    日本内分泌学会雑誌, 2020
    2020 - 2020
  • 2型糖尿病合併高度肥満患者に対する腹腔鏡下スリーブ状胃切除の脂肪肝への影響
    亀田玲奈; 高瀬崇宏; 高瀬崇宏; 海老原裕磨; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 平野聡; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2020
    2020 - 2020
  • 肥満外科手術で腎機能が改善した慢性腎臓病合併肥満2型糖尿病の2例
    上垣里紗; 高瀬崇宏; 中村昭伸; 海老原裕磨; 亀田玲奈; 宮愛香; 亀田啓; 曹圭龍; 平野聡; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2020
    2020 - 2020
  • 腎移植後膵移植施行後の耐糖能の経過を追えた1例
    家坂光; 曹圭龍; 柴山惟; 大森一乃; 亀田玲奈; 宮愛香; 亀田啓; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    糖尿病(Web), 2020
    2020 - 2020
  • 肥満外科手術後に妊娠・出産に至った肥満2型糖尿病の1例
    高瀬崇宏; 海老原裕磨; 亀田玲奈; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 平野聡; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2020
    2020 - 2020
  • 内因性インスリン分泌は2型糖尿病における血糖変動の不安定性を予測する
    宮愛香; 中村昭伸; 半田喬久; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 永井聡; 三好秀明; 渥美達也
    糖尿病合併症, 2020
    2020 - 2020
  • 高齢2型糖尿病では,低血糖域の割合は変動係数と関連する
    半田喬久; 半田喬久; 宮愛香; 中村昭伸; 野本博司; 亀田啓; 曹圭龍; 曹圭龍; 永井聡; 三好秀明; 吉岡成人; 渥美達也
    糖尿病合併症, 2020
    2020 - 2020
  • 1型糖尿病患者へのSGLT-2阻害薬投与の有効性と安全性
    千葉幸輝; 亀田啓; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 山下久美子; 栗原義夫; 渥美達也; 三好秀明
    糖尿病(Web), 2020
    2020 - 2020
  • Type 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy
    Takuya Maeda; Shinya Kitamura; Teruki Yanagi; Atsushi Narahira; Kodai Miyamoto; Hiroo Hata; kyu Yong Cho; Hiraku Kameda; Akinobu Nakamura; Hiroshi Shimizu
    Journal of Cutaneous Immunology and Allergy, 01 Dec. 2019
    01 Dec. 2019 - 01 Dec. 2019
  • Adipose Tissue Insulin Resistance in Overweight and Lean Patients with Impaired Glucose Tolerance or Type 2 Diabetes
    Aika Miya; Akinobu Nakamura; Hiraku Kameda; Kyuyong Cho; Hideaki Miyoshi; Tatsuya Atsumi
    DIABETES, Jun. 2019, English
    Jun. 2019 - Jun. 2019
  • 感染症から死の転帰に至った高齢サブクリニカルクッシング病の一剖検例
    山内 裕貴; 亀田 啓; 馬場 菜月; 関崎 知紀; 平田 恵里奈; 大森 一乃; 高瀬 崇宏; 亀田 玲奈; 大場 知穂; 谷 道夫; 曹 圭龍; 中村 昭伸; 三好 秀明; 田中 伸哉; 渥美 達也
    日本内分泌学会雑誌, Apr. 2019, (一社)日本内分泌学会, Japanese
    Apr. 2019 - Apr. 2019
  • 著明な高Ca血症と骨量減少を呈したatypical parathyroid adenomaの一例
    大場 知穂; 亀田 啓; 桑原 健; 高桑 恵美; 馬場 菜月; 関崎 知紀; 山内 裕貴; 平田 恵里奈; 高瀬 崇宏; 亀田 玲奈; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2019, (一社)日本内分泌学会, Japanese
    Apr. 2019 - Apr. 2019
  • ACTHの一過性上昇後に下垂体性副腎皮質機能低下に至ったニボルマブ誘発性下垂体炎の1例
    関崎 知紀; 亀田 啓; 馬場 菜月; 山内 裕貴; 平田 恵里奈; 柴山 惟; 宮野 有希恵; 高瀬 崇宏; 亀田 玲奈; 大場 知穂; 曹 圭龍; 中村 昭伸; 三好 秀明; 大澤 崇宏; 篠原 信雄; 渥美 達也
    日本内分泌学会雑誌, Apr. 2019, (一社)日本内分泌学会, Japanese
    Apr. 2019 - Apr. 2019
  • DPP-4阻害薬とSGLT2阻害薬併用による血糖変動平坦化の増強効果
    曹 圭龍; 中村 昭伸; 川田 晋一朗; 土田 和久; 大森 一乃; 菅原 基; 野本 博司; 本庄 潤; 竹内 淳; 永井 聡; 横山 宏樹; 萬田 直紀; 栗原 義夫; 青木 伸; 渥美 達也; 三好 秀明
    糖尿病, Apr. 2019, (一社)日本糖尿病学会, Japanese
    Apr. 2019 - Apr. 2019
  • 妊娠後期に発症した一過性尿崩症の一例
    山内裕貴; 亀田啓; 馬場菜月; 関崎知紀; 平田恵里奈; 柴山惟; 高瀬崇宏; 宮野有希恵; 亀田玲奈; 馬詰武; 河口哲; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • DPP-4阻害薬はバセドウ病を増悪させるか?
    関崎知紀; 亀田啓; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 高橋清彦; 和田典男; 竹内淳; 永井聡
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • 高度肥満を伴う2型糖尿病患者に対する腹腔鏡下スリーブ状胃切除は脂肪肝を改善する
    亀田玲奈; 高瀬崇宏; 海老原裕磨; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 平野聡; 渥美達也; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2019
    2019 - 2019
  • パシレオチドにより良好なコントロールが得られた手術困難な先端巨大症の1例
    泉原里美; 亀田啓; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • 急性リンパ性白血病の治療40年後に下垂体前葉機能低下症と診断されたCancer Survivorの1例
    関崎知紀; 亀田啓; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • パシレオチドとメチラポンの併用療法を行ったクッシング病の一例
    亀田啓; 泉原里美; 家坂光; 大江悠希; 千葉幸輝; 上垣里紗; 小野渉; 亀田玲奈; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • 脂肪滴周囲蛋白PLINはマクロファージ内の脂肪貯留調節を介して炎症に対する極性を制御する
    曹圭龍; 曹圭龍; 三好秀明; 三好秀明
    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 2019
    2019 - 2019
  • 副腎ペリリピン1は糖・脂質代謝異常でのステロイドホルモン合成増加に関与する
    亀田啓; 山本浩平; 山本浩平; 川田晋一朗; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • 肥満2型糖尿病患者に対する腹腔鏡下スリーブ状胃切除術は脂肪肝を改善する
    亀田玲奈; 中村昭伸; 高瀬崇宏; 海老原裕磨; 大場知穂; 亀田啓; 曹圭龍; 平野聡; 渥美達也; 三好秀明
    糖尿病(Web), 2019
    2019 - 2019
  • デグルデク/アスパルト配合剤1日1回注射療法は食後,特に夕食後,就寝前血糖を改善する
    曹圭龍; 曹圭龍; 土田和久; 柳谷真悟; 大場知穂; 中村昭伸; 萬田直紀; 栗原義夫; 青木伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2019
    2019 - 2019
  • DPP-4阻害薬とSGLT2阻害薬併用による血糖変動平坦化の増強効果
    曹圭龍; 曹圭龍; 中村昭伸; 川田晋一朗; 土田和久; 大森一乃; 菅原基; 野本博司; 野本博司; 本庄潤; 竹内淳; 永井聡; 横山宏樹; 萬田直紀; 栗原義夫; 青木伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2019
    2019 - 2019
  • メルケル細胞癌に対するアベルマブ投与後に発症した劇症1型糖尿病の1例
    大田翔一郎; 曹圭龍; 柴山惟; 関崎知紀; 山内裕貴; 高瀬崇宏; 大場知穂; 亀田啓; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2019
    2019 - 2019
  • 正常耐糖能者のブドウ糖負荷後血糖推移におけるアルコール摂取の影響
    大場知穂; 竹内淳; 砂土居亮子; 尾崎文乃; 亀田啓; 曹圭龍; 曹圭龍; 中村昭伸; 渥美達也; 三好秀明; 三好秀明
    糖尿病(Web), 2019
    2019 - 2019
  • 肥満を伴う2型糖尿病患者に対する腹腔鏡下スリーブ状胃切除術の代謝疾患改善効果
    大江悠希; 海瀬崇宏; 中村昭伸; 海老原裕磨; 角田玲奈; 宮愛香; 亀田啓; 曹圭龍; 平野聡; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2019
    2019 - 2019
  • 高度肥満症患者に対する腹腔鏡下スリーブ状胃切除術の体重,体脂肪量減少効果
    小野渉; 高瀬崇宏; 中村昭伸; 海老原祐磨; 亀田玲奈; 宮愛香; 亀田啓; 曹圭龍; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2019
    2019 - 2019
  • 肥満外科手術で腎機能が改善した慢性腎臓病合併肥満2型糖尿病の2例
    上垣里紗; 高瀬崇宏; 中村昭伸; 海老原裕磨; 亀井玲奈; 宮愛香; 亀田啓; 曹圭龍; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2019
    2019 - 2019
  • 肥満外科手術前におけるフォーミュラ食置き換えで腎機能障害を認めた2例
    家坂光; 高瀬崇宏; 中村昭伸; 海老原裕磨; 亀田玲奈; 宮愛香; 亀田啓; 曹圭龍; 平野聡; 渥美達也; 三好秀明; 三好秀明
    日本肥満学会・日本肥満症治療学会合同学術集会プログラム・抄録集, 2019
    2019 - 2019
  • 耐糖能異常および糖尿病における脂肪組織インスリン抵抗性
    宮愛香; 中村昭伸; 亀田啓; 曹圭龍; 三好秀明; 渥美達也
    糖尿病(Web), 2019
    2019 - 2019
  • イピリムマブ投与後にGH分泌の一過性上昇を伴う下垂体炎を発症した脈絡膜悪性黒色腫の1例
    宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2019
    2019 - 2019
  • 肥満外科手術で腎機能が改善した慢性腎臓病合併肥満2型糖尿病の1例
    高瀬崇宏; 三好秀明; 三好秀明; 海老原裕磨; 亀田玲奈; 大場知穂; 宮愛香; 亀田啓; 曹圭龍; 中村昭伸; 平野聡; 渥美達也
    糖尿病(Web), 2019
    2019 - 2019
  • 服薬アドヒアランスの悪い高齢者2型糖尿病に週1回GLP-1受容体作動薬が有用であった1例
    高瀬 崇宏; 三好 秀明; 大森 一乃; 高橋 清彦; 北尾 直之; 山本 浩平; 野本 博司; 曹 圭龍; 中村 昭伸; 渥美 達也
    日本老年医学会雑誌, Oct. 2018, (一社)日本老年医学会, Japanese
    Oct. 2018 - Oct. 2018
  • イプラグリフロジンを開始する際にSU薬は中止すべきか少量残すべきか?
    高橋 清彦; 三好 秀明; 宮 愛香; 三次 有奈; 山本 知穂; 野本 博司; 曹 圭龍; 中村 昭伸; 丹羽 祐勝; 高橋 清仁; 萬田 直紀; 栗原 義夫; 青木 伸; 渥美 達也
    糖尿病, Apr. 2018, (一社)日本糖尿病学会, Japanese
    Apr. 2018 - Apr. 2018
  • 高齢者2型糖尿病患者におけるSU薬からレパグリニド切り替えはグリコアルブミン(GA)/HbA1c比を改善する
    大森 一乃; 高瀬 崇宏; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2018, (一社)日本糖尿病学会, Japanese
    Apr. 2018 - Apr. 2018
  • GLP-1受容体作動薬連日投与製剤からデュラグルチド切り替えによる患者満足度の改善効果
    高瀬 崇宏; 三好 秀明; 檀浦 みどり; 山本 知穂; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 栗原 義夫; 青木 伸; 渥美 達也
    糖尿病, Apr. 2018, (一社)日本糖尿病学会, Japanese
    Apr. 2018 - Apr. 2018
  • 肥満2型糖尿病に対する腹腔鏡下スリーブ状胃切除術の治療効果
    土田 和久; 高瀬 崇宏; 三好 秀明; 海老原 裕磨; 北尾 直之; 山本 浩平; 野本 博司; 曹 圭龍; 中村 昭伸; 平野 聡; 渥美 達也
    糖尿病, Mar. 2018, (一社)日本糖尿病学会, Japanese
    Mar. 2018 - Mar. 2018
  • チアゾリジンからSGLT2阻害薬の切替は,糖代謝の増悪なく体液量適正化による体重減少をもたらす
    曹圭龍; 曹圭龍; 大森一乃; 宮愛香; 中村昭伸; 萬田直紀; 栗原義夫; 青木伸; 渥美達也; 三好秀明; 三好秀明
    肥満研究, 2018
    2018 - 2018
  • 短期高脂肪食負荷誘導性膵β細胞増殖におけるグルコキナーゼおよびIRS-2の役割
    北尾直之; 中村昭伸; 高橋清彦; 山本浩平; 曹圭龍; 三好秀明; 寺内康夫; 渥美達也
    日本糖尿病・肥満動物学会年次学術集会プログラム・講演抄録集, 2018
    2018 - 2018
  • ニボルマブ投与後に著明な高血糖を呈し急性発症1型糖尿病と診断した1例
    関崎知紀; 亀田啓; 馬場菜月; 山内裕貴; 平田恵里奈; 枝川幸子; 亀田玲奈; 大場知穂; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2018
    2018 - 2018
  • 甲状腺中毒症における尿L-FABP測定の長期的な臨床的意義
    竹内理恵; 竹内淳; 大場知穂; 曹圭龍; 平田恵里奈; 四枚田奈緒美; 四枚田奈緒美; 片山昭公
    日本内分泌学会雑誌, 2018
    2018 - 2018
  • 甲状腺ホルモンの尿L-FABP測定への影響
    大場知穂; 竹内淳; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2018
    2018 - 2018
  • 鑑別診断に苦慮したACTH依存性Cushing症候群の1例
    高野善成; 続木惇; 曹圭龍; 小林浩之; 木島弘道
    日本内分泌学会雑誌, 2018
    2018 - 2018
  • チアゾリジン薬からSGLT2阻害薬切り替えによる体重減少効果-多施設介入研究-
    半田喬久; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • 高齢者2型糖尿病患者におけるSU薬からレパグリニド切り替えはグリコアルブミン(GA)/HbA1c比を改善する
    大森一乃; 高瀬崇宏; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • 糖尿病治療薬以外での血糖コントロール改善の可能性
    宮愛香; 古川真; 西尾太郎; 佐々木亜衣; 齊藤茉莉子; 宮井理沙; 近藤江利子; 曹圭龍
    糖尿病(Web), 2018
    2018 - 2018
  • 肥満2型糖尿病に対する腹腔鏡下スリーブ状胃切除術の治療効果
    土田和久; 高瀬崇宏; 三好秀明; 海老原裕磨; 北尾直之; 山本浩平; 野本博司; 曹圭龍; 中村昭伸; 平野聡; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • 非肥満2型糖尿病に対するインスリン・SGLT2阻害薬併用療法の糖毒性軽減に関する有用性
    宮愛香; 古川真; 西尾太郎; 曹圭龍; 曹圭龍
    糖尿病(Web), 2018
    2018 - 2018
  • チアゾリジン薬からSGLT2阻害薬への切り替えによる糖代謝および体重への影響
    半田喬久; 半田喬久; 曹圭龍; 曹圭龍; 大森一乃; 宮愛香; 中村昭伸; 萬田直紀; 栗原義夫; 青木伸; 三好秀明; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • Silent pituitary adenomaは代謝異常と関連するか
    馬場菜月; 亀田啓; 関崎知紀; 山内裕貴; 平田恵里奈; 大森一乃; 高瀬崇宏; 亀田玲奈; 大場知穂; 宮愛香; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2018
    2018 - 2018
  • イプラグリフロジンを開始する際にSU薬は中止すべきか少量残すべきか?
    高橋清彦; 高橋清彦; 三好秀明; 宮愛香; 三次有奈; 山本知穂; 野本博司; 曹圭龍; 中村昭伸; 丹羽祐勝; 高橋清仁; 萬田直紀; 栗原義夫; 青木伸; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • GLP-1受容体作動薬連日投与製剤からデュラグルチド切り替えによる患者満足度の改善効果
    高瀬崇宏; 三好秀明; 檀浦みどり; 山本知穂; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 栗原義夫; 青木伸; 渥美達也
    糖尿病(Web), 2018
    2018 - 2018
  • MRIで下垂体腫瘍を認めないクッシング病の1例
    桑原 咲; 川田 晋一朗; 馬場 菜月; 続木 惇; 半田 喬久; 枝川 幸子; 高瀬 崇宏; 山本 浩平; 野本 博司; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2017, (一社)日本内分泌学会, Japanese
    Dec. 2017 - Dec. 2017
  • Glucokinase- and insulin receptor substrate-2 independent pathway was involved in pancreatic beta cell replication induced by short-term high-fat diet feeding in mice
    N. Kitao; A. Nakamura; H. Miyoshi; K. Takahashi; K. Yamamoto; H. Nomoto; K. Cho; Y. Terauchi; T. Atsumi
    DIABETOLOGIA, Sep. 2017, English
    Sep. 2017 - Sep. 2017
  • 当院における肥満2型糖尿病に対する腹腔鏡下スリーブ状胃切除術の治療効果に関する検討
    高瀬 崇宏; 三好 秀明; 海老原 裕磨; 川田 晋一朗; 続木 惇; 馬場 葉月; 半田 喬久; 土田 和久; 柳谷 真悟; 枝川 幸子; 大森 一乃; 高橋 清彦; 檀浦 みどり; 北尾 直之; 山本 浩平; 野本 博司; 曹 圭龍; 中村 昭伸; 平野 聡; 渥美 達也
    肥満研究, Sep. 2017, (一社)日本肥満学会, Japanese
    Sep. 2017 - Sep. 2017
  • 123I-MIBGシンチグラフィで偽陽性を呈し、褐色細胞腫との鑑別が困難であった腎癌副腎転移の一例
    高瀬 崇宏; 野本 博司; 鬼頭 健一; 土田 和久; 平田 恵里奈; 柳谷 真悟; 枝川 幸子; 老田 真佑子; 大森 一乃; 近藤 亜樹; 高橋 清彦; 北尾 直之; 山本 浩平; 亀田 友香; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Apr. 2017, (一社)日本内分泌学会, Japanese
    Apr. 2017 - Apr. 2017
  • インスリン使用中の2型糖尿病患者におけるDPP-4阻害薬からダパグリフロジンへの切替え効果(第二報)
    土田 和久; 野本 博司; 枝川 幸子; 鬼頭 健一; 平田 恵里奈; 柳谷 慎吾; 老田 真佑子; 大森 一乃; 高瀬 崇宏; 高橋 清彦; 北尾 直之; 山本 浩平; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2017, (一社)日本糖尿病学会, Japanese
    Apr. 2017 - Apr. 2017
  • テルミサルタン合剤を用いた糖尿病腎症合併2型糖尿病患者におけるARBの次に追加すべき降圧薬の検討
    山本 浩平; 野本 博司; 宮 愛香; 近藤 琢磨; 栗原 義夫; 青木 伸; 曹 圭龍; 中村 昭伸; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2017, (一社)日本糖尿病学会, Japanese
    Apr. 2017 - Apr. 2017
  • 短期高脂肪食負荷誘導性膵β細胞増殖メカニズムの検討
    北尾 直之; 中村 昭伸; 山本 浩平; 野本 博司; 曹 圭龍; 三好 秀明; 寺内 康夫; 渥美 達也
    日本臨床分子医学会学術総会プログラム・抄録集, Apr. 2017, 日本臨床分子医学会, Japanese
    Apr. 2017 - Apr. 2017
  • 免疫チェックポイント阻害薬投与によりACTH単独欠損症を呈した2症例
    曹圭龍
    Pharma Medica, 2017
    2017 - 2017
  • 脂肪滴周囲蛋白PLINはマクロファージの脂肪貯留に関与し,炎症に対する極性に影響をおよぼす
    曹圭龍; 三好秀明; 山本浩平; 中村昭伸; 渥美達也
    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 2017
    2017 - 2017
  • 甲状腺ホルモンの尿L-FABP測定への影響
    檀浦みどり; 竹内淳; 大森一乃; 高橋清彦; 北尾直之; 山本浩平; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2017
    2017 - 2017
  • チアゾリジン薬からSGLT2阻害薬切り替えによる代謝および体重への影響に関する検討
    曹圭龍; 曹圭龍; 三好秀明; 中村昭伸; 渥美達也
    肥満研究, 2017
    2017 - 2017
  • ペリリピン1過剰発現マウスにおける動脈硬化進展抑制効果についての検討
    山本浩平; 三好秀明; 野本博司; 曹圭龍; 中村昭伸; 渥美達也
    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web), 2017
    2017 - 2017
  • インスリン使用中の2型糖尿病患者におけるDPP-4阻害薬からダパグリフロジンへの切替え効果
    續木惇; 野本博司; 土田和久; 半田喬久; 川田晋一朗; 馬場菜月; 柳谷慎悟; 枝川幸子; 大森一乃; 高瀬崇宏; 高橋清彦; 檀浦みどり; 北尾直之; 山本博平; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    肥満研究, 2017
    2017 - 2017
  • チアゾリジン薬からSGLT2阻害薬への切り替えは糖代謝を悪化させずに体重減少をもたらす
    曹圭龍; 曹圭龍; 三好秀明; 中村昭伸; 渥美達也
    糖尿病合併症, 2017
    2017 - 2017
  • 食事内容変更により低血糖の改善が得られたインスリン自己免疫症候群の一例
    川田晋一朗; 川田晋一朗; 高野善成; 馬場菜月; 半田喬久; 続木惇; 枝川幸子; 高瀬崇宏; 檀浦みどり; 山本浩平; 曹圭龍; 中村昭伸; 三好秀明; 加藤雅彦; 渥美達也
    日本内分泌学会雑誌, 2017
    2017 - 2017
  • テルミサルタン合剤を用いた糖尿病腎症合併2型糖尿病患者におけるARBの次に追加すべき降圧薬の検討
    山本浩平; 野本博司; 宮愛香; 近藤琢磨; 栗原義夫; 青木伸; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2017
    2017 - 2017
  • インスリン使用中の2型糖尿病患者におけるDPP-4阻害薬からダパグリフロジンへの切替え効果(第二報)
    土田和久; 野本博司; 枝川幸子; 鬼頭健一; 平田恵里奈; 柳谷慎吾; 老田真佑子; 大森一乃; 高瀬崇宏; 高橋清彦; 北尾直之; 山本浩平; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2017
    2017 - 2017
  • 持続血糖モニタリング下で術前オクトレオチド投与を行い低血糖の消失を確認できたインスリノーマの一例
    老田真佑子; 柳谷真悟; 土田和久; 大森一乃; 高瀬崇宏; 高橋清彦; 北尾直之; 山本浩平; 亀田友香; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2017
    2017 - 2017
  • 外来迅速L-FABP測定を用いた糖尿病腎症の評価
    檀浦みどり; 竹内淳; 大森一乃; 高橋清彦; 北尾直之; 山本浩平; 野本博司; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2017
    2017 - 2017
  • 血漿アルドステロン濃度120pg/mL以下の高血圧症例の臨床的特徴
    宮愛香; 西尾太郎; 永井聡; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2017
    2017 - 2017
  • 原発性肺癌に対する抗PD-1抗体ニボルマブ投与中にACTH単独欠損症を発症した1例
    鬼頭 健一; 曹 圭龍; 土田 和久; 平田 恵里奈; 柳谷 真悟; 老田 真佑子; 大森 一乃; 高瀬 崇宏; 高橋 清彦; 北尾 直之; 山本 浩平; 亀田 友香; 野本 博司; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2016, (一社)日本内分泌学会, Japanese
    Dec. 2016 - Dec. 2016
  • 局在診断に苦慮した異所性ACTH産生膵神経内分泌腫瘍の一例
    老田 真佑子; 中村 昭伸; 枝川 幸子; 大森 一乃; 高瀬 崇宏; 近藤 亜樹; 菅原 基; 一山 芽衣; 山本 浩平; 山本 知穂; 亀田 友香; 野本 博司; 曹 圭龍; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2016, (一社)日本内分泌学会, Japanese
    Oct. 2016 - Oct. 2016
  • 抗PD-1抗体ニボルマブ投与によりACTH単独欠損症を呈した一例
    高橋 由華; 曹 圭龍; 大森 一乃; 老田 真佑子; 高瀬 崇宏; 高橋 清彦; 北尾 直之; 山本 浩平; 亀田 友香; 野本 博司; 中村 昭伸; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Oct. 2016, (一社)日本内分泌学会, Japanese
    Oct. 2016 - Oct. 2016
  • 高脂肪食誘導性膵β細胞増殖効果の検討
    北尾直之; 中村昭伸; 高橋清彦; 山本浩平; 曹圭龍; 三好秀明; 寺内康夫; 渥美達也
    日本糖尿病・肥満動物学会年次学術集会プログラム・講演抄録集, 2016
    2016 - 2016
  • 高血圧合併高齢糖尿病患者における糖尿病治療薬,降圧薬の併用実態について
    千田泰健; 元木孝; 曹圭龍
    日本高血圧学会総会プログラム・抄録集, 2016
    2016 - 2016
  • インスリン併用2型糖尿病に対する選択的SGLT2阻害薬投与時のインスリン単位数に関する検討
    山本知穂; 三好秀明; 栗原義夫; 曹圭龍; 中村昭伸; 園田祥子; 千葉活; 半田喬久; 浄土智
    肥満研究, 2016
    2016 - 2016
  • 特徴的身体所見を認めなかったGH産生下垂体腺腫の1例
    近藤亜樹; 中村昭伸; 枝川幸子; 老田真佑子; 大森一乃; 高瀬崇宏; 菅原基; 山本知穂; 曹圭龍; 三好秀明; 渥美達也
    日本内分泌学会雑誌, 2016
    2016 - 2016
  • 先端巨大症における成長ホルモン分泌に対するDPP4阻害薬の影響
    山本知穂; 亀田啓; 枝川幸子; 老田真佑子; 大森一乃; 高瀬崇宏; 菅原基; 高橋清彦; 近藤亜樹; 北尾直之; 一山芽衣; 山本浩平; 曹圭龍; 中村昭伸; 永井聡; 三好秀明; 清水力; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • シタグリプチンとグリメピリドの抗動脈硬化作用及び膵β細胞機能改善効果における比較研究Sapporo Athero-Incretin Study1
    野本博司; 野本博司; 三好秀明; 古本智夫; 井上篤; 曹圭龍; 中村昭伸; 渥美達也; 萬田直紀; 栗原義夫; 青木伸
    糖尿病(Web), 2016
    2016 - 2016
  • PLIN1過剰発現マウスにおける動脈硬化進展抑制効果についての検討
    山本浩平; 三好秀明; 枝川幸子; 大森一乃; 高瀬崇宏; 菅原基; 北尾直之; 山本知穂; 曹圭龍; 中村昭伸; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • マウスへの短期高脂肪食負荷はインスリン抵抗性を伴わず膵β細胞を増殖させる
    北尾直之; 中村昭伸; 高橋清彦; 山本浩平; 曹圭龍; 三好秀明; 寺内康夫; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • 2型糖尿病におけるSU薬からSGLT2阻害薬切り替えによる血糖値及びメタボリック関連因子への影響に関する検討
    高橋清彦; 三好秀明; 平井愛見子; 曹圭龍; 中村昭伸; 栗原義夫; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • 脳死/膵腎同時移植の耐糖能改善効果
    老田真佑子; 枝川幸子; 高瀬崇宏; 近藤亜樹; 大森一乃; 高橋清彦; 菅原基; 北尾直之; 一山芽衣; 山本知穂; 山本浩平; 三次有奈; 亀田友香; 曹圭龍; 中村昭伸; 三好秀明; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • インスリン使用中の2型糖尿病患者におけるDPP-4阻害薬からダパグリフロジンへの切替え効果
    菅原基; 三好秀明; 枝川幸子; 老田真佑子; 大森一乃; 高瀬崇宏; 近藤亜樹; 高橋清彦; 北尾直之; 山本知穂; 山本浩平; 曹圭龍; 中村昭伸; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • インスリン非注射部位に脂肪萎縮を認めた後天性部分性脂肪萎縮症
    近藤亜樹; 中村昭伸; 枝川幸子; 老田真佑子; 大森一乃; 高瀬崇宏; 菅原基; 一山芽衣; 山本知穂; 曹圭龍; 竹内淳; 三好秀明; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • リキシセナチドと基礎インスリン製剤との併用療法の体重減量効果ならびに患者満足度の検討
    宮愛香; 中村昭伸; 三好秀明; 曹圭龍; 寺内康夫; 渥美達也
    肥満研究, 2016
    2016 - 2016
  • インスリン頻回注射からリキシセナチドと基礎インスリン製剤との併用療法への切り替えは患者満足度を改善させる
    宮愛香; 宮愛香; 中村昭伸; 三好秀明; 高瀬崇宏; 近藤亜樹; 山本知穂; 曹圭龍; 永井聡; 栗原義夫; 青木伸; 寺内康夫; 渥美達也
    糖尿病(Web), 2016
    2016 - 2016
  • 高血圧合併高齢糖尿病患者における糖尿病薬,降圧薬の併用実態について
    千田泰健; 元木孝; 曹圭龍
    日本高血圧学会総会プログラム・抄録集, 2015
    2015 - 2015
  • 糖尿病透析予防指導の効果
    阿部滝子; 曹圭龍; 齊藤茉莉子; 三笠玲子; 古川真; 稲荷弥生; 西尾太郎
    糖尿病(Web), 2015
    2015 - 2015
  • リアルな療養指導を目指して!調理実習を通して得られるものとは?
    宮井理沙; 信行祐子; 坂田浩子; 田浦光子; 室田享子; 曹圭龍; 古川真
    糖尿病(Web), 2015
    2015 - 2015
  • 外用剤によりSMBGが偽高値を呈した2症例
    三笠玲子; 曹圭龍; 齊藤茉莉子; 阿部滝子; 古川真; 稲荷弥生; 西尾太郎
    糖尿病(Web), 2015
    2015 - 2015
  • シタグリプチンとグリメピリドの抗動脈硬化作用及び膵β細胞機能改善効果における比較研究Sapporo Athero-Incretin Study(1)
    野本 博司; 三好 秀明; 古本 智夫; 井上 篤; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 渥美 達也; 萬田 直紀; 栗原 義夫; 青木 伸
    日本動脈硬化学会総会プログラム・抄録集, Jun. 2014, (一社)日本動脈硬化学会, Japanese
    Jun. 2014 - Jun. 2014
  • 無症状で発見された1型糖尿病の1例
    北尾 直之; 小梁川 直秀; 山本 浩平; 山本 知穂; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Mar. 2014, (一社)日本糖尿病学会, Japanese
    Mar. 2014 - Mar. 2014
  • 糖尿病患者における無症候性心筋虚血罹患率の観察研究
    小梁川 直秀; 三次 有奈; 山本 浩平; 山本 知穂; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Mar. 2014, (一社)日本糖尿病学会, Japanese
    Mar. 2014 - Mar. 2014
  • SEAシートを用いて糖尿病療養指導を考える
    齊藤茉莉子; 古川真; 曹圭龍; 稲荷弥生; 西尾太郎
    糖尿病, 2014
    2014 - 2014
  • DPP4阻害薬投与後にバセドウ病が増悪した糖尿病の2例
    亀田啓; 曹圭龍; 中村昭伸; 永井聡; 近藤琢磨; 三好秀明; 渥美達也
    糖尿病, 2014
    2014 - 2014
  • silent somatotroph adenoma術後に耐糖能障害が改善した1例
    宮愛香; 中村昭伸; 山本知穂; 小梁川直秀; 北尾直之; 野本博司; 亀田啓; 曹圭龍; 近藤琢磨; 三好秀明; 渥美達也
    糖尿病, 2014
    2014 - 2014
  • リラグルチドとグラルギンの抗動脈硬化作用及び膵β細胞機能改善効果における比較研究 Sapporo Athero-Incretin Study 2
    三好秀明; 野本博司; 古本智夫; 曹圭龍; 土田健一; 三次有奈; 中村昭伸; 近藤琢磨; 渥美達也; 萬田直樹; 栗原義夫; 青木伸
    糖尿病, 2014
    2014 - 2014
  • 含糖酸化鉄投与と短腸症候群により多彩な電解質異常を呈した1例
    野本 博司; 北尾 直之; 小梁川 直秀; 宮 愛香; 三次 有奈; 山本 浩平; 山本 知穂; 亀田 啓; 曹 圭龍; 中村 昭伸; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Dec. 2013, (一社)日本内分泌学会, Japanese
    Dec. 2013 - Dec. 2013
  • 術後に耐糖能障害が改善したsilent somatotroph adenomaの一例
    続木 惇; 宮 愛香; 中村 昭伸; 山本 知穂; 小梁川 直秀; 北尾 直之; 高野 善成; 野本 博司; 亀田 啓; 曹 圭龍; 近藤 琢磨; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, Dec. 2013, (一社)日本内分泌学会, Japanese
    Dec. 2013 - Dec. 2013
  • DPP4阻害薬投与後に増悪したバセドウ病の2例
    亀田 啓; 高野 善成; 北尾 直之; 一山 芽衣; 宮 愛香; 三次 有奈; 山本 浩平; 山本 知穂; 小梁川 直秀; 野本 博司; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 三好 秀明; 渥美 達也; 永井 聡; 清水 力
    北海道医学雑誌, Sep. 2013, 北海道医学会, Japanese
    Sep. 2013 - Sep. 2013
  • パラガングリオーマと中毒性多結節性甲状腺腫を合併した一例
    山本 浩平; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 三好 秀明; 渥美 達也; 永井 聡; 清水 力
    北海道医学雑誌, Sep. 2013, 北海道医学会, Japanese
    Sep. 2013 - Sep. 2013
  • 重症成人成長ホルモン分泌不全症患者へのGH補充による代謝への影響の検討
    野本 博司; 三次 有奈; 亀田 啓; 曹 圭龍; 中村 昭伸; 近藤 琢磨; 清水 力; 三好 秀明; 渥美 達也
    肥満研究, Sep. 2013, (一社)日本肥満学会, Japanese
    Sep. 2013 - Sep. 2013
  • 潜在性甲状腺機能低下症ならびに抗甲状腺ペルオキシダーゼ抗体が糖尿病合併症に与える影響についての検討
    亀田 啓; 高野 善成; 北尾 直之; 一山 芽衣; 宮 愛香; 三次 有奈; 山本 浩平; 山本 知穂; 小梁川 直秀; 野本 博司; 曹 圭龍; 中村 昭伸; 永井 聡; 近藤 琢磨; 三好 秀明; 和田 典男; 柳澤 克之; 渥美 達也
    糖尿病合併症, Aug. 2013, (一社)日本糖尿病合併症学会, Japanese
    Aug. 2013 - Aug. 2013
  • 糖尿病教育入院患者における重症慢性歯周病と臨床パラメータの関連性
    三次 有奈; 小梁川 直秀; 山本 浩平; 山本 知穂; 野本 博司; 亀田 啓; 曹 圭龍; 中村 昭伸; 永井 聡; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病合併症, Aug. 2013, (一社)日本糖尿病合併症学会, Japanese
    Aug. 2013 - Aug. 2013
  • 内頸動脈剥離術後プラークを用いたマクロファージ炎症バランスとプラークの脆弱性・破綻に関する検討
    曹 圭龍; 三好 秀明; 小梁川 直秀; 山本 知穂; 野本 博司; 亀田 啓; 中村 昭伸; 近藤 琢磨; 渥美 達也
    糖尿病合併症, Aug. 2013, (一社)日本糖尿病合併症学会, Japanese
    Aug. 2013 - Aug. 2013
  • 血清IgG4高値を示した甲状腺原発MALTリンパ腫の1例
    野本 博司; 小梁川 直秀; 三次 有奈; 山本 浩平; 山本 知穂; 相川 望美; 亀田 啓; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Jun. 2013, (一社)日本内分泌学会, Japanese
    Jun. 2013 - Jun. 2013, 52歳女。2年前頃より周囲の人から頸部の腫脹を指摘されるようになり、同時期より易疲労感を自覚し始めた。1年前に近医受診したところ、橋本病による甲状腺機能低下症・甲状腺腫大と診断され、レボチロキシンの補充を開始されたが、甲状腺機能・腫大とも改善に乏しく、当院に紹介された。外来でレボチロキシンの漸増を行ったが、甲状腺機能の改善に乏しく、一方で高度の高γグロブリン血症を認めたためIgG4の測定を行った。その結果、816mg/dlと高値であったことからIgG4関連疾患の可能性を考え、精査加療目的に入院となった。PET-CTを含む各種画像検査にて全身精査を行ったが、甲状腺以外には明らかな病変は指摘しえなかった。確定診断のため甲状腺生検を行ったところリンパ濾胞の形成を認め、濾胞間にはリンパ球・形質細胞を主体とする炎症細胞の密な浸潤が認められた。免疫染色では濾胞に一致してCD20陽性細胞が確認され、CD79a染色では、CD20陽性のB細胞とともに濾胞間に増生する形質細胞に広く陽性を示した。大部分の形質細胞がIgG陽性を示し、IgG4も全体の40%ほどが陽性であったものの、一方でIgκ優位に軽鎖制限が確認されたことからMALTリンパ腫と診断した。
  • 先端巨大症に対するオクトレオチド徐放性製剤の長期投与による治療効果・糖代謝への影響の検討
    野本 博司; 小梁川 直秀; 三次 有奈; 山本 浩平; 山本 知穂; 亀田 啓; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Apr. 2013, (一社)日本内分泌学会, Japanese
    Apr. 2013 - Apr. 2013
  • 糖尿病教育入院患者における重症慢性歯周病と動脈硬化の指標を含む臨床パラメータの関連性
    三次 有奈; 小梁川 直秀; 山本 知穂; 山本 浩平; 野本 博司; 亀田 啓; 田島 一樹; 曹 圭龍; 野田 学; 中垣 整; 永井 聡; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2013, (一社)日本糖尿病学会, Japanese
    Apr. 2013 - Apr. 2013
  • ピオグリタゾンを対照薬としたインスリン療法へのDPP-4阻害薬の追加投与効果の検討
    野本 博司; 小梁川 直秀; 三次 有奈; 山本 知穂; 山本 浩平; 相川 望美; 亀田 啓; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 清水 力; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2013, (一社)日本糖尿病学会, Japanese
    Apr. 2013 - Apr. 2013
  • 抗TPO抗体陽性の2型糖尿病患者における腎機能と糖尿病合併症についての検討
    亀田 啓; 山本 浩平; 山本 知穂; 小梁川 直秀; 三次 有奈; 相川 望美; 野本 博司; 野田 学; 曹 圭龍; 中垣 整; 永井 聡; 近藤 琢磨; 三好 秀明; 和田 典男; 柳澤 克之; 清水 力; 渥美 達也
    糖尿病, Apr. 2013, (一社)日本糖尿病学会, Japanese
    Apr. 2013 - Apr. 2013
  • 高血圧症と脂質異常症を合併した2型糖尿病患者におけるCa拮抗薬とHMG-CoA還元酵素阻害剤合剤投与による検討
    中垣 整; 山本 知穂; 山本 浩平; 三次 有奈; 小梁川 直秀; 野田 学; 野本 博司; 田島 一樹; 亀田 啓; 曹 圭龍; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Apr. 2013, (一社)日本糖尿病学会, Japanese
    Apr. 2013 - Apr. 2013
  • 動脈硬化進展におけるマクロファージ泡沫化と脂肪滴周囲蛋白の評価
    曹 圭龍; 三好 秀明; 山本 浩平; 山本 知穂; 小梁川 直秀; 三次 有奈; 野本 博司; 亀田 啓; 田島 一樹; 野田 学; 中垣 整; 近藤 琢磨; 渥美 達也
    糖尿病, Apr. 2013, (一社)日本糖尿病学会, Japanese
    Apr. 2013 - Apr. 2013
  • 先端巨大症に対するペグビソマント長期投与症例の検討
    亀田啓; 山本浩平; 山本知穂; 小梁川直秀; 三次有奈; 相川望美; 野本博司; 野田学; 曹圭龍; 中垣整; 近藤琢磨; 三好秀明; 清水力; 清水力; 渥美達也
    日本間脳下垂体腫瘍学会プログラム・抄録集, 2013
    2013 - 2013
  • インスリンアレルギーの1例
    山本浩平; 亀田啓; 相川望美; 野本博司; 田島一樹; 曹圭龍; 中垣整; 近藤琢磨; 三好秀明; 渥美達也
    糖尿病, 2013
    2013 - 2013
  • 先端巨大症患者に対するオクトレオチド徐放性製剤の長期投与効果に関する検討
    野本博司; 小梁川直秀; 山本浩平; 山本知穂; 三次有奈; 相川望美; 亀田啓; 田島一樹; 野田学; 曹圭龍; 中垣整; 近藤琢磨; 三好秀明; 清水力; 清水力; 渥美達也
    日本間脳下垂体腫瘍学会プログラム・抄録集, 2013
    2013 - 2013
  • 糖尿病教育入院患者における重症慢性歯周病と動脈硬化の指標を含む臨床パラメータの関連性
    三次 有奈; 相川 望美; 野本 博司; 亀田 啓; 田嶋 一樹; 曹 圭龍; 中垣 整; 永井 聡; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Jan. 2013, (一社)日本糖尿病学会, Japanese
    Jan. 2013 - Jan. 2013
  • 2型糖尿病患者における持効型インスリンを用いたBOTの有効性および使用単位数の検討
    山本 知穂; 中垣 整; 野本 博司; 亀田 啓; 田島 一樹; 曹 圭龍; 近藤 琢磨; 三好 秀明; 渥美 達也
    糖尿病, Jan. 2013, (一社)日本糖尿病学会, Japanese
    Jan. 2013 - Jan. 2013
  • 低Na血症を契機に腎癌転移による下垂体機能低下症を診断した1例
    三次 有奈; 永井 聡; 亀田 啓; 小梁川 直秀; 山本 浩平; 山本 知穂; 野本 博司; 田島 一樹; 曹 圭龍; 野田 学; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Dec. 2012, (一社)日本内分泌学会, Japanese
    Dec. 2012 - Dec. 2012
  • 血清IgG4高値を示した甲状腺原発MALTリンパ腫の1例
    野本 博司; 小梁川 直秀; 三次 有奈; 山本 浩平; 山本 知穂; 相川 望美; 亀田 啓; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Dec. 2012, (一社)日本内分泌学会, Japanese
    Dec. 2012 - Dec. 2012
  • 2型糖尿病患者における抗TPO抗体の有無と糖尿病合併症についての関連
    亀田 啓; 山本 浩平; 山本 知穂; 小梁川 直秀; 三次 有奈; 相川 望美; 野本 博司; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力; 永井 聡; 和田 典男; 柳澤 克之
    北海道医学雑誌, Nov. 2012, 北海道医学会, Japanese
    Nov. 2012 - Nov. 2012
  • IgG4高値を示しIgG4関連疾患との鑑別を要した甲状腺原発MALTリンパ腫の1例
    野本 博司; 小梁川 直秀; 三次 有奈; 山本 浩平; 山本 知穂; 相川 望美; 亀田 啓; 曹 圭龍; 野田 学; 中垣 整; 近藤 琢磨; 三好 秀明; 清水 力
    北海道医学雑誌, Nov. 2012, 北海道医学会, Japanese
    Nov. 2012 - Nov. 2012
  • IgG4高値を示しIgG4関連疾患との鑑別を要した甲状腺原発MALTリンパ腫の1例
    野本 博司; 三次 有奈; 山本 浩平; 亀田 啓; 田島 一樹; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明; 渥美 達也; 清水 力
    日本内分泌学会雑誌, Sep. 2012, (一社)日本内分泌学会, Japanese
    Sep. 2012 - Sep. 2012
  • 抗TPO抗体陽性の2型糖尿病患者における腎機能と糖尿病合併症の頻度についての検討
    亀田 啓; 山本 浩平; 三次 有奈; 野本 博司; 曹 圭龍; 永井 聡; 三好 秀明; 和田 典男; 柳澤 克之; 清水 力; 渥美 達也
    日本内分泌学会雑誌, Sep. 2012, (一社)日本内分泌学会, Japanese
    Sep. 2012 - Sep. 2012
  • 肥満2型糖尿病患者におけるエキセナチドによる体重減少効果の検討
    野本 博司; 小梁川 直秀; 山本 浩平; 山本 知穂; 三次 有奈; 相川 望美; 亀田 啓; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 近藤 琢磨; 三好 秀明
    肥満研究, Sep. 2012, (一社)日本肥満学会, Japanese
    Sep. 2012 - Sep. 2012
  • インスリン抵抗性を有し医原性副腎皮質機能低下症を合併した両側対称性脂肪腫の一例
    亀田 啓; 山本 浩平; 山本 知穂; 三次 有奈; 小梁川 直秀; 相川 望美; 野本 博司; 田島 一樹; 野田 学; 曹 圭龍; 中垣 整; 永井 聡; 近藤 琢磨; 三好 秀明
    肥満研究, Sep. 2012, (一社)日本肥満学会, Japanese
    Sep. 2012 - Sep. 2012
  • 下垂体疾患患者を対象とした成長ホルモンが骨代謝に与える影響の検討
    亀田 啓; 三次 有奈; 山本 浩平; 野本 博司; 田島 一樹; 曹 圭龍; 中垣 整; 永井 聡; 近藤 琢磨; 三好 秀明
    Osteoporosis Japan, Aug. 2012, ライフサイエンス出版(株), Japanese
    Aug. 2012 - Aug. 2012
  • 閉経前1型糖尿病女性の大腿骨頸部低骨密度に関連する因子
    三次 有奈; 永井 聡; 野本 博司; 亀田 啓; 曹 圭龍; 耒海 公彦; 近藤 琢磨; 三好 秀明; 清水 力
    日本内分泌学会雑誌, Apr. 2012, (一社)日本内分泌学会, Japanese
    Apr. 2012 - Apr. 2012
  • 治療前後における下垂体機能変化を確認しえたリンパ球性下垂体炎5例の検討
    野本 博司; 相川 望美; 國崎 哲; 亀田 啓; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 清水 力; 三好 秀明
    日本内分泌学会雑誌, Apr. 2012, (一社)日本内分泌学会, Japanese
    Apr. 2012 - Apr. 2012
  • 潜在性甲状腺機能低下症と糖尿病合併症の関連についての検討
    亀田 啓; 相川 望美; 國崎 哲; 野本 博司; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 三好 秀明; 和田 典男; 柳澤 克之; 清水 力
    日本内分泌学会雑誌, Apr. 2012, (一社)日本内分泌学会, Japanese
    Apr. 2012 - Apr. 2012
  • 閉経前1型糖尿病女性における多嚢胞性卵巣の検討
    三次 有奈; 永井 聡; 武田 真光; 近藤 琢磨; 野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 吉岡 成人; 三好 秀明
    糖尿病, Apr. 2012, (一社)日本糖尿病学会, Japanese
    Apr. 2012 - Apr. 2012
  • 持効型インスリンへのシタグリプチン追加投与の有効性をCGMS・インクレチン活性の測定にて確認しえた肥満2型糖尿病患者の1例
    野本 博司; 相川 望美; 國崎 哲; 亀田 啓; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 清水 力; 三好 秀明
    糖尿病, Apr. 2012, (一社)日本糖尿病学会, Japanese
    Apr. 2012 - Apr. 2012
  • 内頚動脈剥離術後プラーク内浸潤マクロファージと不安定性評価
    曹圭龍; 相川望美; 國崎哲; 野本博司; 亀田啓; 耒海公彦; 永井聡; 近藤琢磨; 三好秀明
    糖尿病, 2012
    2012 - 2012
  • 機能性甲状腺結節と高Ca血症を合併した先端巨大症の一例
    野本 博司; 相川 望美; 國崎 哲; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 清水 力; 三好 秀明
    日本内分泌学会雑誌, Dec. 2011, (一社)日本内分泌学会, Japanese
    Dec. 2011 - Dec. 2011
  • ホルモン負荷試験における90分値と120分値の意義の検討
    亀田 啓; 相川 望美; 國崎 哲; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力
    日本内分泌学会雑誌, Dec. 2011, (一社)日本内分泌学会, Japanese
    Dec. 2011 - Dec. 2011
  • 先端巨大症と高Ca血症を合併した機能性甲状腺結節の一例
    野本 博司; 相川 望美; 國崎 哲; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 清水 力; 三好 秀明
    北海道医学雑誌, Nov. 2011, 北海道医学会, Japanese
    Nov. 2011 - Nov. 2011
  • 下垂体疾患患者における甲状腺刺激ホルモン分泌低下と骨折リスクに関する検討
    亀田 啓; 相川 望美; 國崎 哲; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力
    日本内分泌学会雑誌, Sep. 2011, (一社)日本内分泌学会, Japanese
    Sep. 2011 - Sep. 2011
  • 先端巨大症と高Ca血症を合併した機能性甲状腺結節の一例
    野本 博司; 相川 望美; 國崎 哲; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 永井 聡; 近藤 琢磨; 清水 力; 三好 秀明
    日本内分泌学会雑誌, Sep. 2011, (一社)日本内分泌学会, Japanese
    Sep. 2011 - Sep. 2011
  • 薬理量グルココルチコイドにより症状の改善を認めた嚢胞構造を伴う下垂体腫瘤病変の妊婦の一例
    野本 博司; 三次 有奈; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    ACTH RELATED PEPTIDES, Sep. 2011, 間脳・下垂体・副腎系研究会, Japanese
    Sep. 2011 - Sep. 2011, 35歳女。妊娠26週頃から頭痛を自覚し、30週に視野欠損が出現した。近医受診し、頭部MRIで下垂体の腫大を認められ、精査加療目的で当院に紹介された。対座法の視野検査で両耳側の視野欠損を認めた。頭部MRIで下垂体部に11×20×16mm大の腫瘤性病変を認め、造影MRIでは比較的均一な強い増強効果を示した。また、腫瘤と後葉の間に嚢胞状構造を認めた。視野障害をきたしているためプレドニゾロン(PSL)30mg/日の投与を行い、1週間で症状の改善と下垂体腫瘤の縮小が得られたが、嚢胞状構造の内部性状には変化がみられなかった。その後PSLを漸減し、腫瘤の再増大なく妊娠38週で健児を出産した。
  • ペグビソマント投与前後の耐糖能の変化を経口ブドウ糖負荷試験にて検討した先端巨大症の3症例
    亀田 啓; 永井 聡; 三好 秀明; 近藤 琢磨; 澤田 享; 中垣 彩; 耒海 公彦; 曹 圭龍; 平井 愛見子; 田島 一樹; 野本 博司; 三次 有奈; 清水 力; 吉岡 成人; 小池 隆夫
    糖尿病, Aug. 2011, (一社)日本糖尿病学会, Japanese
    Aug. 2011 - Aug. 2011
  • 心停止より救命しえた下垂体炎後の下垂体機能低下症の1例
    野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Jun. 2011, (一社)日本内分泌学会, Japanese
    Jun. 2011 - Jun. 2011, 36歳女。頭痛・視野障害が出現した。下垂体MRIにて鞍上部からトルコ鞍にかけてT1強調Gd造影画像にて強く均一に造影される腫瘤性病変を認めた。臨床経過・画像所見より、リンパ球性下垂体炎と診断し、mPSLパルス療法とプレドニゾロン(PSL)内服による後療法を行ったところ、臨床症状・画像所見ともに軽快し、甲状腺ホルモンの補充を開始し退院した。今回、数分間持続する胸痛が出現、数日後に意識消失し搬送中に心停止をきたしたが車中で心拍再開し、救命救急センターへ搬入となった。QT延長症候群に伴う心停止と診断し、ヒドロコルチゾンの補充を開始するとともに、甲状腺機能低下症と低K血症に対し補充を開始した。全身状態改善し退院となり、QT延長・不整脈の再発なく経過している。今回の心停止は副腎不全・甲状腺機能低下症・低K血症に伴う二次性QT延長症候群が原因であったと考えられた。
  • 重症成人成長ホルモン分泌不全症患者へのGH投与による糖代謝への影響の検討
    野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    糖尿病, Apr. 2011, (一社)日本糖尿病学会, Japanese
    Apr. 2011 - Apr. 2011
  • 新規Arginine Vasopressin-NeurophysinII遺伝子変異を認めた家族性中枢性尿崩症の1家
    亀田 啓; 南條 一洋; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Apr. 2011, (一社)日本内分泌学会, Japanese
    Apr. 2011 - Apr. 2011
  • 当院にて経験したTSH産生下垂体腫瘍7症例における検討
    野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Apr. 2011, (一社)日本内分泌学会, Japanese
    Apr. 2011 - Apr. 2011
  • クッシング症候群の診断における深夜唾液中コルチゾール値測定の有用性についての検討
    平井 愛見子; 永井 聡; 三次 有奈; 野本 博司; 亀田 啓; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Apr. 2011, (一社)日本内分泌学会, Japanese
    Apr. 2011 - Apr. 2011
  • 混合型インスリンの1日2回投与から経口薬と持効型インスリンの投与に切り替えた2症例
    亀田 啓; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 小池 隆夫
    糖尿病, Feb. 2011, (一社)日本糖尿病学会, Japanese
    Feb. 2011 - Feb. 2011
  • インスリン療法からリラグルチドへの変更を試みた2型糖尿病の3例
    野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 小池 隆夫
    糖尿病, Feb. 2011, (一社)日本糖尿病学会, Japanese
    Feb. 2011 - Feb. 2011
  • A Case of Ectopic Pituitary Adenoma Occurring in the Sphenoid Sinus
    鴨嶋雄大; 寺坂俊介; 内田和希; 牛越聡; 曹圭龍; 寳金清博
    Neurological Surgery, 2011
    2011 - 2011
  • 2型糖尿病患者におけるシタグリプチンの有効性についての検討
    三次有奈; 亀田啓; 平井愛見子; 曹圭龍; 耒海公彦; 中垣彩; 澤田享; 永井聡; 近藤琢磨; 三好秀明; 小池隆夫
    糖尿病, 2011
    2011 - 2011
  • Silent corticotroph and somatotroph adenomaの一例
    三次 有奈; 野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Dec. 2010, (一社)日本内分泌学会, Japanese
    Dec. 2010 - Dec. 2010
  • 心停止より救命しえた下垂体炎後の下垂体機能低下症の1例
    野本 博司; 三次 有奈; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Dec. 2010, (一社)日本内分泌学会, Japanese
    Dec. 2010 - Dec. 2010
  • 先端巨大症と糖尿病合併症の関連についての検討
    亀田 啓; 三次 有奈; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 中垣 彩; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Dec. 2010, (一社)日本内分泌学会, Japanese
    Dec. 2010 - Dec. 2010
  • 潜在性甲状腺機能低下症と糖尿病合併症についての検討
    亀田 啓; 野本 博司; 平井 愛見子; 耒海 公彦; 曹 圭龍; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Sep. 2010, (一社)日本内分泌学会, Japanese
    Sep. 2010 - Sep. 2010
  • 当院にて経験したTSH産生下垂体腫瘍7症例における検討
    野本 博司; 亀田 啓; 平井 愛見子; 耒海 公彦; 曹 圭龍; 澤田 享; 永井 聡; 近藤 琢磨; 三好 秀明; 清水 力; 小池 隆夫
    日本内分泌学会雑誌, Sep. 2010, (一社)日本内分泌学会, Japanese
    Sep. 2010 - Sep. 2010
  • 副腎性サブクリニカルクッシング症候群(SCS)における低用量デキサメサゾン抑制試験(LDDST)0.5mgの比較検討
    田島一樹; 亀田啓; 平井愛見子; 耒海公彦; 曹圭龍; 中垣彩; 澤田享; 吉田昌弘; 中垣整; 永井聡; 近藤琢磨; 三好秀明; 清水力; 清水力; 吉岡成人; 小池隆夫
    日本内分泌学会雑誌, 2010
    2010 - 2010
  • 先端巨大症の薬物治療が耐糖能に与える影響の検討
    亀田啓; 平井愛見子; 田島一樹; 耒海公彦; 曹圭龍; 中垣彩; 澤田享; 吉田昌弘; 中垣整; 永井聡; 近藤琢磨; 三好秀明; 清水力; 清水力; 吉岡成人; 小池隆夫
    日本内分泌学会雑誌, 2010
    2010 - 2010
  • 飲水超音波検査による糖尿病胃腸症評価の有用性の検討
    耒海公彦; 亀田啓; 田島一樹; 平井愛見子; 曹圭龍; 中垣彩; 永井聡; 近藤琢磨; 三好秀明; 吉岡成人; 小池隆夫; 浅香瑠美子
    糖尿病, 2010
    2010 - 2010
  • インスリン製剤の投与と悪性腫瘍診断率との関連についての検討
    亀田啓; 平井愛見子; 田島一樹; 耒海公彦; 曹圭龍; 澤田享; 中垣彩; 吉田昌弘; 中垣整; 永井聡; 古川真; 近藤琢磨; 三好秀明; 清水力; 柳澤克之; 吉岡成人; 小池隆夫
    糖尿病, 2010
    2010 - 2010
  • 膠原病患者におけるステロイド投与後の糖代謝と合併症・予後についての検討
    平井愛見子; 永井聡; 藤枝雄一郎; 亀田啓; 田島一樹; 曹圭龍; 中垣彩; 澤田享; 中垣整; 吉田昌弘; 近藤琢磨; 三好秀明; 清水力; 清水力; 吉岡成人; 小池隆夫
    糖尿病, 2010
    2010 - 2010
  • 周術期におけるインスリンリスプロ混合製剤50注1日3回注射法の検討
    曹圭龍; 永井聡; 耒海公彦; 中垣整; 吉田昌弘; 近藤琢磨; 三好秀明; 吉岡成人; 小池隆夫; 秋川和聖
    糖尿病, 2010
    2010 - 2010
  • 周術期におけるインスリンリスプロ混合製剤50注1日3回投与法の検討
    曹圭龍; 永井聡; 耒海公彦; 中垣整; 吉田昌弘; 近藤琢磨; 三好秀明; 秋川和聖; 吉岡成人; 小池隆夫
    糖尿病, 2010
    2010 - 2010
  • IgG4陽性細胞の浸潤がみられたリンパ球性下垂体炎の1例
    秋川和聖; 曹圭龍; 耒海公彦
    日本内分泌学会雑誌, 2010
    2010 - 2010
  • 家族性AIMAHにおける臨床病理学的所見と異常レセプター発現の検討
    和田典男; 永井聡; 曹圭龍; 平井愛見子; 柳澤克之; 関利盛; 富樫正樹; 篠原信雄; 野々村克也; 清水力; 吉岡成人; 小池隆夫; 笹野公伸
    日本内分泌学会雑誌, 2009
    2009 - 2009
  • 持効型インスリンデテミルとグラルギン導入前後の臨床経過の検討
    曹圭龍; 中村昭伸; 本間ふみか; 中垣整; 吉田昌弘; 鴨嶋ひかる; 永井聡; 近藤琢磨; 三好秀明; 吉岡成人; 小池隆夫
    糖尿病, 2009
    2009 - 2009
  • 先端巨大症合併妊娠の一例
    曹圭龍; 澤田享; 吉田昌弘; 中村昭伸; 飛騨陽子; 永井聡; 近藤琢磨; 三好秀明; 清水力; 吉岡成人
    日本内分泌学会雑誌, 2008
    2008 - 2008
  • 皮膚腫瘤を形成した慢性リンパ性白血病の1例-Fludarabineの使用経験-
    犬塚宗希; 曹圭龍; 佐々木春喜; 森岡時世; 出野正孝; 沼崎太; 長島仁
    道南医学会大会並びに総会プログラム・抄録集, 2006
    2006 - 2006
■ Syllabus
  • 医学総論, 2024年, 博士後期課程, 医学研究科